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Abstract 
Background 
 
Kidney transplantation is associated with improved survival and quality of life 
compared to dialysis, and is the preferred treatment for many patients with end-stage 
kidney disease being. Nonetheless, long-term treatment after transplantation requires 
a balance between maintaining optimal graft function and serious harms associated 
with immunosuppression including cancer, cardiovascular disease, diabetes and 
infection. Furthermore, drug related side effects impact on patient well-being and 
quality of life. Understanding the net benefits associated with a treatment regimen 
requires knowledge of adverse outcomes as well as benefits. It is increasingly 
recognised that patient values, preferences and priorities should play a role in all 
clinical decisions. To date, as with many chronic diseases, treatment decisions have 
been predominantly driven by clinicians with little systematic, explicit and formal 
patient involvement.  
Aim 
 
The aims of the studies contained in this thesis are: 
• To elicit patient preferences and priorities for outcomes following 
transplantation, and 
• To evaluate the extent to which clinical trials of maintenance 
immunosuppression after kidney transplantation, report outcomes relevant to 
patient preferences and thereby, support an evaluation of both benefits and 
harms. 
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Methods 
 
Qualitative and quantitative techniques have been used to elicit patient preferences 
and evaluate reporting of patient relevant outcomes in clinical trials. 
 
Qualitative study – Chapter 2. The perspectives and priorities of adult kidney 
transplant recipients for outcomes following transplantation were evaluated using a 
focus/nominal group technique. Participants were purposively sampled from three 
transplanting centres in Sydney and Melbourne, Australia. Transplant outcomes raised 
by the group participants, were discussed and ranked in order of importance. Group 
sessions were recorded, transcribed and thematically analysed. 
 
Systematic Reviews. 
Chapter 3 - Quality of life outcomes - A systematic literature review to January 2014, 
was undertaken to identify all randomised controlled trials of maintenance 
immunosuppression. Trials were reviewed to identify those that included any patient 
reported measure of physical, emotional or social well-being. The reliability of 
reporting was assessed using an Equator Network endorsed checklist. Treatment 
effect sizes were estimated. 
 
Chapter 4 - Adverse events. Randomised controlled trials of maintenance 
immunosuppression indexed in the Cochrane Kidney and Transplant Register for the 
period January 2003 to December 2015 were reviewed to identify those that reported 
any drug related side effect (adverse events). Reliability of reporting was appraised 
using the 23 item harms-extension of the Consolidated Standards of Reporting Trials 
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(CONSORT) statement. The type and frequency of reporting adverse events were 
recorded. 
 
Best Worst Scaling Survey 
Chapter 5 - Pilot study. Kidney transplant recipients attending a transplant clinic in 
Sydney, Australia completed a pilot best worst scaling survey (BWS). The BWS 
comprised nine outcomes (the risk of dying, cancer, cardiovascular disease, diabetes, 
infection, gastrointestinal disorders, excessive weight-gain, changes to appearance 
and duration of graft survival). Each outcome was assigned five levels that were 
varied across 20 scenarios. In each scenario participants were asked to choose their 
‘best’ and ‘worst’ outcome. Responses were analysed using a multinomial-logit 
(MNL) model. Selected participants were interviewed after completion of the survey. 
 
Chapter 6 Final study. Based on the findings of the pilot study, a final BWS survey 
was designed comprising of 9 outcomes (years of graft duration and the risk of dying, 
cancer, cardiovascular disease, diabetes, infection, anxiety/depression, 
diarrhoea/nausea, and excessive weight gain). The statistically efficient design 
consisted of four blocks each of 10 scenarios. For the final survey, participants were 
shown one of the four blocks and asked to choose their ‘best’, ‘next-best’, ‘worst’ and 
‘next-worst’ outcomes for each scenario. Responses were analysed using a MNL 
model.   
 
Results. 
 
Chapter 2. The 57 participants identified 47 outcomes relevant to immunosuppression 
after transplantation. Graft survival was consistently ranked more highly than any 
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other outcome, followed by damage to other organs, survival, and cancer. Only 12% 
of the participants ranked survival as more important than graft loss. In contrast, the 
relative importance of side effects varied amongst the participants. Themes 
underpinning priorities were, ‘concern for fatal and serious events’, ‘relevance to life 
circumstance’, ‘acceptance, trivialisation, tolerance’ and; ‘future outlook’. 
Participants described a willingness to tolerate side effects, dependant on personal 
relevance and ability to manage the side effect. 
 
Chapter 3. Of 2,272 reports, only 41 (2%) involving 4,579 participants from 23 trials 
included a quality of life outcome. In all 22 different instruments (8 generic, 2 
disease-specific, 12 symptom-specific) were used. Reporting was incomplete for the 
majority with only 1 (4%) addressing all 11 items of the reporting checklist. Four 
(17%) addressed clinical significance, and 15 (65%) selectively reported outcomes. 
Almost all (n = 92, 95%) effect size estimates for the 97 quality of life outcomes 
across 16 trials of 2,710 participants favoured the interventions, with 35 (38%) being 
statistically significant. In comparison, 23 (66%) clinical outcomes favoured the 
intervention and 11 (31%) were statistically significant. 
 
Chapter 4. Of 233 trials, 163 (69%) reported at least one adverse event. Only 
17(10%) provided definitions or justified the adverse events, 13(8%) described 
methods and 27(17%) measured severity. Forty adverse event types were reported 
with gastrointestinal the most common (116, 71%). Frequency of reporting did not 
reflect known drug side effect profiles. For example, of 90 calcineurin inhibitor trials, 
only 22% reported tremors, 3% paraesthesia, and none anxiety, aggression or mood 
swings. Trials that reported at least one adverse effect were more likely to be industry 
 x  
funded (adjusted OR 7.6: 95%CI 3.4 to 17.1), multi-centre (5.9:1.7 to 18.7), and with 
follow-up time less than 24 months (3.7:1.4 to 10.2).  
 
Chapter 5. Eighty-one patients were approached, and 39 (48%), mean age 50.5 years, 
completed the pilot BWS. Four (10%) were invalid and of the remaining 35, 7 out of 
1400 (0.5%) choices were missing. Most coefficients were significant (P<0.05). After 
the average coefficients values were normalised to a scale from 1 to 0, graft survival 
had the greatest range with an upper value of 1 (95%CI: 0.89 to 1.11) and a lower 
value of 0.06 (-0.03 to 0.16) for 30 and 1 year duration respectively. All other 
attributes had upper values less than 1 (P<0.05) while a 50% risk of cancer and CVD, 
and 100% risk of diarrhoea/nausea were equal to 1 year graft survival (P<0.05). The 
estimated error for dominant attributes ‘100% risk of dying’ and ‘30 years graft 
survival’ were 20% and 2% respectively. Seven participants were interviewed about 
selecting ‘100% risk of dying’ as a ‘best’ outcome. Misunderstanding, not linking 
dying to graft survival, and aversion to dialysis were reasons given. 
 
Chapter 6. Ninety-three patients from two Australian transplant units (aged 18-69 
years, mean time since transplantation, seven years) completed the survey. After 
normalization on a scale from 0 to 1, graft loss at one year (preference value 0.0:95% 
confidence intervals:-0.05 to 0.05) was worst and a zero risk of dying before graft loss 
(1.0:0.92 to 1.08) was best. Graft loss at 15 years (0.46:0.42 to 0.51) was equivalent to 
a 25% risk of dying (0.41:0.36 to 0.46). To achieve zero risk of cancer, dying, and 
cardiovascular disease participants were only willing to trade 3.1(2.1 to 4.7), 1.7(1.1 
to 2.5), and 1.2(0.8 to 1.8) years of graft survival respectively, and less than 1 year for 
all other outcomes. 
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Conclusions 
 
Adults who have had a kidney transplant value graft survival more than life itself and 
show a minimal willingness to trade graft survival to minimise the risk of adverse 
outcomes. Whilst they are willing to accept side effects as being necessary, avoiding a 
high risk of occurrence of potentially debilitating side effects may, for some be as 
important as serious adverse outcomes such as cancer, CVD, diabetes and infection. 
Preferences and trade-offs for outcomes after transplantation show a focus on long-
term outcomes that are poorly addressed in clinical trials. The reporting of outcomes 
relevant to quality of life and adverse events is, selective and unreliable, and in the 
case of quality of life rare. These deficiencies limit clinician’s ability to engage 
effectively with patients in developing individualised care and assessments of the 
benefits and harms of treatment regimens.  
 
Implications arising from the study are: 
• All clinical decisions both before and after kidney transplantation should 
incorporate patient preferences and values. As patient preferences are framed 
by beliefs of the consequences of treatment, decision making must be 
underpinned by a sound understanding of benefits and harms of 
transplantation and immunosuppression. 
• Communication and education both before and after transplantation, must 
acknowledge the overwhelming importance of graft survival and the 
decisional conflicts that this can present for transplant patients.  
• Individual preferences will vary according to medical and non-medical factors 
both of which are relevant in patient-centred care and shared decisions. 
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Similarly, preferences should be expected to vary with factors such as age, 
time on dialysis, and number of transplants.  
• For clinical trials to support patient-centred care, and facilitate shared decision 
making, they must address outcomes that are both relevant and important to 
patients.  
• Reporting of outcomes should be to recognised standards to ensure both 
reliability and consistency. 
• The clinical significance of outcomes should always be reported. 
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1. Introduction 
1.1. Background 
Kidney transplantation is the preferred treatment for many patients with end-stage kidney 
disease as it is associated with improved survival and quality of life and reduction in 
cardiovascular events when compared to dialysis (1). Improvements in quality of life can be 
marked. For example, in a 2004 Swiss study transplant recipients rated the utility of life on 
dialysis to be on average only 2/3 of the value of life after a transplant (2). In a meta-analysis 
of 66 and 226 studies of transplant and dialysis patients respectively, the quality of life 
measured as a utility score (range 0 to 1) was on average 8% to 15% lower for dialysis 
patients than transplant patients (3). A meta-analysis of observational studies that used multi-
domain instruments calculated average effect sizes for changes in going from dialysis to 
transplantation as 0.98 for general quality of life, 0.77 for physical functioning and 0.39 for 
psychosocial functioning (4). Nonetheless, long-term treatment after transplantation requires 
a balance between maintaining optimal graft function and serious harms including cancer, 
cardiovascular disease, diabetes and infection associated with immunosuppression (5-7). In 
addition side effects of maintenance immunosuppression in kidney transplantation can have a 
detrimental effect on patient well-being and are associated with non-adherence, which can 
lead to graft loss (8-12), and morbidity (13).  
 
There has been a marked improvement in short-term graft and patient survival associated 
with advancements in drugs and surgery, but long-term graft survival has remained static 
over the past two decades with little evidence for differences between specific treatment 
regimens (14-16). A recent review of the clinical practice of reducing immunosuppression 
after haematological or solid cancer diagnosis in kidney transplant patients concluded that 
this reduction, whilst not being associated with an impairment in graft function, was also not 
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associated with an improvement in cancer free survival (17). As such, there remains 
significant uncertainty in clinical decisions regarding treatment options aimed at maximising 
long-term-benefits and minimising long-term harms. Long-term follow up of randomised 
controlled trials have not reduced this uncertainty (18-20). In addition to clinical uncertainty, 
transplant patients experience a range of medical, social and financial issues that vary over 
the transplant trajectory that also impact on long-term decisions (21). 
 
It is increasingly recognised that patient values, preferences and priorities should play a role 
in all clinical decisions. Patient values, preferences and priorities may take a lesser role where 
there are clearly defined options and well-understood outcomes, or where interventions 
address a short-term condition with little or no long-term implications. However, if the long-
term benefits and harms are unclear or there are multiple options with differing outcomes 
including side effect profiles, then patient values, preferences and priorities should be as 
important to the clinical decision as the medical factors (22). These circumstances have been 
described as ‘preference-sensitive’ treatments or decisions (22, 23). As noted, issues for 
patients extend beyond medical considerations and include a range of social and financial 
factors all of which may change before, after and during the course of an intervention such as 
a kidney transplant (21). Similarly, medical factors will likely change over the course of the 
transplant, because of acute or chronic rejection, declining renal function or development of 
comorbidities. The collective medical and non-medical factors can contribute to decisional 
conflicts arising from the changing need to balance the benefits and harms, and potential 
discord with patient factors including their values, preferences and priorities (24, 25).   
 
There are many ‘preference sensitive’ decision points before and after transplantation (24, 
26-29). Nonetheless, to date, as with other chronic conditions, treatment decisions have been 
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predominantly driven by clinicians with little patient involvement (24, 26, 29-31). 
Furthermore, patient’s perceptions of their level of involvement may not match their desires 
(32). 
 
1.2.  Concept of patient preferences 
In healthcare research, the term patient or individual preference is widely used, however there 
is no clear definition or understanding of what it means (33). Individual ‘values’ have been 
used interchangeably with preferences or preferences seen as a subset of ‘values’ or vice 
versa. Patient preferences have also been defined as being the final choice or decision in the 
context of shared decisions (34). The Institute of Medicine defines patient values as referring 
“to the unique preferences, concerns, and expectations that are brought by each patient to a 
clinical encounter [that] must be integrated into clinical decisions if the patient is to be 
served” (35). Under this definition, ‘preferences and concerns’ is a broad concept and 
implicitly includes cultural identity, existential and non-existential beliefs, and personality 
traits such as aversion to risk (36, 37) as well as treatment related factors (38). In the context 
of health care, it is more useful to think of values and preferences as separate concepts. 
Values reflect an individual’s identity and world view (36), while preferences reflect an 
individual’s evaluation of benefits, harms, costs, and inconveniences of one treatment option 
compared to another (38). This distinction is important as ‘preferences’ will be underpinned 
by beliefs about the consequences of treatment, expectations of outcomes and anticipation of 
the ability to cope or adjust (38), while ‘values’ largely reflect cultural, social and other 
influences not directly related to the treatment (36, 37). For complex procedures such as 
kidney transplantation, knowledge and experience strongly influence beliefs of the 
consequence of the transplant. This includes expectations of improvement to quality of life 
and anticipation of the range and severity of side effects, and the range and likelihood of 
Chapter 1. Introduction 
 
 4  
adverse outcomes such as cancer and cardiovascular disease. These expectations are strongly 
influenced by interactions with clinicians, other patients, family, friends and the media (39-
42).   
 
A prime distinction between ‘preferences’ and ‘values’ is that as expectations and beliefs 
change with time, experience and health (41), ‘preferences’ for treatment options may vary or 
even reverse (43). This is particularly so with chronic health conditions (27, 44). Indeed for 
complex problems or where there is no clear choice, preferences may be constructed during 
the decision process (43). In contrast, individual values are influenced by cultural and societal 
norms, religious and non-religious beliefs, and close relationships (family and friends). More 
stable aspects of an individual’s ‘world view’ thus define values (36, 37). Furthermore, 
preferences may be underpinned by beliefs and expectations that are erroneous or biased 
(skewed). This is almost certainly the case in kidney transplantation with complex and 
competing outcomes and uncertainty in predicting long-term outcomes. Moreover, there is 
little or no relevant experience for an individual to draw on to formulate well founded beliefs 
and expectations (42). In contrast to values, erroneous or skewed beliefs of consequences 
may be challenged and easily influenced by health professionals (45).  
 
In summary, patient preferences are best defined as “statements made by individuals 
regarding the relative desirability of a range of health experiences, treatment options and 
health statements” (34). An individual’s preference for a treatment … “reflects their 
evaluation of its relative benefits, harms, costs, and inconveniences in comparison with a 
given alternative or alternatives” (38). The goal of patient-centred care or shared decision 
making should be that patient preferences are well founded and lead to decisions that are 
aligned with their values. 
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1.3. Patient preferences and kidney transplantation 
Transplantation is a ‘preference sensitive’ intervention. Clinical decisions in a range of 
chronic diseases that engage patients in a meaningful way are known to lead to increased 
satisfaction with treatment and less decisional conflict between patients and clinicians (46). 
In end stage kidney disease, patient involvement in selection of dialysis modality has been 
shown to lead to improved patient relevant outcomes and higher transplantation rates (47). 
The role and importance of patient preferences and values in treatment options after 
transplantation is implicit in the KDIGO (Kidney Disease Outcomes Quality Initiative) 
‘Clinical Practice Guidelines for the Care of Transplant Recipients’ (48). Consistent with 
most guideline groups, KDIGO uses the GRADE (Grading of Recommendations Assessment, 
Development and Evaluation) process (49) for denoting the quality of evidence and the 
strength of recommendations. The KDIGO guideline includes 248 recommendations 60% of 
which are GRADE Class 2 and of these 50% are 2C or 2D (50). The interpretation of a 
GRADE Class 2 recommendation is described for patients by KDIGO (48): “The majority of 
people in your situation would want the recommended course of action, but many would not” 
and for clinicians “Different choices will be appropriate for different patients. Each patient 
needs help to arrive at a management decision consistent with her or his values and 
preferences.” Level C is described as “Low quality of evidence. The true effect may be 
substantially different from the estimate of the effect” and level D evidence “Very low quality 
of evidence. The estimate of effect is very uncertain, and often will be far from the truth.” 
Thus, the majority of the recommendations for care of transplant recipients are where patient 
preferences and values are particularly relevant to decisions and where there is a high level of 
uncertainty in the outcomes. This highlights the importance of understanding patient 
preferences for alternative treatments/actions. 
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Understanding of survival on the waiting list, quality of life before and after transplantation, 
graft survival and patient survival after transplantation, will all influence preferences for 
transplantation, and for treatment regimens after transplantation (44). Effective 
communication of benefits and harms is therefore paramount to patients being able to clarify, 
and subsequently articulate their own preference, particularly with the complex interventions 
and uncertain outcomes. The preferences and priorities of the clinician and patient may not 
always align. Furthermore, patient preferences may change with time because of changes in 
health, quality of life and personal circumstances (51). Differences in preferences amongst 
patients may reflect a different understanding of consequences in relation to graft survival 
rather than ‘true’ differences in their preferences (51, 52). Preferences may also be influenced 
by the type of donor organ, age, gender and health status (53).  
 
Understandably, patients place a high priority on factors affecting graft survival as do 
clinicians, however this priority may change with the length of time on dialysis, age, 
comorbidities and personal circumstances (2, 51, 54). Patient and clinician expectations of 
quality of life after transplantation may also differ. Clinicians have been shown to anticipate 
greater problems after transplantation in relation to mobility, pain and discomfort, ability to 
undertake usual activities, and anxiety and depression than patients. Patients tend to have 
higher expectations for improvement in all of these areas (55). Understanding the rationale 
for treatment and involvement in treatment decisions may increase motivation and adherence. 
However, differing patient priorities for the consequences of immunosuppression can lead to 
selective patterns of adherence to both drugs and lifestyle factors (53).  
 
In the context of clinical decisions or choices with long-term consequences, communicating 
benefits and harms associated with a treatment regimen requires knowledge of serious 
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adverse events, potentially debilitating side effects and quality of life (28, 56). Clinical 
decisions regarding maintenance immunosuppression after transplantation are largely 
informed by randomised controlled trials that provide evidence on the efficacy of 
interventions on clinical outcomes including acute rejection, graft function, graft loss and 
mortality (48). These same trials should also provide robust evidence on the harms and side 
effects of treatments. Reporting of harms such as infection, diabetes, cardiovascular disease, 
and cancer associated with different treatment regimens is deficient and uncertain (5, 57-59). 
In addition to clinical outcomes, transplant patients experience a range of emotional 
responses to their transplant. For example, a fear of graft loss and feeling of intense 
responsibility to the donor is a constant and disruptive concern for many transplant patients 
(53, 60, 61). Side effects may be viewed by patients as trivial relative to the prospect of graft 
loss and are under reported to their clinicians (62-64). Clinicians may then underestimate the 
potential impact of side effects on their patients’ well-being. A systematic review of factors 
influencing decision making in chronic kidney disease identified interpersonal relationships, 
life values, need for control and individual sensitivity to benefits and harms as being common 
across the continuum of kidney disease (24). This emphasises the need for effective 
communication of benefits and harms to ensure that an individual’s preferences are 
underpinned by an accurate understanding of consequences.  
 
In summary, whilst any clinical decision should be cognisant of patient preferences, the care 
of an individual undergoing a kidney transplant involves many decisions both before and 
after transplantation that are ‘preference sensitive’, due to: 
• The complexity of the treatment options; and 
• Uncertainty in benefits, harms and long-term outcomes. 
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In addition to medical factors and clinical outcomes, patient preferences may be poorly 
aligned with clinicians’ priorities due to: 
• Differing expectations of quality of life after transplantation; 
• Differing or ill-informed beliefs of the consequences and outcomes of treatment; 
• Deep seated fear of graft loss and feelings of responsibility to the donor; and 
• Preferences that change with time, health, knowledge and changing circumstances. 
 
1.4. Eliciting Preferences 
Eliciting and understanding preferences is of relevance to any field that involves decisions or 
choices by individuals or policy makers in Government or business. Development of 
approaches to preference elicitation have been particularly strong in marketing, transport 
planning and environmental and health economics. Broadly speaking there are two types of 
preferences, revealed and stated. 
 
• Revealed preferences are inferred by what people actually choose when presented 
with multiple alternatives within an existing market or program, for example buying a 
car or choosing to undergo cancer screening.  
• Stated preferences are inferred from what an individual says they would do given a 
hypothetical choice. They can be used to predict future real choices or identify the 
attributes of an item (e.g. car) or service (e.g. public health program) that have the 
most influence on their stated choice. Stated preferences are also applied in assigning 
values to health states, health goods and services (65). 
 
Studies in health mostly address stated preferences as there is often no ‘health market’ from 
which individuals can freely choose; nor do individuals ‘choose’ to be in a particular health 
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state. A preference for a treatment or health state reflects a personal evaluation of what it 
would be like to live with one set of outcomes compared to another set. In addition, health 
research is commonly interested in understanding factors that might influence acceptance (or 
not) of public health programs (such as cancer screening) or treatment options (66-68) to 
assist in development of the programs. The following discussion is therefore limited to 
methods most applicable to eliciting stated rather than revealed preferences, as these are 
most relevant to health issues.  
 
An important limitation common to all of the methods described below, is that individual 
preferences are underpinned by expectations and beliefs that are in turn influenced by the 
way in which outcomes or services are framed or communicated. In short stated preferences 
may be a construct of the elicitation method (43). As such, “data from preference elicitation 
tasks partly reflect individuals’ preferences and partly the manner in which the preferences 
were elicited.” (69).   
 
1.5. Qualitative methods 
Qualitative research methods are well suited to providing in depth understanding of patient 
priorities, preferences, experiences, attitudes and perspectives through the conduct of 
interviews and focus groups. Thematic analysis of the data provides for a rich narrative 
description of individual perspectives underpinning preferences (70). The nominal group 
technique, a variant of the focus group (71), is particularly suited to eliciting and 
understanding preferences and priorities. This technique has been used to evaluate health 
services, policies and research (72, 73) as well as patient important outcomes and preferences 
for treatments (74, 75). The nominal group technique uses group brainstorming to develop a 
list that is ranked in order of importance/relevance by individuals in the group. The technique 
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has the benefit of providing a ranking as well as a qualitative evaluation of the reasons and 
rationale behind the ranking. As the items are identified and discussed by the group they 
reflect group composition and dynamics and the emphasis is on identifying concepts and 
theories rather than generalisable quantitative data (70).  
 
Qualitative techniques are particularly useful in generating hypotheses and informing the 
design of quantitative approaches to preference elicitation. The aim of a qualitative study is to 
use sampling strategies that achieve saturation of ideas and perspectives for the study 
population rather than a sample representative of medical and non-medical characteristics 
(70). For example, qualitative studies have been used to elicit community preferences and 
identify barriers related to both deceased and living organ donation (76-78). Whilst these 
studies identify factors influencing preferences and barriers, it is not possible to predict the 
magnitude of effect of policies aimed at addressing the barriers. Qualitative studies can also 
assist in the development of patient-centred interventions. However, quantitative techniques 
are needed to evaluate questions such as which barrier is most important, who are they most 
relevant to (e.g. men vs. women, marginalised groups etc.) and what is the likelihood of 
participation.  
 
In summary, qualitative techniques provide an in depth understanding of reasons and 
rationale underpinning patient preferences. They are best suited to the generation of 
hypotheses and in the design and/or development of quantitative approaches to preference 
elicitation. Qualitative studies can identify the reasons for preferences and barriers however 
estimation of the magnitude of impact on health programs and the trade-offs that individuals 
may be willing to make to achieve desired outcomes requires the use of quantitative 
techniques.   
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1.6. Rating and Ranking 
Rating techniques using for example Likert scales or visual analogue scales (VAS), and 
ranking tasks, where participants are asked to rank the order of importance, have been widely 
used to elicit preferences, priorities and the value (utility) of health states (38, 79). Rating 
exercises where participants are asked to indicate the importance of health states or outcomes 
according to a VAS are the simplest methods of eliciting preferences and the most feasible to 
implement within clinical trials (80). Similarly ranking exercises that force individuals to 
order outcomes according to importance, whilst possibly more cognitively demanding than 
ratings, are simple to design and administer compared to the techniques described in the 
following sections (79, 81). The main benefit of ratings and rankings are that they can be 
simple to administer to a large number of participants with high response and completion 
rates (80). As a consequence of this simplicity there are a number of issues that limit 
application to complex health questions. 
 
Firstly, ranking and ratings do not involve choices between outcomes, and they provide little 
or no information on sensitivity to change in the value of the outcome, the relative 
preferences or the trade-offs between outcomes. Both rating and rankings are subject to a 
range of response biases such as ‘yea’ and ‘nay’ saying, ordering effects, and avoidance of 
extremes (79, 82). The defined endpoints in ratings are subject to ceiling (and floor) effects 
where every attribute may be classed as being equally critical or important. Ratings assume 
that utility (preference) is a cardinal construct and a given score indicates the same preference 
across all individuals and factors, which ignores differences in sensitivity to change in 
magnitude of the outcome and trade-off between outcomes (82). Rankings have ordinal 
properties and in principal, provide a better estimate of preferences (83), however the rank 
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provides only limited information on relative importance. The ordinal score assumes that the 
difference in importance between the top two items is the same as the difference between the 
bottom two  and so on (83). Ranking tasks can be cognitively challenging when they include 
a large number of items.  
 
The VAS rating scale can provide a better estimate of relative importance than an ordinal 
scale (81) as participants can vary the space between outcomes with larger gaps indicating a 
greater difference in importance. The cardinal scales of ratings provide even less information 
on relative importance and preference than ordinal scales. For example, two people may rate 
on a Likert scale, both mortality and quality of life as critically important. On an ordinal scale 
mortality may be ranked as more important than quality of life by one and the other way 
around by the second person. Even if they both ranked mortality as most important, they may 
vary in sensitivity to changes between survival and quality of life. This is reflected in 
differences in the number of years at a poorer quality of life and individual is willing to 
accept to maximise their survival (83, 84). This trade-off or utility cannot be assessed by 
either rating or ranking tasks 
 
In summary, ratings and ranking methods are simple techniques that can be widely applied 
and provide insight into preferences and the value (utility) of health states or outcomes. 
However, they provide little information on the relative importance of multiple outcomes and 
do not account for individual sensitivity to changes in outcomes, or the trade-offs between 
outcomes that an individual is willing to accept. Finally, rankings and ratings are not 
underpinned by any theoretical framework (83). 
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1.7. Standard Gamble and Time Trade-Off  
Standard gamble and time trade-off are the most commonly used techniques to assign a 
preference, also called a utility or value, to a particular health state. These have formed the 
prime basis for the estimation of utility which underpins the calculation of quality adjusted 
life years that are widely used in health economic evaluations (85, 86). As with ratings, 
standard gamble and time trade off assign a cardinal value to the utility of the health state 
(87) and suffer from the same limitations as described for ratings. However, in contrast to 
simple ratings, standard gamble and time trade-off involve a choice where the utility 
(preference) is calculated based on that choice. Schematic representations of a standard 
gamble (Figure 1.1a) and a time trade off (Figure 1.1b) task adapted from Drummond et al 
(81) are shown below.  
 
Figure 1.1. Standard gamble (a) and time trade off (b) tasks used to calculate the utility for dialysis relative to 
living with full health. The standard gamble (a) asks participants to choose between dialysis and the chance (p) 
of full health, but also a chance (1-p) of immediate death. The value of p is varied to estimate utility of dialysis. 
The time trade-off (b) asks transplant recipients to identify their preference for 10 years on dialysis or a shorter 
time (x) in full health. The value of x is varied until the indifference point is reached, which is then used to 
estimate utility.  
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In the standard gamble example shown in Figure 1.1a, the utility of dialysis relative to full 
health is the p value at the point of indifference that is where participants are unable to 
choose between A or B and in this case assumes that the utility of death is 0 and the utility of 
full health is 1. The standard gamble approach is underpinned by classic utility theory which 
was proposed to explain how an individual makes a decision in the presence of uncertainty 
and assumes an underlying rationality of preference (80, 88). In comparison, the time trade-
off technique is a choice under conditions of certainty. In the example shown in Figure 1b the 
utility is again estimated from the point of indifference, that is the point where they cannot 
choose between A and B. In this case, the time trade-off utility of dialysis relative to full 
health is equal to x years (at the point of indifference)/10 years and assumes the same 0 to 1 
scale. In contrast to standard gamble, time trade-off is not underpinned by any established 
theory (38, 89).  
 
There are a number of limitations of the standard gamble and time trade-off in eliciting 
patient preferences. Firstly, both standard gamble and time trade-off assume constant 
proportional trade-off between health states (90). In the case of time trade-off, it is assumed 
that the utility of life duration is constant and for standard gamble it is assumed the utility of 
high and low probabilities are valued in the same way. For example, a change in the 
probability of dying from 15% to 0% is assumed to be valued the same as a change from 90% 
to 75%. This is unlikely to be the case as most individuals regard incremental changes in risk 
to be more important as the risk approaches low values, that is they show ‘zero-risk bias’ 
(91). Whilst standard gamble is underpinned by economic theory, this theory follows strict 
axioms that are rarely met including assumptions that utility is linear and independent of the 
duration of the health state or changing knowledge (80, 92). It also relies on respondents’ 
ability to understand and trade probabilities and risk which has been found to be difficult for 
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some participants. The time trade-off does not include probability or risk, rather it relies on 
trading time as a surrogate for utility. Trading time is thought to be conceptually easier, 
making the task less burdensome, however it is not underpinned by any theoretical 
framework (79, 80). Finally, both techniques address comparisons between a poor health 
state and a better one and do not lend themselves easily to evaluation of changes in 
preferences when specific attributes of those health states differ, nor do they allow for 
assessment of preferences of multiple attributes of a health state (38, 82). 
 
In summary, standard gamble and time trade-off have been used widely in economic 
evaluations to estimate a preference or utility for a specified health state and to calculate 
quality adjusted life years. They are, however limited in the ability to elicit individual 
sensitivity to changes in attributes of a health state or evaluation of multiple health states.  
 
1.8. Discrete Choice Experiments 
A discrete choice experiment (DCE) is a choice based stated preference method that assumes 
that individuals will choose the option that best suits them, that is, the option that maximises 
utility (38). The approach has been widely applied in economics and marketing and more 
recently in health (68). In a DCE, treatments or health programs are described by a set of 
attributes such as specific health outcomes (harms and/or benefits), cost, time, properties of 
the procedure, etc. The participant is asked to choose their preferred treatment or program. 
By systematically varying the attributes across a range of choice tasks, the preference for the 
attributes and levels can be calculated. In a DCE, participants are not asked to rate or rank the 
strength or order of preference for each of the attributes, rather this is estimated from the 
choices they make across multiple choice sets or scenarios (93). Unlike standard gamble and 
time trade-off, in a DCE preferences are assessed for multiple attributes simultaneously and it 
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is not limited to a simple binary comparison of health states (38, 67). In addition to individual 
preferences, the sensitivity to changes in attribute levels and the trade-offs between them can 
also be calculated. An example of a DCE choice scenario adapted from a study of patient 
preferences for selection of dialysis modality (94) is shown in Figure 1.2. 
 
Figure 1.2. A single choice scenario adapted from a discrete choice experiment to elicit patient and caregivers 
preferences for dialysis treatment  modality (94). The treatment options are described by 8 attributes the values 
of which are varied across 12 choice scenarios. In each scenario participants are asked to select the multi-
attribute profile that they most prefer. 
 
Discrete choice experiments are underpinned by the strong econometric theory of random 
utility and this directs both experimental design and analysis (67, 95). Random utility theory 
assumes individuals make choices to maximise their utility, however a portion of this utility 
is associated with factors other than those included in the experimental design or otherwise 
known to the researcher. These unknown factors introduce a random component or error to 
the estimation of utility or preference. Random utility theory has been described by the 
following equation (67): 
𝑈𝑈𝑖𝑖𝑖𝑖 =  𝑉𝑉𝑖𝑖𝑖𝑖 +   𝜀𝜀𝑖𝑖𝑖𝑖   , 𝑗𝑗 = 1, … . J 
Where:  
𝑈𝑈𝑖𝑖𝑖𝑖 is the utility for individual i for choice j 
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𝑉𝑉𝑖𝑖𝑖𝑖 is the explainable component, and 
𝜀𝜀𝑖𝑖𝑖𝑖 is the unexplained or random component 
The random component may reflect attributes of the choice not included in the DCE and/or 
survey completion errors and variation or heterogeneity amongst the participants. The 
explainable component of utility is a function of the properties of the attributes and known 
properties of the participants such as age, gender, and health according to the following 
equation (67): 
𝑉𝑉𝑖𝑖𝑖𝑖 =  𝑋𝑋𝑖𝑖𝑖𝑖′ 𝛽𝛽 +  𝑍𝑍𝑖𝑖𝑖𝑖′ 𝛾𝛾  
Where: 
𝑋𝑋𝑖𝑖𝑖𝑖
′  is the vector of attributes included  in the design 
𝑍𝑍𝑖𝑖𝑖𝑖
′  is the vector of participant characteristics or other covariates 
and, 
𝛽𝛽 and 𝛾𝛾 are the vector coefficients to be estimated. 
Estimation of coefficients is most commonly undertaken using multinomial logit (MNL) 
regression using varying assumptions to account for the error component εij. The simplest 
model assumes that εij is independent of and identically distributed across all participants and 
choices. Models including mixed MNL, nested and latent class MNLs have been used to 
relax this assumption in an attempt to account for heterogeneity between and within 
individuals and also the panel nature of DCEs (67, 95).  
 
Discrete choice experiments have been applied to a wide range of health related questions at 
a patient, clinical, community, and policy level. These have included eliciting patient, 
clinician and community preferences and priorities for outcomes of interventions, treatment 
options, and a range of health programs such as cancer screening, and health service delivery 
(66, 68, 96, 97) as well as health states (98-101). The prime value of DCEs over ratings, 
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rankings, standard gamble, and time trade-off, are that they enable assessment of priorities 
and preferences beyond the cardinal and simple ordinal scales of these other techniques. 
Furthermore, trade-offs between desirable and undesirable outcomes, the willingness to pay 
for services, and estimation of uptake of community wide programs can also be evaluated 
(102-108). 
 
Comparative studies of preference techniques suggest that DCEs encourage greater 
consideration of all attributes and should provide more thorough evaluations of complex 
questions (109, 110). However, as with all survey techniques, DCEs are subject to a range of 
biases that need to be considered in design and analysis. While a DCE should encourage 
consideration of all attributes, individuals may still focus on a limited number or just one 
attribute and ignore the remainder. In addition to ignoring attributes they may take a number 
of mental short cuts (heuristics) in completing the survey and show diminishing attention to 
attributes as the survey progresses (69, 111, 112). Other biases include status quo (113), 
framing effects (114), affect heuristics (115), and a range of survey completion biases (left to 
right, top to bottom) (116). Finally, cognitive burden increases with increasing number of 
attributes and choices and most DCEs are limited to a relatively small number of attributes 
anticipated by the researchers as being most important. Over 90% of the health related studies 
published from 2001 to 2012 had fewer than 10 attributes with the majority having only 4 or 
5 (68). This can limit the ability to address complex questions. As the design of a DCE is 
simplified (e.g. by reducing the number of attributes) a participant’s choice may be 
increasingly determined by unknown factors, thus increasing the error component (95). These 
issues can be addressed to a varying extent by the use of qualitative studies, pilot testing with 
and without qualitative assessment tools such as ‘thinking aloud’ during completion (117), 
and use of experimental designs aimed at limiting cognitive burden (67, 68).  
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In summary, DCEs are well suited and widely used to elicit the stated preferences of patients, 
their caregivers, the general public and health professionals for a range of health related 
questions. The limitation in addressing complex health decisions, such as care of kidney 
transplant patients, is the cognitive demand of including multiple attributes with multiple 
levels and the expectation that individuals will give attention to all scenarios and attributes 
equally. 
 
1.9. Best Worst Scaling survey 
A best worst scaling (BWS) survey is a specific form of DCE that was initially developed as 
a means of increasing the information obtained from a DCE by providing partial or complete 
rankings of choice options rather than a single choice (118). In a BWS, the participant is 
asked to indicate the most preferred or best option and also the least preferred or worst 
option. Depending on the number of options, participants could be asked to indicate the best, 
worst, next best, next worst and so on. There are three broad types of BWS surveys (119) and 
these are briefly described below. 
 
Object scaling (Case 1). These are suited to eliciting preferences for a large list of factors or 
objects. Rather than asking participants to rank all of the factors from least to most important, 
they are shown a small sub-set and asked to choose the best and the worst (most important, 
least important) from that sub-set. They are shown multiple sub-sets where the factors 
presented are varied and the best and the worst is chosen for each sub-set. Analysis of the 
choices provides a basis for identifying the relative importance of all of the factors on a 
continuous scale. An example of an object scaling BWS is shown in Figure 1.3. 
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Figure 1.3. Example of an object scaling (Case 1) BWS. Adapted from a survey of clinicians regarding their 
expectations of the impact of 11 emerging technologies for the treatment of hepatocellular carcinoma (120). 
Participants were shown a series of choice sets each with a different subset of the 5 technologies.  
 
Profile scaling (Case 2). These are applied where a single profile, (e.g. a health state, 
treatment or service) can be described by a set of attributes that can have varying values or 
levels. Multiple scenarios of single profiles are shown to participants all of which have the 
same attributes, however the values of the attributes are varied between scenarios. As for the 
Case 1 BWS participants are asked to select the best and worst attribute from the profile. The 
attribute levels maybe numeric (the probability that a side effect will occur) or descriptive 
(the severity of the side effect). It has been suggested that when there are a large number of 
attributes the Case 2 BWS survey is less cognitively demanding than a DCE and that it 
should result in greater consideration of all attributes (118), although this view is not 
universally accepted (121, 122). An example of a profile scaling BWS is shown in Figure 1.4. 
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Figure 1.4. Example of a profile scaling BWS (case 2). Adapted from a study eliciting preferences of parents 
and adolescents for the control of asthma (123). Each attribute is described by 3 to 4 levels representing the 
range of possibilities for that attribute (e.g. night time symptoms: none, 3 days a week, 5 days a week). Each 
choice set contains the same 5 attributes; however the attribute levels are varied across the choice sets.  
 
Best Worst DCE (Case 3). The best worst DCE is essentially a standard DCE that includes an 
additional best worst task. Each scenario consists of three or more multi-attribute profiles as 
per a DCE and participants are asked to show their preferred option, and then to select the 
worst of the remaining profiles (124). Case 3 aims at augmenting data collected from the 
DCE by providing partial or complete ranking in addition to the preferred choice. An 
example of a best worst DCE is shown in Figure 1.5. 
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Figure 1.5. Example of a best worst DCE task. Adapted from a study of people with a spinal cord injury (125). 
Each attribute is described by 2 levels representing possible outcomes for that attribute (e.g. walking; wheelchair 
or normal). In each choice set the attributes remain the same, however the attribute levels are varied across the 
choice sets. In this example, participants are asked to select the best (i.e. their choice in the DCE as well as the 
worst scenario and their second best scenario. 
 
Since 2008, BWS surveys have gained increasing use in the evaluation of health questions, 
however the absolute number has been relatively small with 53 publications overall and only 
15 and 16 published in 2014 and 2015 respectively (84). They can be cognitively less 
demanding than DCEs, although as noted above, this is not universally accepted (121, 122), 
and enable assessment of the relative importance of a large number of attributes on a 
continuous scale avoiding issues associated with ranking and rating techniques. Compared to 
DCEs a BWS can provide a more realistic approximation of questions where there is no clear 
choice to be made. For example, maintenance immunosuppression after transplantation is 
best described as a series of adjustments with resulting changes to the benefits and harms 
rather than a discrete choice of one option over another. Another advantage is that attributes 
are assessed on the same underlying scale, enabling direct comparison of the relative 
importance of attribute levels both within and between attributes (119, 126, 127).  
 
As BWS surveys are underpinned by the same random utility framework as DCEs, design 
and analysis follows the same general principles (84, 119, 126). At the simplest level, the best 
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and worst choices can be counted for each attribute level with the best minus the worst score 
providing a measure of the preference for the attribute levels. Whilst this has been shown to 
provide a robust estimate of relative importance, it does not allow for estimation of trade-offs 
between attributes (119).  
 
When undertaking more complex analyses, there are considerations specific to the 
completion of a BWS survey that need to be taken into account. Firstly, when completing the 
BWS task a participant may simultaneously select a best-worst pair from each choice set 
(128). Alternatively they may select the best then the worst, or vice versa as a sequential 
selection. In this case the second selection needs to assume that it has been been chosen from 
a reduced set of attributes as if the first selection had been removed (129). However, it is 
equally possible that individuals will mentally rank the outcomes and then assign the best and 
the worst, or the other way around. Some individuals may consider every possible best worst 
pair and choose the pair that represents the maximum difference. These last two strategies 
would be cognitively challenging when the number of attributes is large. Finally, a single 
survey may include participants who use any of these processing strategies and they may vary 
their approach as they progress through the survey. Thus as noted by Louviere and Flynn 
(119), all models used in the analysis of BWS surveys are approximations to reality and all 
require assumptions that cannot be easily tested. In Louviere and Flynn’s view, as the 
differences are most likely minor, the pragmatic approach is to assume that the statistically 
simpler sequential model applies to all participants (119).  
 
Another pragmatic assumption made in most estimation approaches is that a worst choice is 
simply the negative mirror of a best choice. This may not be an accurate representation of 
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cognitive processes and best worst preferences may vary in magnitude and direction between 
desirable (e.g. length of life) and undesirable attributes (e.g. death) (129). 
 
In summary, BWS surveys are an alternate approach to eliciting preferences under the 
general framework of random utility theory. They have potential advantages to DCEs 
including ability to assess attributes and attribute levels on the same underlying scale, and to 
avoid problems associated with rating and ranking techniques. A BWS survey can be used as 
a data augmentation technique for a DCE, or as an alternate solution to elicitation of patient 
preferences for multiple attributes associated with complex health questions. 
 
1.10. Examples of Preference Elicitation in Transplant Populations 
This section provides a brief overview of studies that have used discrete choice and best 
worst survey techniques to address questions relevant to solid organ transplantation. 
• Solomon et al (51) used a maximum difference scaling task analogous to a BWS to 
assess relative importance of factors affecting decisions to accept donor organs. 
• Davison et al (130) used a DCE to elicit preferences for organ procurement and 
allocation and early advanced care planning. The focus of the study was on ethical 
issues and concluded that ‘the current models of care do not consistently reflect the 
preferences and priorities of either healthcare professionals or patients’. 
• Two studies by Howard et al used DCE surveys to elicit community preferences for 
the allocation of donor organs (131) and policy options aimed at encouraging 
deceased organ donation within Australia (132).  
• Three UK studies used DCE surveys in eliciting preferences and priorities for 
allocation and provision of liver transplantation in the UK. The surveys were 
administered to patients, the general public and health care professionals (133-135).  
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• Clark et al (136) used a DCE survey to evaluate the priorities for kidney transplant 
amongst key UK stakeholders. Stakeholders were patients, their caregivers, donors, 
relatives of deceased donors, and healthcare professionals.  
• Reese et al (54) used a survey analogous to a DCE to evaluate the factors influencing 
kidney transplant candidates’ willingness to accept organs at higher risk of blood-
borne viral infections. 
• Cass et al (137) used a survey similar in structure to a DCE in which practicing 
nephrologists were shown 15 patient profiles where the attributes were randomly 
generated so that each profile was different. Participants were asked whether the 
hypothetical patient would be suitable for transplantation. 
 
As can be seen, the studies to date have largely focused on issues relating to organ donation 
and have sought preferences from a range of stakeholders including patients, their caregivers 
and healthcare professionals. To date, discrete choice and best worst studies addressing issues 
other than organ donation in end stage kidney disease have been limited to pre-transplant 
issues (138) such as the factors influencing choice of mode of dialysis (94).  
 
1.11. The need for the study 
Kidney transplantation is commonly regarded as the preferred treatment for end stage kidney 
disease. Whilst patient preferences, priorities and values are relevant to all clinical decisions, 
kidney transplantation is particularly sensitive to preferences due to: 
• The complexity of treatment options;  
• The long-term implications of treatment; and 
• Uncertainty in benefits, harms and long-term outcomes. 
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Whilst the preference sensitive nature of treatment after transplantation has been recognised 
(48), treatment decisions have been predominantly driven by clinicians with little patient 
involvement (24, 26, 29-31). In order to support patient care that addresses preferences the 
following is required: 
• An understanding of patient preferences for outcomes after kidney transplantation; 
• An understanding of the reasons underpinning patient preferences; and  
• An evaluation of whether clinical research provides an adequate basis for informing 
patient preferences, given that preferences are framed in the context of beliefs of 
consequences and expectations of outcomes. 
 
To date, there has been somewhat limited evaluation of factors relating to patient 
involvement in decision making in chronic kidney disease. Existing research has focussed on 
decision making regarding dialysis modality, withdrawal from treatment and whether to have 
a transplant (24). When asked, the majority of end stage renal disease patients would prefer to 
either make decisions alone or on a shared basis rather than leaving it to their clinician (32). 
Incorporation of patients’ preferences and priorities promotes acceptability, can improve 
adherence and therefore clinical outcomes, and lead to greater patient satisfaction (139, 140). 
An understanding of the preferences and priorities of kidney transplant patients is required 
for patient-centred research and care. 
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1.12. Objectives  
The overall objectives of the study were to develop an understanding of patient preferences 
and priorities for outcomes after transplantation and to evaluate whether current clinical trials 
support patient-centred clinical care. 
 
The specific objectives addressed by the individual studies contained in this thesis are: 
1. To elicit the preferences and priorities of kidney transplant recipients for clinical and 
non-clinical outcomes after transplantation and the reasons underpinning those 
priorities. 
2. To assess the extent to which clinical trials provide evidence to support patient 
expectations of the consequences of immunosuppression following transplantation. 
3. To evaluate preferences and trade-offs patients may accept to avoid adverse outcomes 
of long-term immunosuppression. 
 
1.13. Structure of the thesis 
The thesis presents the individual studies completed to address the objectives listed above. 
 
Chapter 2 relates to objective 1 and describes a qualitative study undertaken with adults who 
have had a kidney transplant to explore their preferences and priorities for outcomes after 
transplantation. The study utilised a mixed methods approach that allows for ranking of the 
importance of outcomes raised in focus groups. A thematic analysis of discussions has been 
used to evaluate reasons underpinning the identification and ranking of outcomes. 
 
Chapters 3 and 4 present the findings of two systematic reviews completed to address 
objective two. These reviews address two categories of outcomes arising from the qualitative 
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study that have had limited assessments to date, namely quality of life and treatment related 
side effects. The reviews focus on the extent and reliability of reporting of these outcomes in 
clinical trials.  
  
In chapters 5 and 6 a quantitative assessment of patient preferences and trade-offs for 
outcomes after transplantation is presented to address objective 3. Chapter 5 describes the 
conduct of a pilot study while chapter 6 presents the final BWS study from which priorities 
and trade-offs have been evaluated. 
 
Chapter 7 brings together the overall findings of the studies including the strengths, 
limitations and conclusions. Finally, a discussion of the implications with respect to clinical 
practice and research is provided.   
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2. Important outcomes for kidney transplant recipients: A 
nominal group and qualitative study 
 
The material contained in this chapter has been published as: Howell, M., A. Tong, G. Wong, 
J. C. Craig and K. Howard (2012). "Important Outcomes for Kidney Transplant Recipients: A 
Nominal Group and Qualitative Study." American journal of kidney disease 60(2): 186-196. 
 
The structure reflects the journal requirements. 
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2.1. Abstract 
Background: Immunosuppression is associated with a number of adverse outcomes, but, 
typically it is the physician, not patient, who decides on the drug regimen. The perspective of 
the patient in clinical decision making is increasingly recognised in other settings, but the 
perspective of kidney transplant recipients is largely unknown. The aim of this study was to 
elicit patient perspectives and priorities for outcomes following transplantation and the 
reasons underpinning these priorities.  
Methods: Outcome identification and ranking was undertaken using a focus/nominal group 
technique.  Adult kidney transplant recipients, purposively sampled from three transplanting 
centres, participated in one of eight nominal groups.  Each group (6 to 10 participants) listed 
and ranked outcomes relevant to immunosuppressant medications.  
Results:  The 57 participants identified 47 outcomes relevant to immunosuppression after 
transplantation.  Graft survival was consistently ranked more highly than any other outcome, 
followed by damage to other organs, survival, and cancer. Only 12% of the participants 
ranked survival as more important than graft loss.  In contrast the relative importance of side 
effects was variable.  Themes underpinning priorities were: concern for fatal and serious 
events; relevance to life circumstance; acceptance, trivialisation, tolerance and; future 
outlook.  Participants described a willingness to tolerate side effects, dependant on personal 
relevance and ability to manage the side effect. 
Conclusion:  Graft survival appears to be more important than life itself to kidney transplant 
recipients, suggesting that they may be willing to tolerate a higher level of 
immunosuppression than is assumed by clinicians and researchers. 
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2.2. Introduction 
Life-long immunosuppression is required for successful kidney transplantation, however 
being in a prolonged immunocompromised state is not without complications.  Kidney 
transplant recipients are at increased risk of cancer, infection, diabetes and cardiovascular 
disease (1-3).  In addition, immunosuppressant medications are associated with a range of 
side effects of varying frequency and severity, with important consequences for quality of life 
(4, 5). Combination immunosuppression is standard, and new agents are being developed and 
used, although evidence of long-term patient, graft and quality of life benefits relative to the 
harms of the various combinations of immunosuppressants are limited. Instead, randomised 
trials have focussed on short term outcomes and rarely include measures of quality of life or 
the severity of side effects (6-9).  
 
Despite this lack of strong evidence, decision-making on long-term immunosuppression use 
tends to be predominantly physician driven, is not individualised and often made with limited 
patient involvement(10).  To date, there has been somewhat limited evaluation of factors 
relating to patient involvement in decision making in chronic kidney disease more generally; 
existing research has focussed on decision making regarding dialysis modality, withdrawal 
from treatment and whether to have a transplant (11). When asked, the majority of end stage 
renal disease patients would prefer to either make decisions alone or on a shared basis rather 
than leaving it to their physician (12).  Incorporation of patients’ preferences and priorities 
promotes acceptability, can improve adherence and therefore clinical outcomes, and leads to 
greater patient satisfaction (13, 14). 
 
While patient experiences and quality of life after transplantation (15, 16), and the frequency 
and distress associated with side effects (4, 17)  have been evaluated, there are no studies on 
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patient perspectives of the range of adverse effects associated with prolonged 
immunosuppression.  The aim of this study was to elicit perspectives and priorities of kidney 
transplant recipients for outcomes following transplantation and the reasons underpinning 
these priorities. 
 
2.3. Methods 
A combined focus/nominal group technique (18) was used to generate a list of outcomes that 
kidney transplant recipients identify with taking immunosuppressant medication, and to rank 
the relative importance of these outcomes.   
 
Participants 
The participants were recruited from three large transplant units located in Sydney and 
Melbourne.  They were purposively selected to achieve a mix of sex, age and time since 
transplantation.  Participants were eligible if they were English-speaking, more than 18 years 
of age, able to give informed consent and medically fit enough to attend a focus group 
session.  As individual experiences of side effects and long term outcomes associated with 
immunosuppression may change with time after transplantation as a result of adjustments in 
the level of immunosuppression and increasing prevalence of comorbidities (e.g. cancer and 
cardiovascular disease), the participants were grouped according to whether the date of 
transplantation occurred less than or more than 1 year prior to the study.  Participants were 
offered reimbursement for their time and travel expenses.  Ethics approval was obtained from 
the Human Research Ethics Committee of the Western Sydney Local Health Network, NSW 
Health.  
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Data Collection 
Nominal group techniques have been successfully used to evaluate priorities and/or 
preferences for health services, policies and research  (19, 20) as well as eliciting patient 
important outcomes and preferences for treatments (21, 22).  Each two-hour focus/nominal 
group comprised three phases: group discussion on general experiences on kidney 
transplantation and immunosuppressant medication; individual and group identification of 
outcomes associated with taking immunosuppressant medication; and individual ranking of 
outcomes identified by group discussion.  All groups were convened in a hotel meeting room 
and facilitated by either MH or AT. The participants identified and discussed outcomes they 
believed were important and relevant to immunosuppression medication. The facilitator 
augmented the list with outcomes identified from the literature in relation to side effects (4, 
17)  and clinical outcomes (2, 23-25).  Using the consolidated list, participants were asked to 
individually rank the ten most important outcomes in order of perceived importance.  An 
observer (MH or AT) recorded field notes on group dynamics and interactions and on the 
context surrounding the discussion.  All sessions were recorded and transcribed verbatim.  
Data was collected until theoretical saturation was reached.   
 
Data analysis  
Nominal group ranking: Individual participant rankings were used to calculate ranking scores 
for each outcome identified across all eight nominal groups.  The highest ranked outcome for 
each respondent was given a value of 10, the next most important a value of 9, and so on, 
progressively down to the least important which was assigned a value of 1.  If an outcome 
was not ranked in the 10 most important it was assigned a value of zero.  A mean priority 
score for each outcome across all of the groups was calculated by summing the ranking 
scores and dividing this by the maximum possible ranking score for that item.  The maximum 
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possible ranking score for a given outcome was calculated by multiplying the number of 
participants who considered the outcome by 10 (the maximum rank).  When all participants 
who ranked an outcome scored it as the most important the priority score was 100%, while a 
score of 0% meant that all participants who ranked that outcome did not score it in the top 10 
most important outcomes. .  This approach has been used in a number of studies to provide 
both a rank and an estimate of the relative importance of the group items (19, 21, 22, 26).  
Mean priority scores and the number of times an outcome was voted in the top 10 were 
calculated for all participants and, in order to assess potential influences of time since 
transplant, separately for the groups where the participants’ date of transplantation occurred 
less than one year, or more than one year prior to the study.  Differences in the mean priority 
scores between these groups were assessed using analysis of variance.   
 
Qualitative analysis: Transcripts were entered into HyperRESEARCH (ResearchWare Inc. 
United States. Version 2.8.3) and reviewed line-by-line by MH who searched for concepts, 
themes and ideas, and developed a preliminary coding scheme using an adapted grounded 
theory approach (27). The preliminary coding was discussed among MH, AT and GW.  MH 
refined the coding structure until it captured all relevant concepts.  Through a process of 
constant comparisons between individuals and groups, analytical themes were inductively 
developed to identify the participant reasons underpinning their rankings. 
 
2.4. Results 
Of the 62 kidney transplant recipients who accepted an invitation to attend a focus/nominal 
group 57 (92%) participated in one of eight groups.  Reasons for non-attendance were illness 
(3), unable to arrange transport on the day (1) and not stated (1).  The age ranged from 20 to 
70 years (mean 47.8 years) and 33 (58%) were men (Table 2.1).  Fifty five (95%) had 
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received a kidney transplant, two a combined kidney pancreas transplant and one a combined 
kidney liver transplant. Four (7%) had received more than one transplant and 45 (79%) had 
been on dialysis prior to transplantation. 
Table 2.1. Characteristics of participants. 
 
Characteristics Patients 
 n=57 % 
Sex   
Male 33 57.9 
Female 24 42.1 
Age (years)   
20-29 5 8.8 
30-39 10 17.5 
40-49 15 26.3 
50-59 11 19.3 
60-69 15 26.3 
70-79 1 1.8 
Dialysis before transplant   
Yes 45 78.9 
No 12 21.1 
No. of previous transplants   
0 53 93.0 
1 4 7.0 
Deceased donor 24 42.1 
Type of transplant   
Kidney 54 94.7 
Kidney/pancreas 2 0.04 
Kidney/liver 1 0.02 
Time since last transplant (years)   
< 1 22 38.6 
1-2  13 22.8 
2-5  13 22.8 
5-10  4 7.0 
10-15  2 3.5 
>15  3 5.3 
 
 
Nominal Group Ranking 
The mean number of outcomes identified by each group was 35 (range 28 to 39) with 47 
unique outcomes identified across the 8 focus groups (Table 2.2).  Of the outcomes, 26 (55%) 
were common to all eight groups while 11 (23%) were identified by only one or two groups.  
The outcomes have been categorised into five groups: serious adverse events (including 
death); physical side effects; emotional side effects; social impacts; and medication properties 
(Table 2.2).  The items grouped as ‘serious adverse events’ follow the definition of this term  
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by the European Medicine Agency(28) .  Of the 47 outcomes, only 7 were not ranked by any 
participant as being in the top 10 most important (i.e. a 0% priority score).  The ranking of 
outcomes based on the mean priority score across all participants for those outcomes 
identified by 3 or more groups is shown in Table 2.2 and Figure 2.1. 
 
The nine highest mean priority scores for all outcomes were for ‘serious adverse events’, with 
‘anaemia’ being the only outcome not occurring in the top 10.  The outcomes ‘kidney 
rejection’ and ‘kidney function’ (leading to graft loss) were the most important with mean 
priority scores of 88.6% and 77.9% respectively.  The next highest, ‘damage to other organs’ 
and ‘death’ had mean priority scores close to half that of ‘kidney rejection’ and ‘kidney 
function’ (45.6% and 42.8% respectively).  Only seven (12%) of the participants ranked 
‘death’ as more important than either ‘kidney rejection’ or ‘kidney function’ (i.e. graft loss).  
The mean priority scores for ‘kidney rejection’ and ‘diabetes’ were significantly lower in the 
early transplant group compared to the late transplant group (81.9% versus 94.7%, [P=0.04] 
for ‘kidney rejection’ and 23.7% versus 44.0%, [P=0.02] for ‘diabetes’).  The mean priority 
score for ‘non skin cancer’ was significantly higher in the early groups (50.4 versus 29.0%, 
P=0.02). 
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Table 2.2. Individual ranking of all outcomes identified by kidney transplant recipients in relation to immunosuppressant medication. 
 
Rank 
(identified 
by 3 or 
more 
groups) 
Outcome (sorted on mean priority score) Number of 
groups 
listing 
outcome 
Number of 
participants 
who voted on 
outcome (%) 
Proportion 
of times 
outcome 
voted in top 
10 (%) 
Mean Priority score 
(%) 
 
 
All <1yr >1yr P(a) 
Serious Adverse Events 
4 Death or survival 8 57 (100) 61.4 42.8 47.4 38.7 0.4 
1 Kidney rejection 8 57 (100) 94.7 88.6 81.9* 94.7* 0.04 
2 Kidney function 7 48 (84.2) 93.8 77.9 84.4 74.0 0.2 
3 Damage to other organs 6 45 (78.9) 77.8 45.6 40.5 50.0 0.3 
         
5 Cancer – other than skin 8 57 (100) 64.9 39.1 50.4* 29.0* 0.02 
6 Diabetes  8 57(100) 63.2 34.4 23.7* 44.0* 0.02 
7 Cancer - skin 7 51 (89.5) 62.7 33.9 36.7 30.8 0.5 
8 Cardiovascular disease (cholesterol, blood pressure) 8 57 (100) 57.9 22.1 20.4 23.7 0.6 
9 Prone to infection 8 57 (100) 47.4 18.2 21.1 15.7 0.4 
11 Bone disease 8 57 (100) 28.1 13.3 16.7 10.3 0.3 
30 Anaemia 8 57 (100) 5.3 2.8 1.9 3.7 0.6 
Physical Side Effects 
- Night sweats/tremors 1 7 (12.3) 28.6 14.3 - -  
10 Weight gain and excessive appetite 8 57 (100) 33.3 14.0 13.7 14.3 0.9 
14 Interaction with other drugs and food 8 57 (100) 26.3 11.4 12.6 10.3 0.7 
16 Gastrointestinal problems 8 57 (100) 26.3 10.4 13.3 7.7 0.3 
18 Fertility 3 22 (38.6) 18.2 8.6 12.0 7.6 0.7 
19 Energy levels/fatigue 8 57 (100) 17.5 8.1 4.4 11.3 0.2 
20 Sun sensitivity 5 35 (61.4) 20.0 7.7 2.5 10.4 0.3 
22 Sleep disturbance 8 57 (100) 15.8 6.7 9.6 4.0 0.3 
25 Weak limbs and muscle weakness 8 57 (100) 12.3 5.4 4.8 6.0 0.8 
26 Blurred vision and cataracts 8 57 (100) 12.3 5.3 0.0* 10.0* 0.02 
28 Cosmetic - hair growth/loss, acne, moon face 8 57 (100) 7 4.0 2.6 5.3 0.5 
- Hot flushes 2 11 (19.3) 9.1 2.7 - -  
31 Hand tremors 8 57 (100) 8.8 2.6 4.8 0.7 0.2 
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Table 2.2 (cont.) 
Rank 
(identified 
by 3 or 
more 
groups) 
Outcome (sorted on mean priority score) Number of 
groups 
listing 
outcome 
Number of 
participants 
who voted on 
outcome (%) 
Proportion 
of times 
outcome 
voted in top 
10 (%) 
Mean Priority score 
(%) 
 
 
 
 
P(a) All <1yr >1yr 
Physical Side Effects (cont.) 
32 Joint Pain 8 57 (100) 8.8 2.1 0.4 3.7 0.1 
34 Healing time 7 51 (89.5) 7.8 1.6 1.9 1.3 0.7 
35 Pins and needles 7 51 (89.5) 3.9 1.2 2.2 0.0 0.2 
- Allergies and intolerance 1 5 (8.8) 0 0.0 - -  
36 Bruising 6 42 (73.7) 0 0.0 0.0 0.0  
- Dry mouth 2 13 (22.8) 0 0.0 - -  
- Gums 1 9 (15.8) 0 0.0 - -  
- Headaches 1 8 (14.0) 0 0.0 - -  
Emotional Side Effects 
13 Depression 8 57 (100) 33.3 11.4 10.4 12.3 0.7 
17 Concentration and memory 8 57 (100) 22.8 8.8 4.8 12.3 0.1 
21 Mood swings 8 57 (100) 14.0 7.0 8.9 5.3 0.52 
23 Aggression 3 22 (38.6) 9.1 6.4 4.0 11.4 0.4 
27 Anxiety 8 57 (100) 10.5 4.2 1.9 6.3 0.3 
- Dreams/nightmares 1 8 (14) 0 0.0 - -  
Social impacts 
12 Impact on family 8 57(100) 35.1 13.2 12.2 14.0 0.8 
15 Impact on work 8 57 (100) 17.5 10.5 12.6 8.7 0.6 
- Impact on travel 1 9 (15.8) 0 0.0 - -  
Medication Properties 
- Research/history of drug 2 14 (24.6) 64.3 43.6 - -  
- HLA specificity 1 5 (8.8) 40.0 22.0 - -  
- Schedule of medication 1 7 (12.3) 14.3 10.0 - -  
24 Cost - out of pocket 8 57 (100) 17.5 5.6 9.6 2.0 0.08 
29 Access to medication 6 43 (75.4) 9. 3 3.0 2.6 3.8 0.7 
33 Medication properties 8 57 (100) 7.0 2.1 1.9 2.3 0.8 
  (a) Difference between <1 year and >1 year groups. 
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Figure 2.1: Mean priority scores for outcomes associated with immunosuppressant medication that were 
identified by 3 or more focus/nominal groups. 
 
 
The highest ranked physical side effect, with a mean priority score of 14.0%, was ‘weight 
gain and excessive appetite’ followed by ‘interaction with other drugs and food’ (11.4%) and 
‘gastrointestinal problems’ (10.4%).  The highest ranked emotional side effect was 
‘depression’ (mean priority score 11.4%) with all others less than 10%.  The outcomes 
‘impact on family’ and ‘impact on work’ had mean priority scores greater than 10%.  
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Medication properties were consistently ranked as being of low importance.  There was no 
significant difference in the mean priority scores between the early and late groups with the 
exception of ‘blurred vision and cataracts’. Although this outcome was considered by all 
participants, only seven (12.3%), all of whom were from the late transplant groups, ranked it 
in the top 10 most important outcomes. 
 
Qualitative analysis 
Four main themes underpinning participants ranking of outcomes associated with 
immunosuppressant medication were identified: concern for serious and debilitating 
outcomes; relevance to life circumstance; acceptance, trivialisation, tolerance; and future 
outlook.  These themes largely support the quantitative ranking of outcomes.  Illustrative 
quotes for each theme are provided in Table 2.3 and a thematic schema to illustrate the 
interplay between themes and outcomes is provided in Figure 2.2.  
 
Concern for serious and debilitating consequences. 
Fear of graft loss: Acute and/or chronic rejection were perceived as factors that would result 
in graft loss and that immunosuppression was required to maximise survival of the 
transplanted kidney.  A few participants were however, aware that specific medications such 
as tacrolimus and cyclosporine could have long term harmful effects on their kidney.  
Diabetes and high blood pressure were identified as being harmful to their kidney increasing 
the risk of graft loss and thus ranked as important outcomes.  The outcome ‘weight gain and 
excessive appetite’ was also linked to graft loss through its influence on blood pressure.  The 
participants equated graft loss with a “dreaded” return to dialysis, which some described as 
being worse than death.   
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Apprehension for fatal and serious events:  Many participants described some outcomes as 
having fatal or devastating consequences and ranked these as important.  This applied 
particularly to cancer and to a lesser extent diabetes. To most participants, cancer (both skin 
and other cancers) was a dreaded outcome. There was a strong awareness across all groups of 
an increased risk of cancer, in particular skin cancer, associated with immunosuppression.  
Some participants also described diabetes as a grave consequence.  In contrast, participants 
perceived cardiovascular disease to be related to blood pressure and lifestyle both of which 
could be controlled; and therefore was seen as a less “fatal” or dreaded outcome compared 
with diabetes and cancer. Being “prone to infection” was described as having a “cold or flu” 
and therefore not a potentially serious or fatal outcome and was, with the exception of 
individuals who had experienced serious infections, discussed in terms of the need to limit 
contact with the general public.   
 
Debilitating or highly intrusive outcomes:  Outcomes that were perceived to have a 
debilitating and pervasive impact on daily living and quality of life were considered to be 
important.  This underpinned the evaluation of side effects but also outcomes such as cancer 
and diabetes which were described as being debilitating irrespective of effects on survival.  
The importance of side effects was dependent on whether they were described as: debilitating 
and difficult to cope with (e.g. severe diarrhoea); intrusive but able to be controlled using 
medication or personal strategies (e.g. milder gastrointestinal side effects, depression and 
mood swings); regularly occurring but easily managed (e.g. hand tremors); and occurring 
infrequently and/or of no consequence (e.g. pins and needles, bruising).   
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Table 2.3. Rationale for group consensus of outcomes – description and participant quotations  
 
Main Theme Sub Theme Illustrative Quotes 
1. Concern for 
serious and 
debilitating 
consequences 
Fear of graft loss “Well, if it's a balance between cancer and rejection of the kidney, I'd rather take a non-rejection of the kidney, because…If it meant going on dialysis I think I'd 
rather go the other way, because I'd rather fight cancer than go on dialysis.” Male 40’s 
 
“If you’re over 70 you might not want to go back on dialysis.  If you’ve spent eight years there and you know what it’s like.” Female 60’s 
 
“I know that I definitely came to the conclusion when I was on dialysis that death certainly wasn't the worst thing.” Male 30’s 
 
“Diabetes is the major cause of kidney failure.  It’s probably the single biggest cause of kidney failure is diabetes.” Male 60’s   
 Apprehension for 
fatal and serious 
outcomes 
“But the ones that do make me nervous out of all of them – the other stuff are like symptoms and even infection I think you can manage to a certain extent, but the 
whole cancer thing, that you’ve got a greater – you know the big C, you know the skin cancer thing and also if you like too many glasses of wine, you get a higher 
chance of throat cancer and all of those sorts of [things]…” Male 40’s  
 
“Skin cancers kill more people.  You know, the ones who’ve been on immunosuppressants than any other cause, almost.  It’s probably the most dangerous thing, 
the thing we need to look..” Male 60’s. 
 
“And then the third one I just put down as diabetes I reckon not having ever have it. It would be a shock to the system .. definitely and the impact to your kidney 
again going through that is probably more severe than actually high blood pressure ... that can be controlled with pills.”  Male 30’s 
 Debilitating or 
highly intrusive 
outcomes 
“Well I've been on the Cellcept, and had severe, severe diarrhoea.  Every time I go to the clinic ... I carry on.  Yeah, yeah, yeah.  I'm sitting next to people in the 
clinic, and talking to them, who are having the same experience, and it absolutely destroys your life.  You're just tied basically to home.” Female 60’s 
 
“No, quality of life is for me.  I'd rather die if these were going to take away all my quality of life.”  Female 60’s 
2. Relevance to 
life 
circumstance 
Personal impact “Same here, it's [fertility] probably not my lowest, because it's a bit of a selfish thing to put as my lowest but, I've had my kids and it's not an issue.” Female 40’s 
 
“So when you go for a holiday that’s what I find really hard with the kids and like we went to Surfer’s in Easter and I kind of found that a bit hard not staying in the 
sun. You know, you’ve got 2 little kids and dad’s underneath a tree waiting and looking at the kids. You know what I mean. So, Yeah you wear a big hat and that 
but you can only do so much.” Male 40’s 
 
“Yeah, I really had to push for it [change to medication] because the doctors didn’t think it was kind of a relevant thing to worry about [hair loss] but I was really, I 
was worried about and it just was getting worse.  So it was a risk but I was willing to take it.” Female 20’s 
 
“Facial hair, yeah.  When your movie star days are over you don’t worry too much about that.”  Female 60’s 
 Expected survival “So there was that whole lifestyle thing of being so young, going do I keep trying for a family, stay on the cyclosporin and hope that I can have a child. Or do I then 
go onto this other medication that doesn't have that side effect and I'm probably thinking for me 'cause I was so young, like people who are maybe older had their 
families and all that. That might not be a challenge for them but for me that's probably one of the issues that I've seen with it.” Female 40’s 
 
“I'd take [drug] B [shorter survival lower risk of losing kidney] because ... see, when I had the kidney I was told if I do the right thing I've got 15 to 20 years out of 
this.  It makes me 75, 80.  But [Male 20’s] may look at A.” Male 60’s 
  
“I would look at A [longer survival higher risk of losing kidney] because I'd rather it last 20 years [but] I'll probably need another one anyway.” Male 20’s. 
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Table 2.3 (cont.) 
Main Theme Sub Theme Illustrative Quotes 
3. Acceptance, 
resignation, 
tolerance and 
trivialisation. 
 
Inconsequential 
impact 
“I don’t mind it [moon face] because it sort of fills me out a bit or else I get too gaunt looking.  .....To me it’s a bit of a bonus.”  Female 40’s 
 
“Yeah it [hand tremble] is annoying but it doesn’t have any consequence, like it doesn’t mean I’m damaging another part of my body or something else” Male 30’s. 
 
 Trade-off between 
harms and benefits. 
“That’s right. I think all the others in terms of night sweats and hand trembling – and we’ve all had those at different degrees and hair loss and hair on your face and 
even bone disorders – when it really comes down to it, they’re all sort of ones that you’ve just got to [put up with]” Female 40’s… 
 
“Because whilst my sister and I had pretty good match there was one antibody reaction …. So I was warned that could be a problem down the road.  So I’m 
prepared to put up with a few side effects to make sure that that’s not happening”  Female 50’s 
 Ability to manage “…the first few months I was struggling to answer back to contractors but now I’ve worked out a system in myself where I keep calm and relaxed and take deep 
breaths and now I can respond back to the contractors and the clients and tell the reason why I don’t believe this is correct and still keep a professional attitude and 
keep calm.  Because sometimes when I get this anxiety, I get a little bit aggressive, I found... But it’s just controlling, how can I say, your new body balance.” Male 
20’s 
 
“Whereas if you’ve got depression you can always get some antidepressants and some help but if you’ve got any of those other things, you know.”  Female 60’s 
 
“That one you can control. Sun sensitivity you can control.” Male 30’s 
 Normal process “Sometimes I just have to remember my age.  Just think, you know, these things are going to happen anyway.” Female 50’s 
 
“I disagree with you [about depression and drugs].  I think it’s the actual person themself.  I’ve got a lot of stress in my life at the moment and I can deal with it.  I 
know how to cope.  I think it’s the actual person.  I don’t think it’s the pills because I’ve took pills all my life.  I think it’s the actual person themself.  I don’t think 
you can blame the drugs. Believe me I can be depressed and suicidal, believe me I’ve been through hell and back, but I don’t think it’s, it’s the actual person 
themself I think.” Female 40’s 
 Obligatory gratitude  “…I’m on antidepressants and I sort of feel this urgency that I’ve got to be happy because I’ve had this wonderful reprieve and somebody else [an altruistic live 
donor] has made this wonderful sacrifice for me so I feel it’s urgent to be happy and I am happy.  But I need the antidepressants.” Female 60’s 
4. Future 
outlook 
Fatalism  “The whole survival life thing, I don’t even know about that even being on there really because you can get hit by a bus on the way to the clinic”  Female 40’s 
 
“I think if it’s meant to happen, it’s meant to happen.  That’s the way I look at it.  I mean you would be scared to go anywhere if you think like that.  If it’s meant to 
happen it will happen.”  Female 40’s 
 Optimism. “...I also work on the basis that in 15 years time they will have perfected more drugs, better kidney...  Dialysis will be a thing of the past and there'll be another way 
except dialysis.  So medicine will be on your side.”  Male 40’s 
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Relevance to life circumstances 
Personal impact: Lifestyle, age, gender, family and employment were all described as 
reasons for ranking the importance of outcomes.  For example, fertility was critical to 
participants who were planning to start a family. Younger women felt distressed about 
cosmetic side effects (acne, hair loss, excessive hair growth) and the negative impact 
on their self-esteem and confidence.   
 
Expected survival:  Many participants believed that the importance attached to 
outcomes depended on age and life stage.  Some participants who, as a consequence 
of their age, did not expect to outlive their graft felt that kidney rejection/function was 
more important than survival.  In contrast a male in his 20’s expected to need a 
second transplant, thus his focus was on survival and serious outcomes such as cancer 
as he did not want to die with a functioning graft. 
 
Acceptance, trivialisation and tolerance. 
Inconsequential impact:  Some outcomes were perceived by participants as having a 
negligible impact on life and of low importance.  These included side effects such as 
bruising, dry mouth and pins and needles.  
 
Trade-off between harms and benefits:  Participants believed that tolerating side 
effects was necessary to realise the benefits of immunosuppressant medication, 
namely preventing rejection and graft loss.  Transplantation was described as a 
treatment not a cure and therefore participants expected to have side effects that need 
to be tolerated particularly in the context of returning to dialysis. 
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Ability to manage:  The outcomes that participants perceived as being manageable or 
easy to hide were given a lower importance.  For example, depression could be 
managed using antidepressants, blood pressure using anti-hypertensives and mood 
swings, feelings of aggression and anxiety using personal strategies. 
 
Normal process: Some outcomes were considered by participants to be part of the 
normal ageing process or the chronic illness trajectory, and therefore were to be 
expected irrespective of immunosuppressant medication.  For example poor 
concentration and memory was indicated by some to be just as likely a consequence 
of age; or that depression was “normal” in chronic illness and that everyone 
experienced mood swings and stress. 
 
Obligatory gratitude: Some participants felt extreme gratitude to their donor for 
giving them a “second chance at life”. For this reason, they felt that some side effects 
were not worth “complaining” about.  The feeling of appreciation for the sacrifice 
made was described as a reason for having to “put up with” the negative aspects of the 
medication. This was also described as a point of conflict for a number of the 
participants in that they felt a sense of guilt for having negative feelings about their 
experiences. 
 
Future outlook: 
Fatalism:  A few participants described a fatalistic view of serious adverse events 
including graft failure and survival.  They stated that it was not worth worrying about 
these types of outcomes as they were beyond their control.  For example, some felt 
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that survival was of lessor importance as they could die from many causes unrelated 
to the transplant. 
 
Optimism:  Optimism was expressed as the view that advances in medical research 
are inevitable and a better treatment or even a cure was likely to be developed with 
time.  This was used as a rationale for focussing on graft survival in that the longer 
their graft survived, the more likely that medical research will develop alternatives to 
dialysis.   
 
Figure 2.2: Schematic representation of themes underpinning ranking of outcomes. 
 
2.5. Discussion 
Our study shows that transplant recipients are willing to trade-off not only unpleasant 
side effects of stronger immunosuppression such as weight gain and hair loss, but also 
serious events such as cancer in order to maintain stable and satisfactory allograft 
function and thereby avoid a return to dialysis.  Allograft rejection and declining renal 
function were viewed as inevitably leading to graft loss, the fear of which was so 
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dominant that only a small number of participants identified death as being more 
important than graft loss.  Other complications, such as cardiovascular disease, 
diabetes, cancer and infection, whilst considered important were not identified as 
imminent issues. Whilst cardiovascular disease and infection are both major causes of 
death in kidney transplant recipients (29), participants indicated high blood pressure 
to be important primarily in the context of detrimental effects on kidney function, 
while increased risk of infection was considered to be largely a nuisance.   
 
Serious adverse events were most important, representing nine of the ten highest 
ranked outcomes across all participants.  Graft loss, either through rejection or loss of 
function, was most dominant with priority scores around 40% higher than the next 
most important outcome.  An aversion to returning to dialysis was the commonly 
expressed reason for the importance of graft loss.  In contrast to serious adverse 
events, the importance of physical and emotional side effects was comparatively low 
and there was less consistency between individuals.  The four major themes 
underpinning the ranking of outcomes included: a concern for serious consequences; 
relevance to life circumstances; future outlook; and acceptance, trivialisation and 
tolerance.  Overall the transplant recipients described a willingness to tolerate a range 
of side effects in order to realise the benefits of immunosuppression.  However, this 
was tempered by individual assessment of the relevance and possible impact of that 
side effect and whether the side effect was described as debilitating. 
 
A number of studies have evaluated the frequency and associated distress of the large 
number of side effects associated with immunosuppressant medication in kidney 
transplantation populations (4, 5, 17, 30-32).  These studies also suggest a high degree 
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of variation in identification of the most frequent and distressing side effects, however 
this may in part reflect variation in the dominant drug regimens between the studies 
and thus variation in side effect profiles (33) .  In the study by Prasad et al (5) kidney 
transplant recipients were asked to rate the side effect profiles and the relative 
efficacy of cyclosporine and tacrolimus, and to indicate which drug they would prefer 
to take if mono-therapy was a viable option. Side effects were evaluated as more 
frequent and severe for cyclosporine compared to tacrolimus, however the drugs were 
considered to be of similar efficacy leading to a stated preference for tacrolimus over 
cyclosporine.  Efficacy was not defined in terms of specific outcomes nor were the 
participants provided with comparative information on the drugs, rather it relied on 
prior knowledge and perception. Patient preference was thus based on consideration 
of side effects rather than serious adverse events including graft survival.  
 
In our study, the participants were asked to consider and rank the importance of all 
outcomes together rather than considering side effects in isolation.  In this context, 
participants rated side effects as having very low importance compared to graft 
survival.  Furthermore, graft survival was considered more important than individual 
survival as well as a range of serious adverse events including cancer, diabetes and 
cardiovascular disease.  In the qualitative study by Orr et al (34), kidney transplant 
recipients expressed a strong fear that their kidney would fail necessitating the need to 
return to dialysis, with some expressing that they would prefer to die.  The stress 
associated with fear of graft failure has been noted as being very high and does not 
appear to diminish with time (35, 36).  Nilsson et al (36) identified a higher level of 
stress amongst kidney transplant recipients compared to heart, lung and liver 
recipients which they attributed to the poor quality of life associated with dialysis 
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even though dialysis represented a ‘life saving’ option that was not available to other 
organ transplants.  This underlying fear of graft failure is consistent with ‘kidney 
function’ and kidney rejection’ being ranked as more important than survival in our 
study.   
 
It should be noted, that ranking provides a partial insight into preferences and 
priorities and it cannot be concluded that kidney transplant recipients would seek to 
maximise the length of graft survival at all costs.  However, the thematic analysis 
identifies a willingness by kidney transplant recipients to make significant trade-offs 
between graft survival and side effects that is not evident from a simple evaluation of 
the frequency and severity of side effects.   
 
The participants in our study also described a high level of tolerance to a wide range 
of side effects, however there was a high degree of variability in the level of 
importance of individual side effects, dependant on personal experience and 
relevance.  It is not just severity of the side effect but also the ability to self-manage or 
cope that are important in determining impact on quality of life (37, 38).  One 
consequence of this high level of acceptance and trivialisation is a likelihood of under 
reporting of side effects to clinicians.  Peters et al (39)described how clinicians 
underestimated both the prevalence and emotional and social impacts of cosmetic side 
effects experienced by kidney transplant recipients.  More than half of the recipients 
stated that they “rarely or never” talked to their clinicians about side effects.  
Furthermore, 84% of the transplant recipients affected by cosmetic side effects 
reported feeling happy to endure the changes for the sake of having the transplant 
Chapter 2. Qualitative Study 
 
67 
(39).  Significant underreporting of gastrointestinal side effects by kidney transplant 
recipients to their clinicians has also been noted (40, 41). 
 
There are some potentially important limitations of our study. Only English speaking 
and relatively mobile participants (excluding the very elderly or frail) were included.  
The mixed gender focus groups may have limited the discussion of more gender 
sensitive issues such as impotence and excessive and painful menstruation both of 
which have been identified as stressful side effects associated with 
immunosuppressant medication (4, 17).  Not all outcomes were considered for 
ranking by all groups which limits the comparative analysis across the groups, 
however, with the exception of a small number of outcomes that were identified in 
only 1 or 2 groups, there was a clear consistency in the ranking of outcomes between 
the broad categories namely: serious adverse events; physical and emotional side 
effects; social impacts; and medication properties. 
 
This study has implications in relation to clinical research and practice.  Firstly it 
highlights a number of mismatches between patient preferences and priorities and 
clinical trials of immunosuppressant medication. Overwhelmingly, participants 
focussed on graft survival and described a willingness to make trade-offs with both 
serious adverse events, including individual survival, and a large number of side 
effects in order to achieve long term graft survival.  Systematic reviews show that the 
majority of clinical trials are of short duration (i.e. less than 2 years) (6-9) and as a 
result there is a high degree of uncertainty in predicting the long term effects of 
varying immunosuppressant regimens.  In addition, while patients are willing to 
accept a wide range of side effects, this is dependent on the impact and the ability to 
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control or manage them.  Clinical trials either do not include side effects as outcomes 
or they simply record frequency of occurrence.  The impact of an intervention on an 
individual is a complex relationship between individual experience of the illness, their 
world view and their personal circumstances (42), whereas when included as an 
outcome in clinical trials, quality of life is assessed using standardised instruments 
that focus on pre-specified domains that may be of no relevance to the individual.   
 
Of relevance to clinical practice, transplant recipients believe that side effects are a 
necessary part of their treatment which increases the likelihood that they will not 
accurately report their experiences to their clinicians.  Furthermore, there is little 
evidence relating to patient important outcomes to assist them in understanding the 
impacts of decisions relevant to long term immunosuppression.   Patient reported 
outcomes and recognition of patient preferences, priorities and values should be 
addressed in clinical trials and given the level of uncertainty in predicting long term 
outcomes, they should also be considered when developing maintenance 
immunosuppressant regimens. 
 
Finally, our study demonstrates that many kidney transplant recipients are willing to 
make significant trade-offs in order to maximise graft survival, and may be willing to 
tolerate a higher level of immunosuppression than is assumed by clinicians and 
researchers.   
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3. The consistency and reporting of quality of life outcomes in 
trials of immunosuppressive agents in kidney 
transplantation: systematic review and meta-analysis. 
 
The material contained in this chapter has been published as: Howell, M., G. Wong, R. M. 
Turner, H. T. Tan, A. Tong, J. C. Craig and K. Howard (2016). "The Consistency and 
Reporting of Quality-of-Life Outcomes in Trials of Immunosuppressive Agents in Kidney 
Transplantation: A Systematic Review and Meta-analysis." American Journal of Kidney 
Diseases 67(5): 762-774. 
 
The structure reflects the journal requirements. 
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3.1. Abstract 
Background. Shared-decision making regarding immunosuppression in kidney 
transplantation requires an understanding of effects on quality of life (QoL). Our aim was to 
review the frequency and reliability of QoL measures reported in randomised controlled trials 
of maintenance immunosuppression following kidney transplantation.  
Study Design. Systematic literature review. 
Setting & Population. Kidney transplant recipients enrolled in randomised trials of 
maintenance immunosuppression. 
Selection Criteria for Studies. Systematic search of the Cochrane Kidney and Transplant 
Register, CENTRAL, MEDLINE, Embase, PsycINFO and CINAHL databases to January 
2014, identifying maintenance immunosuppression trials. An Equator Network endorsed 
checklist was used to assess QoL reporting and effect sizes estimated. 
Intervention. Maintenance immunosuppression (comparative studies, dose adjustment, agent 
withdrawal). 
Outcomes. Any quantitative patient reported measure of physical, emotional or social well-
being. 
Results. Of 2,272 reports, 41 (2% involving 4,579 participants from 23 trials) included QoL 
outcomes using 22 instruments (8 generic, 2 disease-specific, 12 symptom-specific). 
Reporting was incomplete for the majority with 1 (4%) addressing all 11itemof the Equator 
endorsed check-list, 4 (17%) addressed clinical significance, and 15 (65%) reported outcomes 
selectively. Almost all (n = 96, 95%) effect size estimates for 101 QoL outcomes (18 trials, 
3,919 participants) favoured the interventions, with 37 (37%) statistically significant. In 
comparison, 30 (73%) clinical outcomes favoured the intervention and 13 (31%) were 
significant. 
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Limitations. Quality of life outcomes are commonly secondary outcomes and may not be 
indexed or found using text word searches. Effect sizes were estimated from different QoL 
measures, populations and interventions. The small number of trials limits the ability to 
identify statistically significant associations between effect size and study/patient related 
factors. 
Conclusions. Quality of life is infrequently reported in immunosuppression trials in kidney 
transplantation, appears subject to major biases, and so may be unreliable for decision–
making. 
 
3.2. Introduction 
Reporting of quality of life (QoL) outcomes in clinical trials is necessary to inform patient-
centred care, particularly where treatments have differing side effects and adverse outcomes 
that impact on patient experience and well-being (1). Although kidney transplantation is the 
treatment of choice for most patients with end-stage kidney disease, lifelong 
immunosuppression is required to maintain optimal graft function. Immunosuppressive drugs 
have differing side effect profiles, impact upon quality of life and increase the recipients’ 
susceptibility to serious adverse outcomes including cancer, infection, cardiovascular disease 
and diabetes (2, 3).  
 
Systematic reviews of clinical trials in kidney transplantation have shown that reporting of 
clinical outcomes, particularly adverse events, are inconsistent and incomplete, which means 
that published estimates of the benefits of treatment effects may be unreliable (4). Inherently, 
subjective outcomes such as patient reported QoL, are at higher risk of bias as a consequence 
of inadequate randomization, allocation concealment and blinding, than objective clinical 
outcomes (5, 6), leading to over-estimation of the effects of interventions. Also, the 
variability of conduct and reporting of QoL outcomes adds additional uncertainty to the 
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interpretation of trial data (7, 8). Consequently, the extent and reliability of data to support a 
full evaluation of the benefits and harms associated with long-term management of post-
transplant immunosuppression is unknown. This is of particular concern given the recent 
focus on patient-centred care, patient relevant outcomes and shared-decision making (9-12). 
 
The aim of this study is to evaluate the frequency and reliability of QoL outcomes from 
randomised controlled trials of immunosuppressive drugs in kidney transplantation. 
Knowledge of the extent to which patient relevant outcomes have been addressed in clinical 
trials can inform ways to develop and optimise strategies for informed shared-decision 
making in kidney transplantation. 
 
3.3. Methods 
We conducted a systematic review based on standard methods and reporting in accordance 
with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
(13). 
 
Inclusion criteria 
All randomised controlled trials of maintenance immunosuppression interventions following 
kidney transplantation were included. Broad inclusion criteria for interventions were used 
including different immunosuppressive agents, withdrawal or substitution of an agent from 
multiple drug regimens, variation in doses or schedules; or interventions aimed at 
maximizing efficacy (e.g. therapeutic monitoring). There was no restriction by language, 
drugs, age of recipient or multiple organ transplants.  
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Literature search 
The Cochrane Kidney and Transplant Group Specialist Register, Cochrane Central Register 
of Controlled Trials, MEDLINE, Embase, PsycINFO and CINAHL databases were searched 
from inception to October 3rd 2015. Medical Subject Headings (MESH) and text words 
relevant to kidney transplantation and immunosuppression were used to identify randomised 
controlled trials of maintenance immunosuppression interventions; and combined with 
MESH headings and text words relating to QoL, adverse events, side-effects, and symptoms 
(see Supplementary Table S1 in Appendix A). Titles and abstracts were reviewed to identify 
articles for full text review. As inclusion of QoL outcomes in a trial may not be clear from a 
title and abstract search, an additional 200 citations were selected at random for full text 
review.  
 
Outcome measures 
We collected data on QoL and clinical outcomes. A QoL outcome was broadly defined as any 
patient reported outcome providing a quantitative measure of: well-being; mental, social or 
physical functioning or; distress, impairment or personal impact. Clinical outcomes reported 
such as mortality, graft failure, acute rejection, renal function, treatment failure and 
hospitalization time were collected. The QoL instruments were classified as generic if 
applicable to a broad range of patient groups, diseases or interventions, specific if they 
targeted a particular patient group, disease, intervention or domain (14). Instruments were 
further classified as being specific to a disease or patient group, or specific to a symptom or 
group of symptoms.   
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Risk of bias assessment  
The risk of bias of included trials was assessed independently by MH (Martin Howell) and 
HTT (Ho-Teck Tan) using the Cochrane tool (15). The reliability of reporting of QoL 
outcomes was assessed using a 11-item check list endorsed by the Equator network (16). The 
checklist included four domains: conceptual (hypothesis and rationale for instrument); 
measurement covering psychometric properties (validity reliability, responsiveness), validity 
for the population and adequacy of domains; methodology (method of administration, 
baseline compliance, timing, and strategy for handling missing data); and interpretation 
(clinical significance and completeness of reporting). Risk of bias was ranked as very low, 
low, moderate or high for the trial and QoL reporting based on the number of items addressed 
by the trials. 
 
Data synthesis and analysis  
We extracted data for QoL and clinical outcomes, and calculated effects sizes as the 
standardised mean difference (SMD) for continuous outcomes and risk ratio (RR) for 
dichotomous outcomes for all included trials where sufficient data was provided or could be 
estimated. In cases where there was inadequate data, authors were approached for missing 
data. As QoL instruments may include multiple domains and single or multiple composite 
scores, all of which may be pertinent to patient experience, we calculated an effect size for 
each outcome reported. We used the QoL and clinical outcomes recorded at the latest time to 
calculate effect size. Where more than one treatment arm was included we compared each 
arm to the control. Effect sizes were calculated so that a SMD greater than zero and/or a RR 
greater than one could be interpreted as favouring the intervention group relative to the 
control.  
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Pre-planned sub group analyses stratified by risk of bias (trial and QoL), trial size, trial 
duration, primary versus secondary outcomes, type of QoL instrument, time since 
transplantation, and incidence of acute rejection, were used to assess sources of 
heterogeneity. Summary estimates of effect sizes were calculated using the inverse variance 
method. To account for the correlation from multiple trial outcomes a study level random 
effect was also included in the models. P-values ≤0.05 were considered statistically 
significant. Calculations were undertaken using RevMan version 5.2 and SAS 9.3. 
 
3.4. Results 
Literature Search 
We identified 2,381 relevant citations of which 1,566 did not address QoL outcomes. Full 
text analysis, excluded 109 reports as non-randomised trials or not including a relevant 
intervention. The 200 randomly selected citations did not include QoL outcomes and were 
excluded after full text review. In total, 41 reports of 23 trials (n=4,549 participants) were 
eligible (Figure 3.1) being 1.8% of the 2,272 citations identified as randomised controlled 
trials of maintenance immunosuppression. One non-English language study was included 
(17) and one trial (n=719 participants) was reported only in abstract form (18). 
 
Trial Characteristics  
The characteristics of included trials are presented in Table 3.1. Twenty-one (91%) trials 
were in adult kidney transplant populations, and two included paediatric patients (19, 20). 
The median number of participants was 124 (range 18 to 666) and median duration of follow-
up was 12 months (range 1 to 48 months). Twelve (52%) trials compared different 
immunosuppressive drugs or differing doses of the same drugs (17-19, 21-28); 9 (39%) trials 
addressed conversion/withdrawal of a drug (20, 29-36), one examined cyclosporine with and 
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without diltiazem (37) and one therapeutic drug monitoring (38). Quality of life was a 
primary outcome in 9 (39%) and a secondary outcome or not defined in 14 (61%) trials.  
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Figure 3.1: Flowchart showing process of identification of trials for inclusion in systematic review.  
CRG=Cochrane Renal Group. QoL=Quality of Life. RCT=randomised controlled trial. 
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Twenty two QoL instruments were used across the 23 trials, with two developed for the trial 
(Tables 3.1 and 3.2). Eight instruments (36%) were generic, two (9%) disease specific and 12 
(55%) symptom specific. The number of instruments used in each study ranged from one to 
six, with the most common being the generic SF36 used in 10 (43%) studies. A visual 
analogue scale was used to provide a generic/global measure and disease/symptom specific 
measure. Two instruments (MTSOSDS and Memphis Survey) are specific to 
immunosuppressive drug related side effects while the GIQLI and GSRS address 
gastrointestinal symptoms not specific to immunosuppression. Nine (39%) trials provided 
only generic outcomes, and 4 (17%) provided only symptom specific outcomes, while 10 
trials (43%) reported both generic and disease/symptom specific outcomes. Additional study 
details are provided in the Supplementary Table S2 (Appendix A). 
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Table 3.1. Characteristics of included trials 
 
Study Setting No. of 
participant 
(n)  
Population Treatment Comparator Duration 
(years) 
QoL Outcome Generic 
Instrument(s) 
Disease Specific 
Instrument(s) 
Symptom Specific 
Instrument(s) 
1o 2o 
Trials of different agents or different doses 
Baltar et al 
(2001)  
Single centre; Spain 26 Adults with primary deceased 
donor organ transplant. 
AZA  MMF 1   
PWGBI, EQ-5D, 
VAS - - 
Bolin et al 
(2008)  
Multi-centre; US 323 Stable graft ≥6 months duration 
and treated with cyclosporine. 
Low tacrolimus, 
standard tacrolimus. 
Standard cyclosporine 1   - - Memphis Survey 
Dobbels (2011) 
[BENEFIT-
EXT] 
Multi-centre; 
international 
543 Extended criteria donor organs. Intensive belatacept; 
less intensive 
belatacept  
Cyclosporine. 
3   SF36 - - 
Dobbels (2011) 
[BENEFIT]  
Multi-centre; 
international. 
666 
 
Living or deceased donor organs 
and low panel reactive antibodies. 
Intensive belatacept; 
less intensive 
belatacept 
Cyclosporine. 
3   SF36 - MTSOSDS 
Langone (2011)  Multi-centre; US. 396 Adults aged <75 years, <1 month 
since transplant; gastrointestinal 
side effects due to MMF 
EC-MPS plus MMF-
placebo ± CNI.  
EC-MPS-placebo plus 
MMF ± CNI. 0.08   - - 
GSRS; GIQLI; 
OTE 
Oppenheimer 
(2009) 
[SYMPHONY]  
Spanish cohort of 
multi-centre 
international study. 
156 Adults scheduled for single-organ 
transplant with low to normal 
immunological risk. 
Low cyclosporine; low 
tacrolimus; low 
sirolimus. 
Standard cyclosporine 
1   SF36 - - 
Ortega (2011)  Multi-centre; Spain. 107 Adults with MMF gastrointestinal 
side effects. 
EC-MPS  MMF 0.08   PGWBI - GIQLI, GSRS 
Polsky (2001)  Multi-centre; US. 135 Adult first or second single organ 
kidney transplant (excluding HLA 
identical living donor organs).  
ATG with delayed 
cyclosporine. 
Basiliximab with early 
cyclosporine. 1   VAS (EuroQol) - - 
Shield (1997)  Multi-centre; US 182 Aged ≥6 years; deceased donor 
organ; stable graft function, low 
immunological risk. 
Tacrolimus. Cyclosporine 
1   
SF36; HS, CH, 
HO, HD - FSE; BPA 
Simmons (1987)  Single centre; US 91 Non-diabetic adults 1 year after 
transplantation. 
Cyclosporine plus 
prednisone.  
ATG plus prednisone plus 
AZA. 1   
PWB, EWB, SWB, 
HS - - 
Wang (1999)  Multi-centre; US 719 Aged ≥13 years and no prior use of 
immunosuppressive agents. 
2 mg sirolimus, 5 mg 
sirolimus.  
AZA 1   
SF36, health 
thermometer KTQ MHI 
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Table 3.1 cont. 
Study Setting No. of 
participant 
(n)  
Population Treatment Comparator Duration 
(years) 
QoL Outcome Generic 
Instrument(s) 
Disease Specific 
Instrument(s) 
Symptom Specific 
Instrument(s) 
1o 2o 
Trials of conversion or withdrawal of an agent 
Alvarez-
Amador (1996)  
Single centre; 
Mexico. 
20 Aged 15 - 60 years with stable 
graft for ≥6 months. 
Deflazacort   Prednisone 0.5   SIP, VAS VAS VAS 
Artz (2004).  Multi-centre; 
Holland. 
124 Stable graft ≥1 year duration and 
treated with cyclosporin. 
Conversion 
cyclosporin to 
tacrolimus 
No conversion 
2   - - MTSOSDS 
Budde et al 
(2002)  
Single centre; 
Germany 
23 Stable graft of ≥1 year duration 
treated with 
AZA/cyclosporine/prednisone 
Steroid withdrawal 
(MMF/cyclosporine). 
Steroid maintenance 
(AZA/cyclosporine/predni
sone 
4   
Welzel-Kohnen 
colour scales - - 
Hilbrands et al 
(1995)  
Single centre; The 
Netherlands. 
120 Aged <65 years and stable graft 3 
months after transplant.  
Steroid withdrawal 
(cyclosporine).  
Cyclosporine conversion 
(AZA and prednisone) 1   SIP - ABS, CES-D 
Kahan et al 
(2008)  
Single centre; US 46 Adults >6 months and <10 years 
post-transplant, treated with 
sirolimus and MMF. 
Immediate conversion 
from MMF to MPS.  
Delayed conversion. 
0.5   SF36 - GIQLI, GSRS 
Painter (2003)  Single centre; US. 23 Adult with unsensitised first 
transplant. 
Rapid steroid 
withdrawal  
Standard therapy. 1   SF36 - - 
Russ et al 
(2007)  
Multi-centre; 
international. 
430 Aged ≥13 years of age; receiving 
first or second transplant. 
Cyclosporine 
withdrawal (sirolimus 
plus steroid).  
Cyclosporine maintenance 
(Sirolimus plus 
cyclosporine plus steroid). 
3   
SF36, health 
thermometer KTQ - 
Shehata (2009)  Multi-centre; UK. 129 Adults with MMF gastrointestinal 
side effects. 
Conversion to EC-
MPS.  
Maintenance of MMF 0.25   SF36 - 
GSRS; GIQLI; 
OTE 
Sommerer et al 
(2011)  
Multi-centre; 
Germany 
128 Adults with stable graft function 
≥12 months after transplantation 
and low immunological risk. 
Intensified EC-MPS 
dose plus 
cyclosporine. 
Standard EC-MPS dose 
plus cyclosporine. 0.5   - - GSRS 
Walker (2007)  Single centre; 
Australia 
20 Aged ≥15 years and ≥3 months use 
of cyclosporine. 
Conversion to 
tacrolimus.  
Cyclosporine. 1   SF36 - VAS x 2 
Other trials 
Kumana (2003)  Multi-centre; Hong 
Kong. 
114 Adults treated with cyclosporine. Diltiazem plus 
cyclosporine. 
Placebo plus cyclosporine 0.5   SF36 - - 
Lee (2000)  Single centre; 
Taiwan. 
40 Adults greater than 1 year duration 
since transplantation treated with 
cyclosporine. 
Therapeutic drug 
monitoring service. 
Usual care 
0.5   SF36 - - 
Abbreviations; SF36 – Short Form-36; KTQ – Kidney Transplant Questionnaire; MTSOSDS - Modified Transplant Symptom Occurrence and Distress Scale; PWGBI – Physical Well Being Global Index; VAS – Visual Analogue Scale; 
EQ-5D – EuroQol-5D; MHI – Mental Health Index; CH – Current Health; HO – Health Outlook; HD – Health Distress; FSE – Flemming Self-Esteem; BPA – Bergner Physical Appearance; SIP – Sickness Impact Profile; ABS – Affect 
Balance Scale; CES-D – Centre for Epidemiologic Studies Depression scale ;GSRS - Gastrointestinal Symptom Rating Scale; GIQLI – Gastrointestinal Quality of Life Index; OTE – Overall Treatment Effect; PWB - Physical Well Being; 
EWB - Emotional Well Being; SWB - Social Well Being; HS - Health Satisfaction; CH - Current Health; HO - Health Outlook; HD - Health Distress; AZA – Azathioprine; ATG - Anti-thymocyte globulin; MMF - Mycophenolate mofetil; 
EC-MPS - enteric-coated mycophenolate sodium; CNI - calcineurin inhibitor. 
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Table 3.2. Quality of life instruments used in trials of maintenance immunosuppression in kidney 
transplantation. 
  
Instrument No. of trials Study reference 
Generic instruments 
PGWBI 2 (17,25)  
SF36 10 (20, 22, 24, 27, 32, 33, 34, 37, 38) 
SIP 2 (19, 31)  
EQ-5D 1 (17)  
EQ-5D VAS 1 (26) 
VAS - General health 2 (17, 19)  
Wenzel coloured scale 1 (30)  
Health thermometer 2 (18, 20)  
Disease specific (kidney transplantation) 
KTQ 2 (18, 20)   
VAS - impact of disease 1 (19) 
Symptom specific instruments 
VAS - impact of symptom 2 (19, 36)  
ABS 1 (31)  
CES-D 1 (31)  
FSE 1 (27)  
BPA 1 (27)  
MHI 1 (27)  
Study specific 2 (27, 28) 
GSRS 5 (25, 23, 32, 34, 35)  
GIQLI 4 (25, 23, 32, 34)  
MTSOSDS 2 (22, 29)  
Memphis Survey 1 (21)  
OTE 2 (23, 34)  
 
SF36 – Short Form-36; KTQ – Kidney Transplant Questionnaire; MTSOSDS - Modified Transplant Symptom 
Occurrence and Distress Scale; PWGBI – Physical Well Being Global Index; VAS – Visual Analogue Scale; 
EQ-5D – EuroQol-5D; MHI – Mental Health Index; CH – Current Health; HO – Health Outlook; HD – Health 
Distress; FSE – Flemming Self-Esteem; BPA – Bergner Physical Appearance; SIP – Sickness Impact Profile; 
ABS – Affect Balance Scale; CES-D – Centre for Epidemiologic Studies Depression scale ;GSRS - 
Gastrointestinal Symptom Rating Scale; GIQLI – Gastrointestinal Quality of Life Index; OTE – Overall 
Treatment Effect. 
 
Risk of bias  
Reporting was incomplete in most trials. Randomisation and allocation concealment was not 
defined in 14 (61%) trials; participants were blinded in 5 (22%) trials and outcome assessors 
were blinded in 3 (13%). Selective reporting was identified in 14 (61%) trials (Figure 3.2). 
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Overall risk of bias was classified as ‘very low’, ‘low’, ‘moderate’ and ‘high’ in 4 (17%), 4 
(17%), 6 (26%) and 9 (39%) trials. Of 12 trials published before 2007, 8 (67%) were assessed 
as having a ‘high’ risk of bias compared to 1 (9%) of 11 published after 2007.  
 
Reporting of QoL outcomes was incomplete for the majority of trials. A pre-defined 
hypothesis for inclusion of QoL outcomes and rationale for instrument selection was included 
in 18 (78%) and 16 (70%) trials respectively, however the psychometric properties and 
validity of the instruments for the study population was addressed by a minority namely 9 
(39%) and 8 (35%) trials respectively. Adequacy of QoL domains for the interventions and 
populations was addressed by 15 (65%) trials. The method of instrument administration, 
adequate baseline reporting and specification of timing of QoL assessments was addressed by 
12 (52%), 11 (48%) and 19 (83%) trials respectively while details of missing data were 
provided in 15 (65%). Only 4 (17%) addressed clinical significance of QoL outcomes, whilst 
selective reporting was evident in 15 (65%) (Figure 3.2). Overall the risk of bias was 
classified as ‘very low’, ‘low’, ‘moderate’ and ‘high’ in 6 (26%), 12 (52%), 2 (9%) and 3 
(13%) trials. Of 12 trials published before 2007 two (17%) were assessed as having a ‘high’ 
risk of bias compared to 1 (9%) of 11 trials published after 2007. 
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Alvarez-Amador 1996       High            Low 
Artz 2004       High            Low 
Baltar 2002       High            Low 
Bolin 2008       Moderate            High 
Budde 2002       High            High 
Dobbels 2011a       Very low            Low 
Dobbels 2011b       Very low            Low 
Hillbrands 1995       Moderate            Very low 
Kahan 2008       High            Low 
Kumana 2003       Low            Moderate 
Langone 2011       Very low            Very low 
Lee 2000       High            High 
Oppenheimer 2009       Moderate            Low 
Ortega 2011       Moderate            Low 
Painter 2003       Moderate            Low 
Polsky 2001       High            Low 
Russ 2007       Moderate            Very low 
Shehata 2009       Low            Very low 
Shield 1997       High            Low 
Simmons 1987       High            Low 
Sommerer 2011       Low            Low 
Walker 2007       Low            Low 
Wang 1999       Very low            Moderate 
 
Figure 3.2: Risk of bias of randomised controlled trials of maintenance immunosuppression in kidney 
transplant recipients that report quality of life outcomes. 
      - Yes.       - No.      - Partially addressed.       - Unclear. 
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Effects of immunosuppression medication on QoL 
Of the included trials, estimation of effect sizes for QoL outcomes was possible in 18 (3,919 
participants) with a total of 101 outcomes. Of these, 78 outcomes were from generic and 23 
from disease/symptom specific instruments (Table 3.1, Supplementary Tables S3 and S4 in 
Appendix A). Point estimate of the effect size favoured the intervention in 96 (95%) of the 
QoL outcomes (76 (97%) generic and 20 (87%) specific outcomes), with 37 (37%) 
statistically significant (at a threshold of P<0.05) (Figure 3.3a and 3.3b). In comparison, 41 
clinical outcomes were reported in the same 18 trials, and the point estimate favoured the 
intervention in 30 (73%) with 13 (31%) statistically significant (Figure 3.3c and 
Supplementary Table S5 in Appendix A).  
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Figure 3.3: Effect sizes (standardised mean differences or log risk ratios) and 95% confidence intervals for:  
(a) outcomes from generic quality of life instruments, (b) outcomes from disease and symptom specific quality of life instruments 
and (c) clinical outcomes.  SF36 – Short Form-36 (GH – general health, VT – vitality, PF – physical functioning, RP – role physical, BP – 
bodily pain, RE – role emotional, SF – social functioning, MH – mental health, MCS – mental component score, PCS – physical component 
score); KTQ – Kidney Transplant Questionnaire; MTSOSDS - Modified Transplant Symptom Occurrence and Distress Scale; PWGBI – 
Physical Well Being Global Index; VAS – Visual Analogue Scale; EQ-5D – EuroQol-5D; MHI – Mental Health Index; CH – Current Health; 
HO – Health Outlook; HD – Health Distress; FSE – Flemming Self-Esteem; BPA – Bergner Physical Appearance; SIP – Sickness Impact 
Profile; ABS – Affect Balance Scale; CES-D – Centre for Epidemiologic Studies Depression scale ;GSRS - Gastrointestinal Symptom Rating 
Scale; GIQLI – Gastrointestinal Quality of Life Index; OTE – Overall Treatment Effect; CrCl – creatinine clearance; SrCr– serum creatinine, 
SrCsA – serum cyclosporine; Gft – graft, AR – acute rejection; AE – adverse event; FGlu – fasting glucose ; Hirs – hirsutism, Trt - treatment.
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Sources of heterogeneity 
Subgroup analysis of the effect size of QoL outcomes accounting for outcome clustering 
within trials are shown in Figure 3.4. Overall the QoL outcomes did not vary with our 
hypothesised, study-level, sources of heterogeneity. The summary estimate of effect sizes for 
all QoL outcomes across all trials was 0.34 (95%CI: 0.22 to 0.46) (P<0.001) favouring the 
intervention.  The effect size for generic, disease-specific and symptom-specific instruments 
were 0.32 (95%CI: 0.20 to 0.43), 0.31 (95%CI: 0.16 to 0.46) and 0.39 (95%CI: 0.25 to 0.54) 
respectively.  
 
Smallest effect sizes occurred in trials having the lowest risk of bias for QoL reporting, 
longest duration (more than 24 months) and largest size (more than 250 participants) with a 
summary estimate of 0.13 (95%CI: -0.31 to 0.56), 0.13 (95%CI: -0.31 to 0.56) and 0.16 
(95%CI: -0.07 to 0.40) respectively.  In comparison effect sizes for trials with highest risk of 
bias, shortest duration (<12months) and smallest size (<50 participants) were 0.45 (95%CI: -
0.03 to 0.92), 0.40 (95%CI: 0.19 to 0.61) and 0.44 (95%CI: 0.23 to 0.65) respectively. 
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Sub Group
Number 
of 
Studies
Standardized 
mean 
difference(95%CI)
Risk of bias - RCT
        1 (high risk) 6 0.34 (0.15, 0.53)
        2 5 0.42 (0.22, 0.63)
        3 3 0.30 (0.02, 0.57)
        4 (low risk) 2 0.18 (-0.13, 0.49)
Risk of bias - QoL reporting
        1 (high risk) 1 0.45 (-0.03, 0.92)
        2 7 0.32 (0.14, 0.50)
        3 7 0.37 (0.19, 0.56)
        4 (low risk) 1 0.13 (-0.31, 0.56)
Size of trial
        <50 5 0.44 (0.23, 0.65)
        50-150 6 0.35 (0.17, 0.53)
        151-250 2 0.36 (0.07, 0.64)
        >250 3 0.16 (-0.07, 0.40)
Trial duration
        <12 months 5 0.40 (0.19, 0.61)
        12-24 months 9 0.33 (0.18, 0.49)
        >24 months 1 0.13 (-0.30, 0.56)
QoL Endpoint
        Primary 8 0.41 (0.25, 0.57)
        Secondary 8 0.27 (0.12, 0.42)
Type of instrument
        Generic 14 0.32 (0.12, 0.43)
        Disease specific 2 0.31 (0.16, 0.46)
        Symptom specific 9 0.39 (0.25, 0.54)
Trial setting
        Single centre 7 0.39 (0.21, 0.56)
        Multi centre 9 0.30 (0.16, 0.45)
Time since transplantation
        ≤1 year 8 0.27 (0.03, 0.51)
        >1 year 6 0.30 (0.10, 0.50)
Acute rejection
        <10% 6 0.40 (0.21, 0.59)
        10-30% 4 0.27 (0.33, 0.51)
        >30% 5 0.30 (0.10, 0.50)
All 16 0.34 (0.22, 0.46)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Effect size (standardised mean difference) and 95% confidence intervals for quality of life outcomes calculated for 
subgroups allowing for correlation of multiple outcomes within individual trials. 
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3.5. Discussion 
Complications associated with immunosuppressive drugs are known to adversely affect the 
QoL of kidney transplant recipients, however QoL outcomes are rarely reported in clinical 
trials of immunosuppressive agents in kidney transplantation. Only 1.8% of the reports of 
trials of maintenance immunosuppression included QoL outcomes.  There is inconsistency in 
how QoL is measured with 22 different instruments covering generic and, disease/symptom 
specific measures across the 23 trials. As these instruments provide measures of multiple 
domains including health status; physical, mental and social functioning; symptom frequency 
and distress; general well-being; psychological well-being and treatment satisfaction, it is 
difficult to make meaningful inferences of the impact of differing drug regimens on the QoL 
of kidney transplant recipients.   
 
Achieving differences in QoL outcomes and treatment effects between interventions that are 
meaningful to patients requires the magnitude of the change for an individual to be clinically 
and statistically reliable, that is, beyond the scope of what could reasonably be attributed to 
chance or measurement error. Few trials (17%) provided a basis for evaluating minimally 
important or clinically significant differences and the majority did not report a mean score or 
mean change in score from baseline, thus making interpretation of results problematic.  
Multiple approaches can be taken to defining minimally important differences (39) including 
a simple application of 0.5 times the standard deviation which has been shown to be robust 
for patient reported outcomes in-lieu of instrument derived values which would provide some 
guidance (40). Without this assessment it is difficult to assess whether differences reported 
are of practical or clinical significance. No trials reported differences in proportions of 
patients showing minimally important change which provides a more meaningful basis for 
interpreting likely individual benefits (41, 42). 
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Collectively, the selective outcome and/or reporting bias for QoL outcomes was apparent 
with almost all effect sizes (95%) favouring the interventions over the control groups.  This 
compares to the clinical outcomes where the effect size favoured the intervention for two 
thirds (66%) of the outcomes. We know that studies of better methodological quality are 
associated with reduced bias and smaller effect sizes (43, 44). However, in our review there 
were no significant associations between the magnitude of the summary effect size and trial 
and participant related factors including whether the QoL measure was a primary or 
secondary outcome. Whilst the subjective nature of patient reported outcomes may contribute 
to an exaggeration of treatment effects on QoL compared to objective clinical outcomes (5, 6) 
the observed bias in the QoL outcomes to favour the intervention is consistent with the 
known and common occurrence of outcome reporting bias in RCTs (45, 46). In addition to 
the methodological limitations this reporting bias further limits the ability to draw meaningful 
assessments of the relationship between differing regimens and QoL. The risk of bias 
assessment however, suggests an improvement in reporting quality (lower risk of bias) with 
time.  
 
Advances in immunosuppression after transplantation have led to a reduction in the incidence 
of acute rejection and improvement in short term graft survival, however, long term graft 
survival rates after kidney transplantation have remained largely unchanged (47). As a 
consequence the selection of immunosuppressive drugs best suited to an individual should 
involve an evaluation of outcomes associated with complications and harms including health 
outcomes such as cancer, diabetes and infections and QoL.  
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An editorial published in the Lancet in 1995 (48) noted three implicit assumptions in QoL 
outcomes in clinical trials: first, that we know what is being measured; second, that we 
understand why particular variables are being measured and thirdly, that the estimate is valid. 
Based on a review completed in 1994 (49) the editorial considered that there was strong 
evidence that all three assumptions are wrong. Polonsky (50) commented that many 
researchers use an arbitrary approach in selecting instruments choosing the most commonly 
used or they assume that QoL equates to psychosocial status and use measures indicative of 
depression and anxiety. Although QoL is increasingly measured in clinical trials, there is a 
lack of definition of what is being measured and inadequate attention to why or how it is 
being measured and reported. This has been confirmed in numerous systematic reviews of 
QoL outcomes in clinical trials across a range of diseases and interventions (8, 49, 51-58). 
Our analysis demonstrates that clinical trials in kidney transplant populations have also failed 
to address these issues (48).  
 
Limitations of QoL assessments in clinical trials from other clinical contexts are also 
apparent with inadequate justification of instrument selection, ad hoc reporting and lack of 
definition of clinically significant/minimally important differences (7, 16, 52-54, 56, 58-66). 
This is in spite of increasing recognition of the importance of patient reported outcomes in 
capturing the full impact of interventions and evidence for the clinical importance of QoL 
outcomes (67). Another consistent short coming is the use of population means for reporting 
QoL scores.  These are of limited relevance for an individual and trials rarely report measures 
such as the proportion of patients above and below a meaningful cut off value or the 
proportion that achieved a meaningful improvement or deterioration from baseline (39, 42, 
57).  
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Our study has potential limitations. Quality of life outcomes are commonly secondary 
outcomes or reported ad-hoc and therefore may not be indexed or found using a text word 
search, and so we may have missed some eligible trials. Screening of abstracts and titles may 
exclude trials that have reported QoL outcomes. We evaluated this possibility by randomly 
selecting 200 full text articles from the 1,566 citations excluded on the basis of abstracts and 
titles none of which reported any QoL outcome. This increases the confidence that the review 
strategy has identified the overwhelming majority of trials reporting QoL outcomes. 
Secondly, the meta-analysis of effect sizes compared multiple outcomes from single trials as 
well as different QoL measures, populations and interventions. This is a consequence of the 
very broad criteria for identifying a QoL outcome which resulted in the inclusion of multi-
domain instruments down to simple scales assessing the severity of a single symptom. 
However, the focus of the review was the frequency and reliability of reporting of QoL 
outcomes rather than assessment of the association between interventions and QoL. The 
standardised mean difference has been used to provide a basis for assessment of bias 
associated with outcome reporting as well the magnitude of effect across instruments and 
studies. Relationships between the magnitude of pooled effect size and trial characteristics 
also provides information relevant to the assessment of reporting bias. The summary 
assessments assumed that outcomes within trials were correlated thereby limiting the 
potential for trials with multiple outcomes to dominate the pooled effect size.  Finally, the 
small number of trials may limit the ability to identify statistically significant associations 
between effect size and study and patient related factors. 
 
Kidney transplant recipients are willing to tolerate serious adverse outcomes such as cancer 
and cardiovascular disease and potentially debilitating side effects in order to maximise graft 
survival (68). However, to do this they need to be informed not only of the prevalence of 
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serious adverse events but also the severity and impact of these side effects on their quality of 
life, and this can only be achieved by inclusion of relevant patient reported outcomes in 
clinical trials and utilization of reporting standards that focus on providing clinically 
meaningful assessments (57, 69, 70). In short, inclusion of patient reported outcomes in 
clinical trials should pay particular attention to identifying outcomes that are relevant to the 
intervention and the patient, providing a measure that is both valid and meaningful and 
reporting data that can be interpreted in terms of clinically relevant differences for 
populations and individuals. The core outcome measures in effectiveness trials (COMET) is 
an international initiative fostering a consensus approach to development of consistent 
measures and reporting requirements for patient important outcomes that should be applied to 
clinical trials in the kidney transplant population (71).  
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4. Completeness of reporting of adverse events in trials of 
maintenance immunosuppression in kidney 
transplantation: a systematic review. 
 
The material contained in this chapter has been submitted for publication as: Howell, M., R. 
Yeo, A. Tong, J. C. Craig, K. Howard and G. Wong (2016). "Completeness of reporting of 
adverse events in trials of maintenance immunosuppression in kidney transplantation: a 
systematic review." Submitted to the American Journal of Kidney Disease. 
 
The structure reflects the journal requirements. 
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4.1. Abstract 
Background: Decision-making regarding immunosuppression after transplantation relies 
upon robust evidence on the benefits and harms of available drugs. We aimed to evaluate the 
reporting of adverse events in trials of maintenance immunosuppression in kidney 
transplantation.  
Study design: Systematic review and appraisal against the 23 item harms-extension of the 
Consolidated Standards of Reporting Trials statement.  
Setting & population: Kidney transplant recipients. 
Selection criteria: Randomised controlled trials in the Cochrane Kidney and Transplant 
Register (January 2003 to December 2015). 
Intervention: Maintenance immunosuppression. 
Outcomes: Reporting of adverse events. 
Results: Of 233 trials, 163(69%) reported at least one adverse event. Only 17(10%) provided 
definitions or justified the adverse events, 13(8%) described methods and 27(17%) measured 
severity. Forty adverse event types were reported with gastrointestinal the most common 
(116, 71%). Frequency of reporting did not reflect known drug side effect profiles. For 
example, of 90 calcineurin inhibitors trials, only 22% reported tremors, 3% paraesthesia, and 
none anxiety, aggression or mood swings. Trials that reported at least one adverse effect were 
more likely to be industry funded (adjusted OR 7.6:95%CI:3.4 to 17.1), multi-centre (5.9:1.7 
to 18.7), and with follow-up time less than 24 months (3.7:1.4 to 10.2).  
Conclusions: Adverse events in kidney transplant immunosuppression trials appear to be 
selectively reported and may be unreliable for clinical decisions. Adherence to the 
CONSORT harms-extension should be mandatory to ensure transparent reporting of adverse 
events that are important to patients and clinicians. 
 
Chapter 4. Adverse Events – Systematic Review 
 
109 
4.2. Introduction 
Kidney transplantation improves survival and quality of life outcomes in many patients with 
end-stage kidney disease (1). However, the side effects of maintenance immunosuppression 
following transplantation may have a detrimental effect on patient well-being and are 
associated with non-adherence, which can lead to graft loss (2-6). Recommendations for the 
choice of maintenance immunosuppression after transplantation are largely based on the 
improvements in acute rejection, graft function, graft loss and mortality from trial-based 
evidence (7). The potential toxicities of these agents are considerable. Understanding the net 
benefits associated with a treatment regimen requires knowledge of adverse effects as well as 
benefits (8).  
 
Inadequate reporting of adverse events in trials has been well-recognised (9), and in response, 
the harms extension of the Consolidated Standards of Reporting Trials (CONSORT) 
statement (10) was developed and has been widely adopted (11). An adverse event refers to 
any undesirable effect of an intervention including serious outcomes and drug related side 
effects (11, 12). In trials of maintenance immunosuppression following kidney 
transplantation, reporting of harms such as infection, diabetes, cardiovascular disease, and 
cancer, as well as quality of life, has been shown to be infrequent, incomplete and of poor 
quality (15-19), while the reporting of drug related side effects has not been assessed. 
Reporting of harms in clinical trials may be limited by the need for extended follow-up and 
the rarity of the harm (13), however, drug related side effects generally occur within a short 
time frame and can affect a sizeable proportion of patients (14). 
 
The aim of our study was to determine the completeness of reporting of adverse events, 
specifically drug related side effects, in randomised controlled trials of maintenance 
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immunosuppression in kidney transplantation. Knowledge of the frequency and completeness 
of reporting of drug related side effects in clinical trials can inform both patient-centred 
research and care. 
 
4.3. Methods 
Literature search and inclusion criteria 
We searched the Cochrane Kidney and Transplant Specialist Register from January 2003 to 
December 2015 for all randomised controlled trials of maintenance immunosuppression in 
kidney transplant recipients published in peer reviewed journals using text words related to 
kidney transplantation and immunosuppression. This search was limited to 2003 to focus on 
trials relevant to contemporary practice in maintenance immunosuppression. Titles and 
abstracts were reviewed, and the full text of all relevant trials retrieved. Comparative trials 
between immunosuppressive medications, withdrawal or substitution of an 
immunosuppressive agent from multiple drug regimens or variation in doses or schedules of 
one or more drugs were eligible. There was no restriction by language of trial report or age of 
recipients. Non-randomised trials and trials published only as abstracts in proceedings of 
meetings and conferences were excluded. Trials of novel or experimental immunosuppressive 
agents and patients undergoing multiple organ transplants were also excluded. 
 
Outcome measures 
From eligible studies, all drug related adverse events, defined as any undesirable symptom or 
side effect, were included (11, 20). As the focus of this study was on side effects directly 
related to drugs rather than outcomes that have a more complex causal pathway, we did not 
include harms such as malignancy, diabetes, or cardiovascular disease or adverse events such 
as effects on blood pressure and biochemical outcomes.  
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Appraisal of completeness of reporting of adverse events 
Because there is no standardised tool for the assessment of quality of reporting of adverse 
events, we used the approach recommended by Mahady et al (12) in their review of adverse 
events reporting in systematic reviews. In this approach the harms extension of the 
Consolidated Standards of Reporting Trials (CONSORT) statement (11) is used as a checklist 
for reporting quality as it “..captures many aspects such as clearly defining adverse events, 
providing numerical data on incidence, and recording methods of data collection”.(12) The 
checklist consists of 23 criteria covering 10 domains addressing definition of adverse events, 
methodology of data collection, and reporting (see Appendix B Supplementary Table S1). 
Each trial that reported relevant adverse events was reviewed against the checklist and 
compliance was recorded for each criteria (yes, no or not applicable). Where trials were 
reported in multiple publications, the full-text of each report was reviewed and only the 
publications reporting unique adverse events were selected as the basis for review of 
compliance with the checklist. 
 
Data extraction and synthesis 
A standardised spreadsheet was used by two researchers (MH and RY) to extract 
characteristics for all trials and adverse event outcomes. Where trials were reported in 
multiple publications, all were reviewed to capture all adverse events reported for that trial as 
adverse events may not be reported in the first publication and later reports may include 
adverse events unique to that report. A trial was identified as not reporting adverse events if 
no details about any adverse event were available from all publications of that trial. For each 
trial reporting adverse events the adverse event(s) at the level of detail provided was 
recorded. For example, gastrointestinal symptoms may be reported as a gastrointestinal 
disorder or as specific symptoms such as diarrhea and nausea. Where an adverse event was 
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not associated with a specific symptom or for example reported simply as an ‘adverse event’ 
or ‘pain’, it was recorded as ‘not defined’. The reporting of types of adverse events by trials 
was recorded as a binary outcome. 
 
We evaluated the characteristics of trials that we postulated may be associated with the 
completeness of reporting adverse events based upon similar studies undertaken in other 
disciplines (12, 13, 21-25). Characteristics included source of funding, type of intervention, 
trial setting, study population (adults/children), year of publication, size of trial, duration of 
trial, and the journal type (specialist transplant, specialist nephrology, other). Associations 
between these characteristics and reporting of any adverse events were assessed using 
univariable and multivariable logistic regression. Variables that had an association with the 
reporting of adverse events at p< 0.20 in the unadjusted analyses were included in the 
multivariable-adjusted analyses. The least significant variables were then removed from the 
base model using a step-wise backward elimination process until only variables with p< 0.05 
remained in the final parsimonious model. All calculations were undertaken on the basis of 
the number of trials rather than publications using IBM SPSS version 22 software.  
 
4.4. Results 
Characteristics of included trials 
Overall, 314 published reports of 233 trials including 45,896 patients fulfilled the inclusion 
criteria (Figure 1). One hundred and fifty-six (67%) trials were industry funded, 198 (85%) 
enrolled adult kidney transplant recipients only, and 133 (58%) focused on interventions 
involving calcineurin inhibitors (Table 1). Most were relatively small with 143 (61%) 
including fewer than 150 participants, and of short duration with 145 (62%) being less than 
24 months follow up. 
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Figure 4.1: Flowchart showing process of identification of trials for inclusion in review. 
 
Full text review 
Excluded (n=125) 
Intervention not relevant  65 
Not an RCT   26 
Other   23 
Multiple organ transplants  11 
Relevant 
233 trials (314 reports) 
Citations (Cochrane 
Kidney and Transplant 
Register) 
n=1,696 
Citations 
n=439 
Title and abstract review 
Excluded (n=1,257) 
Meetings and conferences  859 
Not a randomized controlled trial     380 
Duplicates                                              18 
Adverse events reported 
163 trials (total 197 reports - 184 
reports included at least one unique 
adverse event) 
Adverse events not reported 
70 trials (112 reports) 
Chapter 4. Adverse Events – Systematic Review 
 
114 
Table 4.1 Characteristics of included trials of interventions of maintenance 
immunosuppression following kidney transplantation. 
 
Characteristic 
Trials that did not 
report any adverse 
trials  
N = 70 (%) 
Trials that reported 
any adverse event 
 
N = 163 (%) 
Total (%) 
P 
Year of publication     
  2003-2004 19 (27) 36 (22) 55 (24) 0.24 
  2005-2006 19 (27) 30 (18) 49 (21)  
  2007-2008 12 (17) 34 (21) 46 (20)  
  2009-2010 8 (11) 28 (17) 36 (16)  
  2011-2012 5 (7) 18 (11) 23 (10)  
  2012-2015 7 (10) 17 (10) 24 (10)  
Funding     
   Industry 21 (30) 135 (83) 156 (67) <0.001 
   Not stated 17 (24) 12 (7) 29 (12)  
   Non industry 32 (46) 16 (10) 48 (21)  
 Setting     
   Single centre  46 (66) 45 (28)  91 (39) <0.001 
   Multicentre – single country 20 (29) 55 (34) 75 (32)  
   Multicentre - international 4 (6) 63 (39) 67 (29)  
Duration - months     
  <12  13 (19) 43 (27) 56 (25) 0.01 
  12-23  21 (31) 68 (42) 89 (39)  
  24-47  16 (24) 38 (24) 54 (24)  
  ≥48  18 (27) 12 (8) 30 (13)  
No. participants     
  <50 23 (33) 22 (14) 45 (19) 0.002 
  50-99 17 (24) 30 (18) 47 (20)  
  100-149 14 (20) 37 (23) 51 (22)  
  150-199 2 (3) 16 (10) 18 (8)  
  200-499 13 (19) 41 (25) 54 (23)  
  >500 1 (1) 17 (10) 18 (8)  
Population     
  Adults 61 (90) 137 (84) 198 (85) 0.13 
  Adults and children 3 (4) 20 (12) 23 (10)  
  Children 4 (6) 4 (3) 8 (9)  
  Not stated 0 (0) 2 (1) 2 (1)  
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Table 4.1 (cont.) 
Characteristic 
Trials that did not 
report any adverse 
trials  
N = 70 (%) 
Trials that reported 
any adverse event 
 
N = 163 (%) 
Total (%) 
P 
Interventions (type/dose)     
  CNI Sparing 19 (27) 57 (35) 76 (33) 0.03 
  CsA v 17 (24) 24 (15) 41 (18)  
  Steroid sparing 16 (23) 24 (15) 40 (17)  
  mTORi 5 (7) 24 (15) 29 (12)  
  Mycophenolate 5 (7) 21 (13) 25 (11)  
  CNI other 9 (13) 9 (6) 18 (8)  
  Belatacept 0 (0) 4 (3) 4 (2)  
Journal     
  Specialist transplant  51 (73) 135 (83) 186 (80) 0.02 
  Specialist nephrology 12 (17) 14 (9) 26 (11)  
  General medical 10 (14) 14 (9) 21 (9)  
Number of adverse event reported     
  1  29 (18)  NA 
  2  21 (13)   
  3 to 4  34 (21)   
  5 to 8  53 (33)   
  9 to 22  26 (16)   
 
* - Pearson χ2. CNI – calcineurin inhibitors, CsA – cyclosporine, Tac – tacrolimus, mTORi – 
mTOR inhibitors. 
 
 
Adverse events  
A total of 163 (70%) trials including 36,523 (80%) patients, published in 197 reports, 
reported at least one adverse event (Table 1). Of the 163 trials, 22 (13%) reported adverse 
events in more than one report. Overall, 40 different types of adverse events were reported, 
ranging from 1 to 22 (mean 4.9 standard deviation 4.0). The most frequently reported adverse 
events (Figure 2) were gastrointestinal symptoms in 116 (71%) trials, ranging from 58% of 
the 26 steroid-focused trials to all of the 21 mycophenolate and all of the four belatacept 
trials. (Table S2 and S3, and Figure S1 in Appendix B). The next four most commonly 
reported adverse events were peripheral oedema (55, 34%), skin disorders (42, 26%), non-
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specified ‘adverse events’ (38, 23%), and tremor (37, 23%). Of the 40 adverse events 
reported, 26 (65%) were reported in fewer than 16 (10%). Five adverse event types were 
generic or non-specified namely, ‘adverse events’, ‘nervous system disorders’, ‘general 
disorders’, ‘pain (not defined)’, ‘psychiatric disorders’ and ‘appearance change’ and were 
reported in 72 (44%) of the 163 trials. Other poorly defined categories were reproductive and 
rectal disorders reported in less than 4 reports.  
 
Figure 4.2. Adverse events reported plotted as the proportion of the 163 trials that reported at 
least one adverse event. ‘Adverse events’, ‘nervous system disorders’, ‘general disorders’, 
‘pain (not defined)’, ‘psychiatric disorders’, and ‘appearance disorders’ are all unspecified.  
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Figure 2 shows the frequency of adverse event types reported across all 163 trials and 
supplementary Table S2 and Figure S1 in Appendix B shows the breakdown according to 
intervention drugs. The most frequently reported adverse events in the calcineurin inhibitor 
trials (n=90, 18913 patients) were gastrointestinal disorders (61%), peripheral oedema (39%), 
skin disorders (28%), tremor (24%), gingival overgrowth (24%), and non-specified adverse 
events (23%). Paraesthesia, a common and known side effect, was reported in only 3% of the 
trials and no trial reported anxiety, aggression or mood swings. All mycophenolate trials (n = 
21, 4235 patients) reported gastrointestinal disorders with the next most common being non-
specified adverse events (14%), pain (headache) (14%), pain (abdominal) (14%), and 
gingival overgrowth (10%). In the mTOR inhibitor trials (n=24, 6497 patients) the most 
commonly reported adverse events were gastrointestinal disorders (92%), peripheral enema 
(58%), skin disorders (46%), oral (other than gingival overgrowth) (42%), and pain 
(musculoskeletal) (33%). All belatacept trials (n=4, 1297 patients) reported gastrointestinal 
disorders and tremor, while peripheral oedema was reported in 75% of the trials. All of the 
remaining adverse events (n=8) were reported in one trial. The most commonly reported 
adverse events in the steroid sparing trials (n= 24, 5581 patients) were gastrointestinal 
disorders (58%), undefined ‘adverse events’ (46%), tremor (25%), skin disorder (21%), and 
pain (musculoskeletal) (21%) which is similar to the calcineurin inhibitors trials in turn 
consistent with cyclosporine or tacrolimus being common to the interventions in these trials. 
Predictors for reporting 
The association between trial characteristics and the odds of reporting adverse events in trials 
are summarised in Table 2. In the final adjusted model, predictors of reporting adverse events 
were, industry funding (adjusted odds ratio 7.62, 95%CI:3.39 to 17.1), multicentre studies 
(5.93, 1.72 to 18.65), duration of follow-up less than 24 months (3.71, 1.35 to10.16) and 
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publication in a specialist transplant journal (3.90, 1.40 to 10.88). The year of publication was 
not associated with reporting of adverse events. 
Table 4.2. Association between reporting of any adverse event and characteristics of trials  
 
Characteristic 
Univariate 
Odds Ratio* (95%CI) 
Adjusted 
Odds Ratio* (95%CI) 
Year of publication   
   2003-2005 1 - 
  2006-2008 1.21 (0.60-2.42) - 
  2009-2011 1.88 (0.82-4.33) - 
  2011-2015 1.37 (0.60-3.14) - 
   
Funding   
   Non industry 1 1 
   Industry 10.78 (5.63-20.65)** 7.62 (3.39-17.10)** 
   
    
 Setting   
   Single centre  1 1 
   Multicentre - international 14.67 (4.94-43.65)** 5.93 (1.72-18.65)** 
   Multicentre – single country 2.83 (1.47-5.48)** 1.24 (0.55-2.81) 
    
 Duration - months   
<24 4.85 (2.13-11.08)** 3.71 (1.35-10.16)** 
24-35 3.66 (1.44-9.30)** 2.50 (0.81-7.73) 
>36 1 1 
   
No. participants (n)   
<100 1 - 
100-199 2.55 (1.27-5.10)** - 
>200 3.19 (1.56-6.51)** - 
   
Interventions (type/dose of immunosuppression)   
  CNI 1  
  Mycophenolate acid 2.68 (0.87-8.28) - 
  mTORi 3.07 (1.00-9.37)** - 
  Belatacept 2.04 (0.22-18.82) - 
  Steroid sparing 0.82 (0.39-1.71) - 
   
Journal    
  Specialist nephrology 1 1 
  Specialist transplant  2.67 (1.17-6.08)** 3.90 (1.40-10.88)** 
  General medical 1.3 (0.43-3.94) 4.71 (1.15-19.20)** 
   
 
 
* - Odds ratio values greater than 1 indicate factor to be positively association with trials reporting any adverse event. 
** - P<0.05 
CNI – calcineurin inhibitors, mTORi – mTOR inhibitors. 
 
Chapter 4. Adverse Events – Systematic Review 
 
119 
Completeness of reporting  
Compliance with the harms extension of the CONSORT checklist for the 163 trials that 
reported adverse events is summarised in Figure 2. The lowest area of compliance was found 
in domains relating to the definition, measurement and collection of adverse events (domains 
3 and 4). Only 24 (15%) of the trials listed the adverse events, 17 (10%) provided justification, 
17 (10%) provided definitions, 27 (17%) measured severity), 8 (5%) described the instrument, and 
13 (8%) described the method of collection and whether the event was reported by the 
patient, clinician or researcher. Less than half of all studies (n= 63, 39%) described the 
methodology for presentation and analysis of adverse events (item 5). The majority (146, 
90%) of trials provided quantitative data with, 118 (72%) tabulating adverse events and 134 
(82%) reported separate results for each trial arm. No studies undertook subgroup analysis 
(item 9). Despite a high level of compliance in reporting withdrawal (n=130, 80%), 53 (33%) 
did not give the reasons for withdrawal. Adverse events were included in the discussions of 
129 (79%) of the trials (item 10a), while in 79 (48%) trials adverse events were judged to 
have influenced the conclusions (item 10b) either positively or negatively. 
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Figure 4.3. Proportion trials that reported any adverse event complying with the harms 
extension of the Consolidated Standards of Reporting Trials (CONSORT) statement. AE- 
adverse event. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
10b AEs in conclusion
10a AEs in discussion
9 Sub group analysis
8c Report for trial arms
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2a Introduction
1b Abstract
1a Title
Proportion  complying with CONSORT Harms Extension item.
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4.5. Discussion 
Side effects associated with maintenance immunosuppression after kidney 
transplantation are common and have the potential to profoundly impact on the 
quality of life of kidney transplant patients (14, 26). However, we have shown that 
this is not reflected in the reporting of adverse events in trials of these interventions, 
with about a third of all trials not reporting any drug related adverse effect. Without 
access to the individual patient study data we are unable to determine whether this is 
because no adverse effects were experienced by any participating patient or that 
adverse effects were either not measured or reported (or both). The former 
explanation is implausible, and so we can conclude there is substantial under-
reporting of drug related adverse events. Of concern there does not appear to be any 
improvement over time, but industry funding, multi-centre design, and publication in 
a specialist transplant journal increase the likelihood of reporting at least one adverse 
event. Furthermore, even trials that reported adverse events were deficient in a 
number of important areas, including providing definitions and/or justification for the 
adverse events reported, measurement and definition of severity, describing the 
methodology used to measure or collect the adverse events. Despite the lack of 
justification and detail on definition and methodology, adverse events were included 
in discussions of nearly 80% of the trials and were judged to have influenced the 
conclusions, either positively or negatively in just under half.  
 
Outcomes were reported in very heterogeneous ways, with 40 different types of 
adverse events recorded. Of these 26 were reported in fewer than 10% and 16 in less 
than 2% of trials reporting one or more adverse events. Gastrointestinal disorders 
were the most frequently reported adverse event (70% of the trials). The reporting 
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within trials for single classes of drugs suggests selective reporting and/or recording 
of adverse events. For example, in the calcineurin inhibitor trials, 36 different adverse 
events were reported of which 21 (58%) were reported in fewer than 10% of those 
trials reporting adverse events. In trials focused on mycophenolate, gastrointestinal 
disorders were reported in all of the trials, with only three other adverse events 
reported in more than 10% of these trials. 
 
The frequency of reporting of adverse events casts further doubt on reliability of 
reporting and whether the adverse events reported provide an appropriate reflection of 
drug related side effect profiles. Moreover, while gastrointestinal disorders were most 
frequently reported, unspecified adverse events such as ‘adverse event’ or ‘psychiatric 
disorder’, accounted for almost half (44%) of all adverse events report which further 
limits the value of the adverse event data. The deficiencies in reporting have 
implications when interpreting results as an absence of an adverse event reported in a 
trial, as this may reflect a true absence of an adverse event, or due to a lack of 
measuring and/or reporting a potentially relevant finding.  
 
The most frequently occurring outcomes in reviews of observational studies are 
unusual hair growth, acne, muscle weakness, bruising, sleeplessness, depression 
fear/anxiety, tremors, gum disorders, swollen and painful joints, fatigue, and 
impotence (14, 26). The top 10 most frequent symptoms reported in a 2009 review of 
five kidney transplant observational studies did not include gastrointestinal disorders 
the most frequently reported in our review (14). However, diarrhea was recorded as 
the fifth most distressful symptom in one study. These findings are inconsistent with 
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the adverse events recorded in review and further suggest underreporting in 
randomised controlled trials.  
 
The harms extension of CONSORT was published in 2004 in response to consistent 
empiric studies that highlighted inadequacies in reporting of adverse events (11, 13). 
Subsequent systematic reviews have continued to show inadequacies in reporting of 
adverse events across a range of disciplines. For example reviews of 60 randomised 
trials on interventions for persistent depressive disorder (24), 290 solid organ 
transplant trials published between 2007 and 2009 (23), 956 oncology trials published 
over the periods 2005-2007 and 2010-2012 (22), and 49 randomised controlled trials 
of antiretroviral therapy published between 2000 and 2008 (13) all showed major 
deficiencies in reporting with no evidence for improvement with time. Similar 
findings have been reported for trials in gastroenterology (12), cancer drug trials (25, 
27), urology(21), and for trials published in high impact journals (28). Many studies 
have noted the subsequent impact of poor adverse event reporting on systematic 
reviews and meta-analyses (12, 29-32).  
 
A particular strength of our study was that all of the reports of randomised controlled 
trials of maintenance immunosuppression were subject to full text review thus 
maximizing the potential of detecting all adverse events reported. Nonetheless 
adverse events are difficult to search for being either secondary or ad hoc outcomes 
(29, 33) and may not be indexed or easily found using text word searches. To address 
this, the criteria for exclusion of studies from full text review was limited to meetings 
and conferences, and duplicates. The search dates included trials that started before 
publication of the CONSORT harms extension and compliance with the checklist may 
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therefore provide a misleading assessment of reporting quality. The harms extension 
was published in 2004 (11), and poorer compliance might be expected for trials 
published before 2007 given that most of these are likely to have commenced before 
2004. Despite the time lag, compliance amongst trials published after 2007 remained 
poor, lacking in the reporting of key domains such as justification, definition and 
methodology. The majority of the trials in this review are of relatively short duration 
and adverse events may not occur within the time frame of a trial (13), however the 
focus of our review was on drug related side effects that occur within a short time 
frame. 
 
4.6. Conclusions 
 
It appears that reporting of adverse events in randomised trials of immunosuppression 
following kidney transplantation is generally inadequate. Adverse events are often 
poorly defined and lack description of how they are measured, and expected, common 
side effects rarely reported. As a consequence, despite the large number of 
randomised trials, it is very difficult to draw meaningful conclusions as to the 
frequency and severity of side effects associated with current treatment regimens. 
This is of particular concern as patients tend to under report side effects to healthcare 
professionals, who may also under estimate the frequency and importance of side 
effects (34-36). Transplant patients are willing to accept drug related side effects as a 
necessary downside of maintenance immunosuppression (37), however, particularly 
in the context of shared decisions, this should be underpinned by knowledge of the 
likely frequency and severity of the side effects. As a minimum, reporting of adverse 
events in trials should adhere to key domains of the CONSORT harms extension in 
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particular definition, justification, collection methods, and reporting. Attention should 
be given to adverse events that are commonly experienced or important to patients as 
this can inform patient-centred clinical decision-making. 
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APPENDIX B  
Supplementary Material 
Table S1. Harms extension of CONSORT Checklist 
Table S2. Adverse events reported in trials published between January 2003 and 
December 2015 of interventions of maintenance immunosuppression following 
kidney transplantation.   
Figure 1S. Adverse events reported in randomised controlled trials of maintenance 
immunosuppression in kidney transplant patients plotted as the proportion reporting 
the adverse events (a) All trials n=163, (b) calcineurin inhibitors n=90, (c) mTOR 
inhibitors n= 24, (d) mycophenolic acid n=21(e) belatacept n=4, (f) steroid sparing 
n=24. The following adverse events are unspecified; adverse events, nervous system 
disorders, general disorders, pain (not defined), psychiatric disorders, and appearance 
disorders 
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5. Eliciting patient preferences, priorities and trade-offs for 
outcomes following kidney transplantation: a pilot best-
worst scaling survey. 
 
The material contained in this chapter has been published as: Howell, M., G. Wong, J. Rose, 
A. Tong, J. C. Craig and K. Howard (2016). "Eliciting patient preferences, priorities and 
trade-offs for outcomes following kidney transplantation: a pilot best–worst scaling survey." 
BMJ Open 6(1). 
 
The structure reflects the journal requirements. 
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5.1. Abstract 
Objectives: Eliciting preferences, and trade-offs patients may make to achieve important 
outcomes, can assist in developing patient-centred research and care. The pilot study aimed to 
test the feasibility of a Case 2 best-worst scaling survey (BWS) to elicit kidney transplant 
recipient preferences after transplantation. 
Design: Preferences for graft survival and dying, cancer, cardiovascular disease, diabetes, 
infection, and side-effects (gastrointestinal, weight-gain and appearance) were assessed in 
transplant recipients using a BWS (20 scenarios of nine outcomes). Participants chose ‘best’ 
and ‘worst’ outcomes. Responses were analysed using a multinomial-logit model. Selected 
participants were interviewed.  
Outcomes: Attribute coefficients and survey completion error rates. 
Results: Eighty-one transplant recipients were approached, and 39 (48%), mean age 50.5 
years, completed the BWS. Four (10%) surveys were invalid with major errors and of 35 
remaining, 7 of 1400 (0.5%) choices were missing. Twenty three (59%) took >20 minutes to 
complete the survey.  One was unable to finish and one did not understand the survey. Two 
(5%) very hard and 14 (35%) moderately hard. Most attribute coefficients were significant 
(P<0.05) and showed face validity. Graft survival was most important with normalised 
coefficients from 1 (95%CI:0.89,1.11) to 0.06 (95%CI:-0.03,0.16) for 30 and 1 year duration 
respectively. Attribute level coefficients decreased with increasing risk of adverse outcomes. 
Error rates of 20% and 2% were estimated for dominant attributes ‘100% risk of dying’ and 
‘30 years graft survival’ respectively. Seven participants were interviewed regarding counter 
intuitive selection of ‘100% risk of dying’ as a ‘best’ outcome. Misunderstanding, not linking 
dying to graft survival, and aversion to dialysis were reasons given.  
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Conclusion: Transplant recipients successfully completed a complex Case 2 BWS with 
attribute coefficients having face validity with respect to duration of graft survival and risk of 
adverse outcomes. Areas for refinement to reduce complexity in design have been identified. 
 
5.2. Introduction 
Compared to dialysis, kidney transplantation offers improved survival and quality of life in 
most patients with end-stage kidney disease, but lifelong immunosuppression is required to 
maintain graft function. Immunosuppression is not without harms and may lead to 
bacterial/fungal or viral infections, post-transplant diabetes mellitus and malignancy (1-3). 
Prior research has quantified the frequency and severity of adverse effects associated with 
long-term immunosuppression (4-7), and there is a body of evidence showing that kidney 
transplant recipients have a strong focus on graft survival, an aversion to returning to dialysis, 
and a willingness to accept side effects and adverse outcomes as being a necessary part of the 
treatment (8-12). However, no studies have quantified the trade-offs patients may be willing 
to make to reduce the impact of debilitating side effects or adverse events such as cancer 
through minimisation or withdrawal of immunosuppression and the risk of graft dysfunction. 
To date, as with many chronic diseases, treatment decisions have been predominantly driven 
by clinicians with little patient involvement (13-17) thus understanding patient preferences 
and trade-offs is key to facilitating communication and shared decisions.  
 
Understanding patient preferences and values are important to effective communication and 
facilitating informed and shared decisions that recognise the variation in tolerance of risk (18-
20). Whilst preferences reflect an individual’s tastes (likes or dislikes) and ideals (personal 
values and commitments), they will also reflect their reference point (such as having 
experienced dialysis or not), psychological traits (imaginative capacity, optimism, inertia), 
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social influences (norms and laws, influence of family and friends), and beliefs 
(understanding of the likelihood and consequences of an outcome) (21, 22). In the context of 
a complex and long-term treatment that involves trade-off between potentially debilitating 
side effects and adverse outcomes of immunosuppression and graft dysfunction, clinicians 
can have a substantial influence on patient preferences through the content and style of 
communication (18). Understanding the extent to which patient preferences are underpinned 
by personal beliefs and how they vary with factors such as age, gender, and previous and 
current health states, provides a basis for identifying potentially erroneous beliefs (11, 23) 
and the development of communication strategies best suited to facilitate construction of 
preferences that align with the transplant recipient’s own values (24, 25). 
 
The aim of this pilot study was to evaluate the feasibility of best worst scaling  (BWS), a type 
of discrete choice experiment (26), to elicit kidney transplant patients’ preferences, priorities 
and trade-offs in outcomes following transplantation.  In contrast to conventional discrete 
choice experiments, some authors have suggested that BWS offer a number of potential 
advantages relevant to the assessment of complex treatment outcomes (27) including 
statistical efficiency (28, 29), the ability to estimate attribute level coefficients on a common 
scale allowing for direct comparison both between and within attributes, and may also be less 
cognitively demanding than conventional discrete choice or ranking experiments (30). For 
these reasons, there has been growing interest in the use of BWS surveys in health related 
research (27).  However, the application of BWS surveys to complex treatment regimens, 
such as transplant immunosuppression, has not been undertaken previously.    
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5.3. Methods 
Participant selection 
Adult kidney transplant patients (aged ≥18 years) attending a single transplant centre in 
Sydney, Australia were eligible to participate.  Respondents could complete the survey while 
attending the out-patient clinic, by phone or by email. The survey was in English and non-
English speaking patients were excluded. Ethics approval was obtained from the Human 
Research Ethics Committee of the Western Sydney Local health Network, NSW Health 
(HREC2009/6/4.15 (2956) AU RED09/WMEAD/56). 
 
Best-Worst Scaling Methodology 
Best worst attribute scaling or ‘Case 2’ BWS (26, 27) methodology was used. A ‘Case 2’ 
BWS requires participants to choose the best and worst attribute from a single multi-attribute 
profile (26). Preferences for attributes are inferred from the choices made within the multi-
attribute profiles rather than from choices made between multi-attribute profiles as is the case 
for traditional discrete choice experiments. Unlike discrete choice experiments, a BWS 
provides estimates of attribute level coefficients on a common scale allowing direct 
comparison of attribute levels within and between attributes. Utility functions are constructed 
and estimated in accordance with random utility theory as for discrete choice experiments, 
however with a BWS the utility functions are constructed for individual attributes rather than 
for profiles (27).  
 
Based on the findings of an earlier qualitative study (10), attributes considered most likely to 
be of importance to transplant patients were included. To minimise complexity, nine 
attributes were presented; dying with a functioning graft, malignancy, cardiovascular disease, 
diabetes, infection, excessive weight gain, gastrointestinal side effects, changes to 
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appearance, and graft survival.  A clinically realistic range of probabilities was provided for 
the nine outcomes (1-3, 31). The options for graft survival were expressed in years. The 
attributes and attribute levels are shown in Table 5.1. 
 
 
 
Table 5.1: Best worst scaling survey attributes and levels. 
 
Attribute Description Attribute Levels 
Graft survival The length of time that the transplanted 
could last. 
1, 5, 10, 20, 30 years 
Serious adverse outcomes 
Length of life Chance of dying before the graft fails. 0, 25, 50, 75, 100 % 
Cancer Chance of cancer other than skin cancer 0, 10, 20, 30, 50 % 
CVD Chance of serious heart disease 0, 10, 20, 30, 50 % 
Diabetes Chance of diabetes after transplant 0, 10, 20, 30, 50 % 
Infection Chance of serious infection 0, 10, 20, 30, 50 % 
Potentially debilitating side effects 
Weight gain Chance of excessive weight gain 0, 25, 50, 75, 100 % 
Cosmetic side effects Chance of side effects that will change 
appearance 
0, 25, 50, 75, 100 % 
Gastrointestinal side 
effects 
Chance of severe diarrhoea or nausea 0, 25, 50, 75, 100 % 
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Survey Design and Administration 
A d-efficient survey design was generated using parameters selected to reflect expected 
direction of attribute preference (32). The survey consisted of 20 multi attribute profiles and 
was presented in paper or an on-line form. Attribute levels that were expressed as risk of 
occurrence were represented by words and numbers, and using pictograms to express the 
probability. Graft survival was presented descriptively and graphically using a horizontal bar 
graph showing years of graft survival (Figure 5.1). At the end of the survey respondents were 
asked whether they ignored any attributes, how long it took to complete the survey, and how 
hard they found the survey to complete. An open text box inviting any comments was 
included at the end of the survey. The survey also included questions on demographic and 
relevant medical details including medication, number of transplants, and the time since last 
transplant. A paper version of the BWS was either handed out or mailed, or a link was 
emailed to the on line version for those who agreed to complete the survey. The surveys were 
self-completed without assistance from researchers.  
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Figure 5.1. Example of a single scenario from the best-worst scaling survey.  
 
Analysis  
All completed surveys were included for analysis with the exception of those containing 
major errors where it was not possible to identify the best and/or the worst selection. 
Attribute specific constants and attribute level coefficients were estimated using a 
multinomial logit (MNL) model with NLOGIT 5.0 software (www.limdep.com). For the 
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purpose of the choice analysis, it was assumed that the ‘best’ and ‘worst’ choices were 
selected sequentially with the ‘best’ selected first and that attribute then not available to be 
selected for the ‘worst’ choice. This assumes that all 9 attributes were available for the ‘best’ 
choice and that the ‘worst’ choice was made from only 8 attributes. The attribute specific 
constant for ‘risk of change in appearance’ and the attribute level coefficient for ‘a 100% risk 
of change in appearance’ were normalised to zero.  The attribute specific constants thus 
represent the average of the unobserved effects for the attributes relative to ‘appearance’ (29). 
The variables were coded such that a ‘best’ choice for an attribute level was assigned a value 
of 1, a worst choice a value of -1 and a value of 0 assigned when the attribute level was not 
selected either as a ‘best’ or a ‘worst’. Attribute level coefficients were estimated from the 
combined data set of the ‘best’ and the ‘worst’ choices and assumes that a best choice mirrors 
a worst choice and that there are no positive or negative framing effects (29). As the attribute 
level coefficients have the same underlying scale, the coefficients have been normalised to a 
range of 0 to 1 based on the highest and lowest values from the MNL model. A value of 0 
means that attribute level was least preferred and a value of 1 most preferred. All coefficients 
are expressed as an average with a 95% confidence interval (CI). 
 
Respondent Interviews 
As an additional check of the validity of the BWS attributes and results, a subsample of 
respondents (n=7) were interviewed by phone to assess the understanding of concepts 
presented in the pilot survey. The questions focussed on the meaning of the attribute of dying 
with a functioning graft. Individuals were selected on the basis of choices where responses 
appeared to be counter intuitive, for example those who choose a very high risk of dying as 
being the best attribute were interviewed. Interviews were recorded and transcribed. 
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5.4. Results  
Participant characteristics 
A total of 81 patients agreed to complete the BWS and 39 (48%) completed surveys were 
returned (Figure 5.2). The respondents, who were aged between 19 and 70 years (mean 50.5, 
SD 9.7), were predominantly male (66%) and spoke English as a first language (87%) with a 
majority (69%) having completed education beyond high school.  The time since the last 
transplant ranged from 0.2 to 21.7 years (median 4.7) with 44% having received grafts from 
deceased donors.  Twenty eight (72%) of the respondents were currently taking tacrolimus 
and 35 (90%) prednisone. A summary of respondent characteristics is presented in Table 5.2. 
 
Figure 5.2. Flow of patients in best-worst scaling survey. A valid survey was one in which 
single ‘best’ and ‘worst’ choices were clearly indicated by the participant. A valid survey 
may include individual scenarios that were not completed or with an error making the 
selection unclear and thus have fewer than the 20 valid scenarios available for analysis. 
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Table 5.2:  Characteristics of participants. 
 
Characteristic Respondents 
n (%) 
Age 19 – 40 years 
41 – 50 years 
51 – 60 years 
61 – 70 years 
5 (13) 
14 (36) 
14 (36) 
6 (15) 
Gender Male 
23 (66) 
Ethnicity Anglo Saxon 
Asian 
European 
Mid East 
Samoan 
Mauritian 
23 (59) 
6 (15) 
5 (13) 
3 (8) 
1 (3) 
1 (3) 
First language English 34 (87) 
Marital status Married/Defacto 
Separated/Divorced 
Single 
34 (81) 
3 (8) 
2 (5) 
Employment Full time 
Part time 
Retired 
Student 
Not able to work 
24 (62) 
2 (5) 
6 (15) 
1 (3) 
6 (15) 
Highest Education University 
Techical college 
High school 
Primary school 
14 (36) 
13 (33) 
11 (28) 
1 (3) 
No. of transplants 1 only 32 (82) 
Donor organ type Deceased 
Living related 
Living non related 
17 (44) 
18 (46) 
4 (10) 
Type of transplant Kidney 
Kidney/pancreas 
35 (89) 
4 (10) 
Time since transplant Not stated 
0 to 1 year 
1 to 3 years 
3 to 5 years 
5 to 10 years 
10 to 15 years 
15 to 20 years 
More than 20 years 
3 (8) 
4 (10) 
6 (15) 
11 (28) 
5 (13) 
5 (13) 
3 (8) 
2 (5) 
Immunosuppression 
 
Tacrolimus 
Cyclosporine 
Prednisone 
Mycophenolate mofetil 
Sirolimus 
28 (72) 
4 (10) 
35 (90) 
25 (64) 
7 (18%) 
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Supplementary Questions 
A summary of responses to the supplementary questions is provided in Figure 5.3.  The 
majority of the respondents (n=23 (59%)) reported that they took more than 20 minutes to 
complete the survey (Figure 5.3).  One respondent was unable to finish the questionnaire and 
one respondent reported that they did not understand the survey, while 2 (5%) and 14 (35%) 
found it very hard or moderately hard respectively.  
 
Twenty three respondents (59%) stated that they ignored one or more outcomes when 
completing the BWS. The most frequently ignored outcomes were ‘gaining a large amount of 
weight’ and ‘change to your appearance’ both of which were ignored by 16 (40%) of the 
respondents followed by ‘severe diarrhoea and nausea’ which was ignored by 7 (18%).  All 
other outcomes (risk of cancer, CVD, serious infection, death and graft survival) were 
ignored by 3 (8%) or fewer respondents (Figure 5.3).  
 
Figure 5.3. Summary of responses to supplementary questions included in the best worst 
scaling survey. 
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BWS Analysis 
Of the 39 surveys returned 35 (90%) provided valid data while the remaining 4 had major 
errors (missing or multiple choices for either best and/or worst) affecting all 20 scenarios and 
were excluded from further analysis (Figure 5.2). Of the valid surveys 7 out of the 1400 
(0.5%) choices were either invalid (more than one choice entered) or missing and were 
entered as missing data giving a total of 1393 choices. Attribute specific constants and 
attribute level coefficients are summarised in Table 5.3. The attribute specific constants for 
‘death’ and ‘graft survival’ were both significant (P<0.001) and positive which suggests that, 
all else being equal, respondents were more likely to choose these attributes as either a best or 
worst outcome. All other attribute specific constants were not significant (P>0.05).  
 
 
Figure 5.4 Attribute-level coefficients normalised to range 0–1 relative to lowest attribute 
coefficient for risk of cancer of 50% and highest coefficient for graft survival of 30 years. 
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Table 5.3 Attribute specific constants and attribute level coefficients from a 
multinominal logit model of the best worst scaling survey. 
 
Attribute Level β Lower Upper P 
Attribute specific constants 
Appearance  Ref Ref Ref Ref 
Weight  -0.04 -0.49 0.41 0.848 
Gastro  -0.31 -0.81 0.20 0.234 
Diabetes  -0.39 -0.89 0.11 0.124 
Death  1.59 1.23 1.94 0.000 
CVD  -0.14 -0.61 0.33 0.548 
Cancer  0.06 -0.39 0.51 0.796 
Infection  -0.49 -1.16 0.17 0.146 
Graft  1.47 1.09 1.84 0.000 
Attribute levels* 
Appearance 0 1.87 0.65 3.09 0.003 
 25 1.43 0.56 2.30 0.001 
 50 1.33 0.53 2.12 0.001 
 75 0.64 -0.17 1.46 0.122 
 100 Ref Ref Ref Ref 
Weight 0 1.57 0.51 2.62 0.004 
 25 1.49 0.70 2.27 0.000 
 50 0.26 -0.51 1.03 0.508 
 75 -0.67 -1.47 0.13 0.100 
 100 -1.39 -2.09 -0.69 0.000 
Gastro 0 2.45 1.36 3.54 0.000 
 25 0.44 -0.41 1.29 0.313 
 50 -0.88 -1.73 -0.03 0.041 
 75 -1.65 -2.49 -0.81 0.000 
 100 -2.42 -3.14 -1.70 0.000 
Diabetes 0 2.30 1.14 3.46 0.000 
 10 1.13 0.18 2.08 0.020 
 20 0.66 -0.14 1.46 0.105 
 30 0.32 -0.52 1.16 0.453 
 50 -1.27 -2.07 -0.46 0.002 
Death 0 2.10 1.31 2.90 0.000 
 25 0.28 -0.31 0.87 0.356 
 50 -0.95 -1.58 -0.32 0.003 
 75 -0.52 -1.17 0.12 0.108 
 100 0.22 -0.38 0.81 0.472 
CVD 0 3.00 2.08 3.96 0.000 
 10 0.71 -0.07 1.50 0.075 
 20 0.00 -0.80 0.78 0.987 
 30 -1.57 -2.42 -0.73 0.000 
 50 -2.40 -3.12 -1.70 0.000 
Cancer 0 3.12 2.31 3.94 0.000 
 10 0.98 0.24 1.72 0.010 
 20 0.20 -0.54 0.95 0.595 
 30 -0.99 -1.80 -0.17 0.018 
 50 -2.61 -3.32 -1.89 0.000 
Infection 0 3.36 2.38 4.34 0.000 
 10 1.97 1.07 2.88 0.000 
 20 2.14 1.26 3.01 0.000 
 30 0.71 -0.19 1.61 0.124 
 50 -1.56 -2.44 -0.68 0.001 
Graft 30 4.58 3.79 5.38 0.000 
 20 2.47 1.81 3.13 0.000 
 10 1.11 0.52 1.71 0.000 
 5 -0.43 -1.05 0.19 0.178 
 1 -2.16 -2.83 -1.48 0.000 
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Attribute coefficients were statistically significant (P<0.05) for 30 (69%) of the 44 
attribute levels with the highest (most preferred) value of 4.58 (95%CI 3.79, 5.38) 
being for graft survival of 30 years and the lowest (least preferred) value of -2.61 
(95%CI -3.32, -1.89) for a 50% risk of cancer following transplantation. The 
normalised (0 to 1) attribute level coefficients are plotted in Figure 5.4.  The overall 
preference for an attribute is indicated by the value of the attribute level coefficient 
with 1 being most preferred and 0 being least preferred. The range of the coefficients 
for a specific attribute provides an indication of the relative contribution that the 
attribute is likely to make to the overall ‘value’ or utility of a given scenario with the 
wider range indicating a greater contribution. For example, graft survival has the 
greatest range with an upper value of 1 (95%CI 0.89, 1.11) for 30 years and a lower 
value of 0.06 (95%CI -0.03, 0.16). All other attributes have coefficient values and 
upper 95% confidence limits less than 1. The attribute level coefficients for graft 
survival decreased with decreasing years of survival and all attribute level coefficients 
were significantly different from each other on the basis of the 95% confidence 
intervals (Figure 5.4). A 50% chance of cancer, a 50% chance of CVD, and a 100% 
chance of debilitating gastrointestinal side effects were not significantly greater than 0 
with 95% confidence limits all less than 0 and they thus have an equivalent preference 
to 1 year of graft survival (i.e. least preferred). The attribute least likely to contribute 
to overall utility (i.e. the one with the narrowest range of attribute level coefficients) is 
the risk of side effects that change appearance with an upper value of 0.62 (95%CI 
0.45, 0.79) and lower value of 0.45 (95%CI 0.34, 0.57) for a 0% and 75% chance of 
occurrence after transplantation respectively none of which were significantly 
different from each on the basis of the 95% confidence limits.  
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Within each attribute the coefficients for the attribute levels generally moved in line 
with a priori expectations (Figure 5.4). A higher risk of harm, and lower graft survival 
were less preferred to lower risk of harms, or higher graft survival. The only 
exception is ‘dying before the kidney transplant fails’ where the point values for the 
attribute level coefficients show a ‘U’ shaped trend (Figure 5.4). A 0% chance of 
dying, had an attribute level coefficient of 0.65 (95%CI 0.54, 0.77) and was greater 
than all other risk levels, however , attribute level coefficients were not significantly 
different from each other for a 25, 50, 75 or 100% chance of dying with overlapping 
95% confidence intervals. This atypical trend in attribute level coefficients for the risk 
of dying may reflect an indifference to an increasing risk of dying for probabilities 
greater than 25%, a rational choice made by some respondents, or the result of 
misinterpretation of the intended meaning of the attribute.   
 
A 100% risk of dying and 30 year graft survival are dominant attribute levels and a 
choice of ‘best’ for 100% risk of dying would be ‘irrational’ and a choice of ‘worst’ 
for 30 years graft survival would be ‘irrational’. The frequency of ‘irrational’ choices 
provides an indication of error associated with these dominant attributes. A 100% risk 
of dying was available for selection as a ‘best’ or a ‘worst’ choice for 138 cases and 
was selected as a ‘best’ choice in 28 cases (20%), which is indicative of a high error 
rate. In contrast 30 years graft survival was selected as a ‘worst’ choice in 2 (2%) of 
138 cases and suggests a relatively low error rate particularly compared to a 100% 
chance of dying. Reasons for the high error rate associated with the risk of dying were 
explored further through the interviews with selected respondents. 
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Participant Interviews 
Seven participants were purposively selected for interview based on their selection of 
a high risk of dying as a ‘best’ choice. The three reasons for the selection are:  
Misunderstanding meaning: The meaning of the attribute was interpreted differently 
to the intended definition. For example, the response to a question as to what was 
meant by 100 out of 100 people will die was: “To me that just means that the kidney 
will last a hell of a long time or will outlast you.”  
Not linking the risk of dying with the length of graft survival: The risk of dying was 
considered in isolation from graft survival rather than meaning a high risk of dying 
before the graft fails, which in the case of 1 year graft survival would mean a short 
life span.  For example: “Why I said 75 out of 100 people will die before their kidney 
fails?  Well as long as you don’t take the questions above [the kidney could last 1 
year] into account.” 
Aversion to returning to dialysis: Dying with a functioning graft was a better option 
than returning to dialysis even if graft survival was relatively short for example: 
“……and dying from other reasons rather than having to go on dialysis wait for 
another one etc. etc.” 
 
5.5. Discussion 
This pilot study identified several key findings in relation to the use of a BWS to elicit 
the preferences and priorities of kidney transplant recipients for outcomes following 
transplantation. Firstly, even with a relatively small sample size the majority of the 
attribute level coefficients were statistically significant (P<0.05), and demonstrate 
face validity with respect to relative importance both within and between attributes. 
Graft survival of 30 years is more important than any other outcome and a low risk of 
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serious adverse outcomes is also highly preferred. A low risk (0%) of serious 
infection, cancer and CVD has the same level of importance as approximately 20 
years of graft survival. A very high risk (100%) of severe gastrointestinal side effects 
has the same relative importance as a high risk (50%) of cancer and CVD and short 
graft survival of 1 year. In contrast a high risk (100%) of changes to appearance is of 
low importance relative to all other attributes. Similarly, the range of the attribute 
level coefficients indicate that graft survival is likely to have the greatest contribution 
to assessment of overall utility of the outcomes after transplantation with changes to 
appearance the smallest contribution. 
 
Secondly, the pilot study had a low major error rate despite the use of a self-complete 
paper based format for a complex survey with 20 ‘best’/‘worst’ choice scenarios each 
containing 9 attributes. Of the surveys returned 10% were unusable and of the valid 
surveys only 0.5% of the individual ‘best’ or ‘worst’ selections were invalid. 
However, the estimated error rate for the attribute of ‘dying before the transplanted 
kidney fails’ (as indicated by the rate of ‘irrational’ choice, assuming that a high risk 
of dying would be ‘rationally’ identified as an undesirable outcome) was in the order 
of 20% compared to 2% for graft survival. The interviews with respondents suggest 
that this error reflected misunderstanding of the meaning of the attribute and a 
tendency to view the risk of dying in isolation of the years of graft survival. 
Nonetheless, it may be a ‘rational’ choice for some individuals reflecting a stated 
preference for dying over returning to dialysis 10.  
 
Thirdly, with the exception of the risk of dying, the attribute level coefficients for 
adverse outcomes are highest (most preferred) for low risk of occurrence and lowest 
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(least preferred) for high risk of occurrence of the outcomes. Similarly attribute level 
coefficients for graft survival, are lowest (least preferred) for 1 year graft survival and 
increase with increasing years with the maximum value (most preferred) at 30 years. 
In the case of the risk of dying, the trend for decreasing preferences with increasing 
risk is less apparent. As noted by de Bekker-Grob et al (33), whilst most discrete 
choice evaluations in health assume linearity in both attributes and attribute 
coefficients, there are substantive reasons for this to not be the case and that 
nonlinearity should be taken into account when estimating trade-offs between 
attributes. 
 
Limitations 
A number of observations from the pilot study warrant consideration in on-going 
studies of this type. While the overall response rate for the study was close to 50%, it 
differed by method of approach: following contact in the clinic and by phone it was 
less than 30%, compared to email contact which had a 65% response rate. The 
characteristics of the respondents were, in terms of gender and age, generally 
representative of the kidney transplant population, however the sample is biased 
towards those with higher levels of education, who were white and who had English 
as a first language. These factors may have influenced the low error rate found in the 
returned surveys. The patient sample had a restricted range of immunosuppressive 
agents which may limit representativeness in relation to variation in experience of 
side effects, for example 90% of the respondents were taking prednisone and 72% 
tacrolimus. However, the immunosuppression is characteristic of current clinical 
practice in Australia and New Zealand (34). 
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The upper range of graft survival at 30 years was close to being a dominant attribute 
with almost all respondents selecting this as the best outcome when it was included in 
a choice scenario. This may over emphasise the relative importance of graft survival 
particularly given the low clinical probability of achieving 30 years. In contrast the 
relative importance of the ‘risk of dying with a functioning graft’ may be under 
estimated because of participant misinterpretation and the subsequent error rate.  
 
The analysis assumed symmetry of the ‘best’ and ‘worst’ choices and that they come 
from the same underlying utility function. This follows from the approach of using a 
BWS as a data augmentation technique allowing for smaller sample sizes and less 
complex experimental designs. This assumption of symmetry may not be the case and 
the ‘best’/‘worst’ choice may be influenced by positive and negative framing (28, 29). 
Furthermore, the analysis assumes that the ‘best’ and ‘worst’ choices are made 
sequentially as ‘best’ then ‘worst’ for all scenarios, whereas it may the other way 
around i.e. ‘worst’ then ‘best’ for all or for some scenarios or the choice may be made 
simultaneously (28). The assumption of symmetry of choice and sequential selection 
may result in biased estimates of the attribute level coefficients. 
 
Implications for future research. 
The findings of the pilot BWS have implications for future research of patient 
preferences. The face validity and the low major error rate indicate that a BWS is a 
feasible approach for eliciting preferences for long term outcomes associated with 
complex treatment regimens and should also be applicable to conditions other than 
immunosuppression after transplantation. The types of situations suited to a BWS 
would be most applicable where treatment regimens cannot easily be described by 
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discrete choices. In the case of kidney transplant recipients, treatment after 
transplantation is more a process of adjusting the level and type of 
immunosuppression to balance benefits (graft survival) against harms (side effects 
and serious adverse outcomes) rather than a choice between clearly distinct treatment 
options. Describing treatment outcomes as multi-attribute single scenarios with 
differing attribute levels, as in a BWS, is more realistic than the choice scenarios of a 
discrete choice experiment. The pilot study has shown that the conduct and analysis of 
a BWS for complex treatment regimens should carefully consider the meaning and 
understanding of outcomes and this may require participant interviews or a ‘think out 
loud’ approach (35). Finally, the complexity of the survey may limit participation and 
result in selection bias. Future studies should explore survey administration 
techniques aimed at increasing accessibility and response rates.  
 
Specific to the ranking of importance of outcomes after kidney transplantation, the 
findings of the pilot study can be used to provide for more efficient designs by use of 
better informed priors and development of design formats that minimise error 
resulting from cognitive burden. For example the use of a ‘best’ ‘worst’ ‘next best’ 
next worst’ format to reduce the number of scenarios.  
 
5.6. Conclusions 
The pilot study has indicated that transplant patients were able to complete a complex 
BWS of preferences for multiple long term outcomes after transplantation and are 
willing to trade-off benefits and adverse outcomes. The pilot survey identified some 
key findings with respect to kidney transplant recipient’s preferences and priorities 
that have implications for patient-centred research. In particular whilst graft survival 
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is the most important outcome, the pilot study suggests that a low risk of serious 
adverse outcomes including potentially debilitating side effects such as severe 
diarrhoea and nausea may be of similar importance. This pilot has also helped us 
identify refinements needed before administration in a larger patient sample, which is 
now being undertaken. 
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6. Patient preferences for outcomes after kidney 
transplantation: a best-worst scaling survey. 
 
The material contained in this chapter has been submitted for publication as: Howell, M., G. 
Wong, J. Rose, A. Tong, J. C. Craig and K. Howard (2016). "Patient preferences for 
outcomes after kidney transplantation: a best-worst scaling survey." Submitted to the 
American Journal of Transplantation. 
 
The structure reflects the journal requirements. 
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6.1. Abstract 
Decision-making regarding the use of immunosuppressive medications following 
transplantation is complex, involving a balance between what is optimal for the graft and 
what is optimal for the patient. Using a best-worst scaling survey, we aimed to quantify 
patients’ preferences and trade-offs for important outcomes following transplantation. 
Plausible risk values for each outcome were provided, and preferences on a scale from 0 
(worst) to 1 (best) were estimated. Ninety-three patients from two Australian transplant units 
(aged 18-69 years, mean time since transplantation, seven years) completed the survey. Graft 
loss at one year (preference value 0.0:95% confidence intervals:-0.05 to 0.05) was worst and 
a zero risk of dying before graft loss (1.0:0.92 to 1.08) was best. Graft loss at 15 years 
(0.46:0.42 to 0.51) was equivalent to a 25% risk of dying (0.41:0.36 to 0.46). To achieve zero 
risk of cancer, dying, and cardiovascular disease participants were only willing to trade 
3.1(2.1 to 4.7), 1.7(1.1 to 2.5), and 1.2(0.8 to 1.8) years of graft survival respectively, and less 
than 1 year for all other outcomes. Transplant recipients regarded graft loss as worse than 
death and showed minimal willingness to trade a reduction in this outcome with an 
improvement in any other outcome. 
 
6.2. Introduction 
Decision-making to optimise the care of kidney transplant recipients involves a balance 
between maximizing graft survival and potentially serious adverse outcomes including 
cancer, cardiovascular disease and infection associated with immunosuppression (1-3). There 
has been a marked improvement in short-term graft and patient survival associated with 
advancements in drugs and surgery, but long-term graft survival has remained static over the 
past two decades (4-6). Opportunities for shared decision-making before and after 
transplantation have been identified, (7-9) including acceptance of higher risk donor organs 
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(10). To date, as with many chronic diseases, treatment decisions have been predominantly 
driven by clinicians with little systematic, explicit and formal patient involvement (7, 11-14). 
 
Shared decision-making that respects patient autonomy (15, 16) has been associated with 
improved psychological health status, self-management and adherence to treatment regimens 
(17). Understanding patient preferences is key to ensuring that decisions reflect patient values 
and variation in tolerance of risk (15, 18, 19). As preferences are underpinned by beliefs of 
consequences, patients need to be provided with an unbiased assessment of uncertainties, 
benefits and harms (20, 21). Prior research has quantified the frequency and severity of 
adverse effects associated with long-term immunosuppression (22-25). Kidney transplant 
recipients have indicated a strong focus on graft survival, aversion to returning to dialysis, 
and willingness to accept side effects and adverse outcomes as a necessary part of the 
treatment (26-31). Despite the clear role of patient preferences and values in decisions 
relating to kidney transplantation, no studies have quantified the trade-offs patients may be 
willing to make in order to reduce the impact of adverse outcomes through change to, or 
withdrawal of, immunosuppression, and the risk of graft dysfunction and loss.  
 
The aim of this study was to evaluate preferences and trade-offs patients may accept to avoid 
adverse outcomes of long-term immunosuppression using a quantitative technique, a best-
worst case scaling survey (BWS). A BWS is a type of discrete choice experiment that is 
increasingly used to evaluate preferences for health policy, programs and interventions (32), 
particularly for complex treatment regimens such as immunosuppression after 
transplantation.  
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6.3. Methods 
Participant selection 
Adult kidney transplant patients (aged 18 years and older) were recruited from two large 
transplant units in Sydney, Australia, and an Australia wide on-line research panel 
administered by an external organization (Survey Sampling International). English-speaking 
patients able to provide informed consent were eligible to participate and contacted in clinics, 
email, phone or letter. Ethics approval was obtained from the Human Research Ethics 
Committee of the Western Sydney Local Health Network, NSW Health (HREC2009/6/4.15 
(2956) AU RED09/WMEAD/56). 
 
Best-Worst Scaling Methodology 
Best-worst case scaling requires participants to choose ‘best’ and ‘worst’ attributes from a set 
of multi-attribute profiles with preferences inferred from the choices (32, 33). Utility 
functions for the individual attributes are constructed and estimated in accordance with 
random utility theory (33). The BWS uses a common scale to estimate attribute level 
coefficients allowing direct comparison of levels within and between attributes. 
  
Based on findings of a qualitative study (28) and pilot BWS (34), nine attributes representing 
those most likely to be important to transplant patients were included. Eight attributes (dying 
before graft loss, cancer other than skin cancer, cardiovascular disease, diabetes, serious 
infection, excessive weight gain, severe diarrhoea/nausea, and severe anxiety/depression), 
were presented as the risk of occurrence and the ninth attribute, graft survival, was expressed 
as years. Attribute levels covered clinically plausible ranges (Figure 6.1). 
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Attribute Levels 
Serious infection 0, 10, 20, 30, 50 % 
Weight gain 0, 25, 50, 75, 100 % 
Severe diarrhoea/nausea 0, 25, 50, 75, 100 % 
Severe depression/anxiety  0, 25, 50, 75, 100 % 
Serious heart disease 0, 10, 20, 30, 50 % 
Diabetes 0, 10, 20, 30, 50 % 
Graft survival  1, 5, 10, 15, 25 years 
Die before graft failure 0, 25, 50, 75, 100 % 
Cancer other than skin cancer  0, 10, 20, 30, 50 % 
 
Figure 6.1. Example of a single scenario from the best-worst scaling survey and attribute 
levels used across choice scenarios.  
 
Survey Design 
A d-efficient design informed by parameters estimated from the pilot (34) was used to 
combine attribute levels into profiles. To maximise the amount of data collected from each 
profile and minimise survey fatigue by limiting the number of profiles, respondents were 
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asked to make four choices for each profile, namely their ‘best’, ‘worst’, ‘next-best’ and 
‘next-worst’. The final design included 4 blocks of 10 multi-attribute profiles. Online 
participants were randomly assigned by the survey software to one block while paper 
versions were distributed to give approximately equal numbers of each block. Online surveys 
required all four choices before moving to the next scenario and prevented an attribute being 
marked both best and worst. For each profile, respondents were asked to consider the profile 
as a hypothetical treatment and asked the question: “If you were offered a treatment that 
resulted in all of the above outcomes, would you take it?” (Figure 6.1). Self-reported 
demographic and medical details including medication, comorbidities, duration of dialysis 
prior to transplant, type of donor, number of transplants, and time since last transplant were 
collected. The paper version was either handed out in the clinic or mailed with a unique link 
to the on-line version, so participants could choose to complete the survey online. All were 
self-completed without assistance from researchers. The design did not include a check or 
consistency question, however the count of choices of ‘worst’ for the longest graft duration 
(25 years) and ‘best’ for a 100% risk of dying, provided an estimate of the error rate. All 
surveys were included for analysis and responses excluded only where choice selection was 
unclear or missing on paper versions.  
 
Analysis  
Attribute specific constants, and attribute level and covariate coefficients were estimated with 
a multinomial logit model (MNL) using Python BIOGEME (www.biogeme.epfl.ch) (35). 
Utility functions were constructed for each attribute and for each of the four choice options 
(Appendix C - Note 1). Attribute levels were dummy coded with ‘1’ if the attribute level was 
present in the scenario and ‘0’ if not. Best choices were coded with ‘1’ if chosen and ‘0’ if 
not and worst choices coded with ‘-1’ if chosen and ‘0’ if not. We assumed that choices were 
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sequential with ‘best’ selected first, then ‘worst’, ‘next-best’ and ‘next-worst’ and the chosen 
attribute level to be unavailable for subsequent choices (36). Attribute specific constants were 
estimated relative to weight. The middle attribute level coefficients were set at zero allowing 
estimation of the remaining four levels. Age, gender, number of comorbidities, time on 
dialysis, time since transplantation and number of transplants were included as covariates in 
utility functions.   
 
Mean attribute level coefficients and 95% confidence limits were estimated from the 
combined data set of the ‘best’, ‘worst’, ‘next-best’ and ‘next-worst’ choices and assumed 
that a best choice mirrors a worst choice (36, 37). A preference score for each attribute level 
was obtained by normalizing the mean attribute level coefficients to the range 0 to 1 where 0 
indicates the least preferred and 1 the most preferred. The preference scores can be compared 
across all attributes. Within an attribute the magnitude of change between the preference 
scores indicates sensitivity to change in that attribute. Indifference to change is evident where 
the level preference scores are the same. 
 
To examine effects of covariates on best and worst choices, covariate coefficients were 
estimated separately for ‘best’ and ‘worst’ where ‘best’ includes both the ‘best’ and ‘next-
best’ choices and ‘worst’ both the ‘worst’ and ‘next-worst’ choices for each attribute relative 
to weight gain. To assist in interpretation of the coefficients they are expressed as an odds 
ratio. An odds ratio less than one indicates that the covariate is associated with a lower 
probability of that attribute being selected and greater than 1 indicates a higher probability of 
being selected, all else being equal. When interpreting the odds ratios, we would expect a 
priori, that a ‘best’ choice would be for lower rather than higher risks of adverse outcomes 
and longer rather than shorter graft survival with the converse for ‘worst’ choices. 
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Interpretation of the magnitude of the odds ratio is difficult as it is dependent on whether the 
covariate has been modelled as a continuous or categorical variable.  
 
Responses to the choice question for each scenario (“If you were offered a treatment that 
resulted in all of the above outcomes, would you take it?”) were modelled using a mixed-
MNL model with panel specification with ‘No’ as the reference. Initially all attribute 
coefficients were assumed to be normally distributed, however to maintain parsimony the 
final model only included attributes as random parameters with significant standard 
deviations (P<0.05) (Appendix C – Note 2) with the remainder entered as fixed parameters. 
An odds ratio greater than one indicates a higher probability that ‘Yes’ will be chosen as the 
value of the attribute becomes more favourable i.e. for graft survival as the years of duration 
increase or as the risk of the adverse outcomes reduces.  
 
Benefit/harm trade-offs for graft survival and risk of adverse outcomes were estimated 
following the marginal rates of substitution method described by de Bekker-Grob, Rose and 
Bliemer (2013) (38) (Appendix C - Note 3) with confidence limits estimated using the 
Krinsky-Robb procedure (38, 39). The benefit/harm trade-off is the years of graft survival 
that would be ‘traded’ in order to achieve a specified risk of the attribute and calculated for 0, 
10, 30 and 50% risk.  
 
6.4. Results 
Participant characteristics 
Ninety-three patients completed the BWS, with 30 (32%) and 63 (68%) recruited from the 
community panel and transplant clinics respectively. Respondents were aged between 18 and 
69 years (mean 50.5, standard deviation (SD) 9.7), 59 (63%) were male, 88 (95%) spoke 
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English as the first language, and 60 (65%) completed high school. Time since the last 
transplant ranged from 0.9 to 31 years (mean 7.7, SD 5.7) and 49 (53%) received a deceased 
donor graft. Sixty-nine (74%) were on dialysis before transplant, of whom 38 (41%) had been 
dialyzed for more than 2 years. The most common immunosuppressive agents were 
prednisone (84%), tacrolimus (62%) and MMF (66%). The most common comorbidities were 
hypertension (75%), high cholesterol (50%), diabetes (33%) and skin cancer (22%). Multiple 
comorbidities were reported by the majority with 61 (66%) reporting two or more 
comorbidities (Table 6.1). 
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Table 6.1:  Characteristics of participants (n=93). 
Characteristic Number (%) 
Age (years):                                            18 – 30 
31 – 40 
41 – 50 
51 – 60 
61 – 70 
7 (8) 
9 (10) 
31 (33) 
27 (29) 
19 (20) 
Gender:                                                   Male 59 (63) 
Ethnicity:                                                White Caucasian 
European 
Asian 
Middle Eastern 
Other 
56 (60) 
21 (23) 
11 (12) 
2 (2) 
3 (3) 
First language:                                        English 88 (95) 
Marital status:                                         Married/defacto 
Single 
Separated/divorced 
Widowed 
65 (70) 
18 (19) 
8 (9) 
2 (2) 
Employment:                                          Full time 
Part time 
Unable to work 
Unemployed 
Retired 
Student 
35 (38) 
15 (16) 
21 (23) 
11 (12) 
9 (10) 
2 (2) 
Highest Education:                                 University/Technical college 
High school 
Primary school 
60 (65) 
32 (35) 
1 (1) 
Years on dialysis before transplant:       No dialysis 
<1 
1 to <5 
5 to <10 
≥10 
24 (26) 
16 (17) 
37 (41) 
11 (12) 
5 (5) 
Comorbidities:                                        Hypertension:           
High cholesterol 
Diabetes 
Skin cancer 
CVD 
Stroke 
Cancer other than skin 
None 
70 (75) 
46 (50) 
31 (33) 
20 (22) 
16 (17) 
4 (4) 
4 (4) 
8 (9) 
Donor type:                                             Deceased 
Living related 
Living non related 
49 (53) 
29 (31) 
15 (16) 
Number of kidney transplants:               One 81 (87) 
Type of transplant:                                  Kidney 
Kidney/pancreas 
Kidney/liver 
82 (88) 
9 (10) 
2 (2) 
Time since transplant (years):                 <1 
1 to <5 
5 to <10 
10 to <15 
15 to <20 
≥30 
2 (2) 
34 (37) 
34 (37) 
13 (14) 
7 (8) 
3 (3) 
Current Immunosuppression:                 Prednisone 
Mycophenolate mofetil 
Tacrolimus 
Cyclosporine 
Sirolimus 
Azathioprine 
Leflunomide 
78 (84) 
61 (66) 
58 (62) 
15 (16) 
14 (15) 
12 (13) 
2 (2) 
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Survey completion 
Of 93 surveys completed, 71 (76%) were online and all 10 scenarios were completed. Invalid 
paper surveys (missing choices and double entries) occurred for 139 of the 3,720 selections 
(4%). The unintuitive ‘best’ choice for 100% chance of dying and ‘worst’ choice for 25-year 
graft survival occurred for 2 of 178 choices (1.1%) and 8 of 176 choices (4.5%) respectively.   
 
Preference scores  
Preferences scores, with a range of 0 (worst) to 1 (best) calculated from attribute level 
coefficients (Table S2) are plotted in Figure 6.2, and allow comparison of the relative 
importance of levels within and between attributes. The worst (least desirable) outcome was 
graft failure after one year with a preference score of 0.0 (95% confidence interval -0.05 to 
0.05), while the best (most desirable) was a 0% risk of dying before graft failure with a 
preference score of 1.0 (0.92 to 1.08). In line with a priori expectations, as risks of adverse 
outcomes increased, preferences decreased, and as duration of graft survival increased, 
preferences increased.  
 
Comparison of preference scores between attributes implies that graft loss after one year (the 
least preferred attribute level) was worse than a 100% risk of dying before graft failure. Five 
years of graft survival was as important as 100% to 75% risk of dying and 
anxiety/depression, 100% risk of diarrhoea/nausea, 50% to 30% risk of cancer, 50% risk of 
CVD, diabetes and serious infection. Fifteen years of graft survival was as important as 0% 
risk of diabetes and weight gain; 10% risk of cancer, CVD, and infection; 25% risk of dying, 
diarrhoea/nausea, and weight gain; and 30% risk of infection. Finally, 25 years of graft 
survival was as important as 0% risk of cancer, CVD, depression/ anxiety, infection and 
diarrhoea/nausea and only 0% risk of dying before graft failure was more important. 
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Sensitivity to change in levels 
On average, respondents were most sensitive to changes occurring at low risk values and less 
sensitive or indifferent to changes at high risk (Figure 6.2). This was particularly evident for 
dying with a functioning graft where the preference score at 0% was more than double that at 
25% with values of 1.0 (0.92 to 1.08), and 0.41 (0.36 to 0.46) respectively. In contrast 
respondents were indifferent to change between 75% and 100% risk with scores of 0.20 (0.14 
to 0.25) and 0.17 (0.12 to 0.23) respectively. Variation in sensitivity to change was also 
evident for cancer, CVD and anxiety/depression. Preference scores for graft survival showed 
similar sensitivity over the full 1 to 25 years with preference scores of 0.0 (-0.05 to 0.05), 
0.19 (0.14 to 0.23), 0.46 (0.42 to 0.51) and 0.72 (0.66 to 0.78) respectively (Figure 6.2).  
 
Chapter 6. Final Best Worst Scaling Survey 
 
168 
 
Figure 6.2. Mean preference scores normalised to a range 0 to 1 relative to the lowest and highest attribute level coefficients. Interpretation: Preference scores 
can be compared both within and between attributes. For example the most preferred outcome (0% risk of dying) is more preferred than any other outcome 
while the least preferred (one year duration of graft survival) is worse than any other outcome. Within the risk of dying, there is no difference in preference 
between 75% and 100% which indicates indifference to these 2 outcomes 
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Benefit/harm trade-off 
We also examined the extent to which respondents were willing to trade-off shorter 
graft survival to achieve a certain level of risk of adverse outcomes (Table S3 and 
Figure 6.3). To achieve a 0% risk of cancer, dying, CVD, diabetes and 
depression/anxiety, respondents, were willing to trade 3.10 (2.10 to 4.69), 1.66 (1.12 
to 2.51), 1.21 (0.82 to 1.83), 0.87 (0.59 to 1.32) and 0.81 (0.55 to 1.22) years of graft 
survival, respectively. To achieve 30% risk for the same outcomes respondents were 
willing to trade only 0.09 (0.06 to 0.13), 0.38 (0.26 to 0.57), 0.28 (0.19 to 0.42), 0.21 
(0.14 to 0.31) and 0.27 (0.18 to 0.41) years, respectively.  
 
Figure 6.3. Benefit/harm trade-off for adverse outcomes and graft survival with 
estimated 95% confidence limits. Interpretation. The benefit/harm trade off represents 
the years of graft survival that would be traded in order to achieve a specified risk of 
the adverse outcomes. For example approximately 3 years of graft survival would be 
traded to achieve a 0% risk of cancer. However, only 1 year would be traded to 
achieve a 10% risk and less than 1 year to achieve 20% or greater risk.  
Influence of respondent characteristics 
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The influence of respondent characteristics on choices is indicated by the odds ratios 
for best and worst choices (Table S3). On average, with increasing age respondents 
were less likely to select a low risk of infection, diarrhoea/nausea, depression/anxiety 
and diabetes as best with odds ratios of 0.94 (0.92 to 0.97), 0.94 (0.92 to 0.97), 0.95 
(0.91 to 0.98), 0.95 (0.93 to 0.98) respectively and more likely to select short graft 
survival as worst with an odds ratio 1.07 (1.03 to 1.12). This suggests lower concern 
for these adverse outcomes and greater concern for avoiding short graft survival with 
increasing age. Compared to men, women were more likely to select a low risk of 
depression/anxiety, CVD and cancer and long graft survival as best with odds ratios 
of 2.77 (1.39 to 5.54), 2.89 (1.45 to 5.74), 2.38 (1.19 to 4.73) and 1.68 (1.06 to 2.66) 
respectively and more likely to select a high risk of diarrhoea/nausea and 
depression/anxiety as worst with odds ratios of 2.47 (1.08 to 5.64) and 2.13 (1.02 to 
4.48) respectively. Thus on average women had a greater concern for these adverse 
events and long graft survival compared to men. Increasing comorbidity was 
associated with more concern for long graft survival and less for short graft survival, 
diabetes and dying. Increasing years on dialysis prior to transplantation was 
associated with greater concern for long graft survival and CVD. Increasing years 
since the last transplant was associated with greater concern for cancer and less for 
long graft survival and CVD. Finally, having had more than one transplant was 
associated with a greater concern for long graft survival, dying before graft failure, 
cancer, CVD, diabetes and anxiety/depression compared to those who have had only 
one transplant.  
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Acceptance of treatment outcomes 
Preferences for single profiles as hypothetical treatments are reported in Table S5. 
The constant term was not significant (P>0.05) indicating no bias towards accepting 
or rejecting the scenarios. Graft survival and dying were the only significant 
coefficients (P<0.05). Odds ratios indicated an increasing likelihood (1.54, 1.22 to 
1.94) of accepting the scenario for every extra year of graft survival and a decreasing 
likelihood (0.96, 0.93 to 0.91) of accepting the scenario for a 25% increase in the risk 
of dying.  
 
6.5. Discussion 
This BWS has demonstrated the overwhelming importance of graft survival to 
transplant recipients, which dominates all other outcomes. Quantifying choice is 
inherently a difficult concept but this consistent finding is exemplified by the 
following results. Very short duration of graft survival (one year) is worse than any 
outcome, including a 100% risk of dying before graft failure. Five to 15 years of graft 
survival is regarded by transplant recipients as equivalent to a high risk of serious 
adverse outcomes including dying before graft failure. It is only beyond 15 years of 
graft survival that low risks of serious adverse outcomes are of equal or greater 
importance, which suggests that this may be an important threshold for their decision 
making. There is a willingness to trade only a small number of years of graft survival 
to avoid adverse outcomes, and then only to achieve an improbably low risk. Graft 
survival was the only attribute positively associated with acceptance of the 
hypothetical treatment profile. This means that on average, acceptance was 
determined by the years of graft survival. 
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The prime importance of graft survival is largely consistent with expectations, albeit, 
the magnitude of dominance compared with all other outcomes, is now apparent, at 
least up to 15 years duration for a functioning graft. This contrasts with clinical 
research in kidney transplantation that is largely limited to reporting outcomes less 
than 5 years after transplantation (40-44). In a recent review of the 233 randomised 
controlled trials published between January 2003 and December 2015, 64% were less 
than 2 years duration and only 13% were more than 4 years (45). Clearly there are 
logistical issues in ascertaining long-term outcomes, but if research is to be relevant 
and to inform decision making, then outcomes need to match patient expectations.  
 
After dying with a functioning graft, among the serious adverse outcomes, cancer was 
the most important in terms of preference and trade-offs while diabetes was least 
important. This may reflect aversion to cancer (28, 46) and/or limited patient exposure 
to this outcome (4% of respondents). Similarly, the low importance of diabetes may 
reflect the high rate of exposure (33%), resulting in familiarity and normalization 
(47). Zero risk of depression/anxiety and diarrhoea/nausea was as important as 25 
years graft survival and both were more important for women compared to men. 
Whilst patients may be willing to accept side effects as necessary (26-28, 30), they 
tend not to discuss them with clinicians, who in turn may underestimate frequency 
and severity (48). The findings of our study suggest greater focus on prevalence and 
severity of side effects in research and clinical care is warranted.  
 
The willingness to trade years of graft survival to avoid adverse outcomes is strongly 
dependent on the level of risk of that outcome. The benefit/harm trade-off to achieve a 
0% risk of cancer and dying before graft failure was 3.1 and 1.7 years respectively, 
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and less than 1 year for a 20% risk. These findings have implications for risk 
communication and assisting patients to make decisions that are congruent with 
preferences, values and risk tolerance. No intervention will entirely eliminate risk and 
risks may be better explained by contextualizing absolute event rates across alternate 
regimens, or by comparing to patients on dialysis or the general population (49).  
 
The importance of graft survival and adverse events varies with age, gender, dialysis, 
comorbidities, number of kidney transplants and duration since transplantation. 
Variability of preferences should be anticipated given that they are underpinned by 
experience, knowledge, values and beliefs (50). A recent qualitative study found that 
some transplant recipients were cautious about treatment options involving changes to 
immunosuppression, however, this was shaped by prior experience of dialysis, age, 
gender and acceptance of medication side-effects as a ‘necessary evil’ (31). Patient-
centred care requires acknowledgment of patients’ informed preferences, and 
avoidance of those preferences framed by ‘ill-informed’ beliefs (12, 31).  
 
Studies of transplant patient preferences, and trade-offs have mostly addressed 
acceptance of donor organs. A maximum difference scale (similar to a BWS) has been 
used to assess patient and clinicians priorities for deceased donor organs with both 
identifying donor organ quality and function as most important (51) and the longer a 
patient was on dialysis the less important was graft function. However, adverse 
outcomes and graft/patient survival after transplantation were not included, and 
patients may not have considered these outcomes.  In a discrete choice experiment 
(52), older age and time on dialysis was associated with a greater likelihood of 
accepting high risk organs. Attributes included donor age, additional waiting-list time, 
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if the organ was refused and the risk of HIV infection, but patient/graft survival was 
omitted. A survey of Slovenian dialysis patients who had chosen to remain on dialysis 
instead of transplantation, identified the prime reason for their decision was concern 
for adverse and uncertain outcomes after transplantation. The most important were 
cancer, diabetes and serious infection, but patient and graft survival were not included 
in the survey (53). Acceptance of a reduction in life expectancy after acute rejection 
treatment compared to no treatment and return to dialysis was conducted using a 
modified standard gamble technique (54). Consistent with our study, preferences were 
found to vary with patient characteristics including age, gender, time on dialysis and 
waiting time on the transplant list. A significant limitation of all of these studies is 
that they did not present realistic scenarios or provided restricted attributes from 
which preferences have been elicited. In contrast, the multi attribute approach in our 
BWS combined adverse outcomes, with mortality and duration of graft survival using 
a clinically realistic range.  
 
Our study has implications in relation to the use of extended criteria donor organs. 
Ross et al (9) argue that a ‘rational’ decision for accepting poorer quality organs 
should be based on risk of mortality on the waiting list, however, this assumes that 
mortality is the only outcome of importance to patients. Our study, and previous 
qualitative work (28, 31), indicates that other factors are likely to be more important 
for some patients. Acceptance of extended criteria organs with short graft survival 
may contribute to psychological distress and morbidity (55) which on balance would 
favour not accepting these organs. This view is supported by our findings where short 
and medium term graft survival was ranked as worse than, or equivalent to dying. 
Compared to graft survival, dying with a functioning graft would be a preferred 
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outcome only after a suitably long duration of graft survival. However, our study only 
included transplant patients, and the preferred duration may be shorter for those on 
dialysis. 
 
There are potential limitations with this study. While gender and age were 
representative of adult kidney transplant patients, there is a bias to educated, white 
Caucasians with English as a first language. The range of immunosuppressive agents 
was restricted with 84% prescribed prednisone and 62% prescribed tacrolimus 
reflecting current practice in Australia and New Zealand (56), but limiting 
generalizability. Assumed symmetry of choices allows for smaller sample sizes and 
less complex surveys, however choice may be influenced by positive and negative 
framing (36, 37). The analysis assumes the ‘best’/‘worst’ choices are made 
sequentially, whereas for all or some scenarios patients may have chosen the worst, 
then best or the choice may be made simultaneously (37). Different assumptions 
about symmetry and order of selection of best and worst could give slightly different 
estimates particularly where an attribute is consistently chosen as for dying and graft 
survival. To reduce respondent burden, we considered it more important to allow 
flexibility in the way individuals made selections rather than forcing a pre-specified 
order. Finally, the survey did not include outcomes after graft loss. Mortality may be 
higher than for transplant naïve patients (57), graft intolerance syndrome may occur 
(58), and there may be a lower likelihood of being wait-listed with longer waiting 
times (59) all of which could influence preferences.  
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6.6. Conclusions 
 
In conclusion, elicitation of preferences and trade-offs, expressed quantitatively for 
outcomes after transplantation has demonstrated graft survival to be the outcome of 
prime importance for kidney transplant patients. Adverse outcomes of transplantation 
and drug related side effects were also regarded as important, but graft survival of 5 to 
15 years duration is worse than any other outcome including dying. Recipients may 
rather not receive this ‘gift of life’ if it is going to be ‘taken away from them’ during a 
period they regard as unacceptably short. Which for transplant patients appears to be 
around 15 years duration. This focus on graft survival is reflected in the limited 
willingness to trade graft duration, which is contingent on achieving a very low risk of 
any serious outcome (i.e. less than 10 %). Given the level of uncertainty in predicting 
long-term outcomes, understanding patient preferences is essential to the development 
of treatment regimens for long-term immunosuppression. Research questions and 
outcomes should be aligned with patient priorities and preferences; and patient-
centred care should acknowledge patients’ preferences.  
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APPENDIX C  
Supplementary Material 
Supplementary Note 1. Best-worst scaling survey utility functions 
Supplementary Note 2. Yes/No utility function 
Supplementary Note 3. Calculation of marginal rates of substitution 
Supplementary Table S1. Attribute specific constants from a multinominal logit 
model of the best-worst scaling survey. 
Supplementary Table S2. Attribute level coefficients from a multinominal logit model 
of the best-worst scaling survey. 
Supplementary Table S3. Benefit/harm trade-off between adverse outcomes and graft 
survival. The value indicates the number of years of graft survival that would be 
traded in order to achieve a given risk for the adverse outcome. 
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7. Discussion and conclusions 
7.1. Summary of findings 
The potential for improvement in survival and quality of life means that kidney 
transplantation has become the preferred treatment for people with end stage kidney disease 
(1). Nonetheless, kidney transplantation presents uncertainties and challenges for patients 
arising from both medical and non-medical factors (2). There are many decision points both 
before and after transplantation that are particularly sensitive to individual preferences and 
priorities (2-6). Understanding patient preferences and priorities is key to patient-centred 
research, patient-centred care and shared decision making (7-9).  
 
The aims of the studies contained in this thesis are twofold: 
• To elicit patient preferences and priorities for outcomes following transplantation. 
This aim has been addressed by the qualitative study described in Chapter 2 and the 
quantitative study described in Chapters 5 and 6. 
• To evaluate the extent to which clinical trials of maintenance immunosuppression 
after kidney transplantation, report outcomes relevant to patient preferences and 
thereby, support an evaluation of both benefits and harms. This aim has been 
addressed through the conduct of systematic reviews of randomised controlled trials 
of maintenance immunosuppression following kidney transplantation. Chapter 3 
examined the reporting of QoL outcomes, while Chapter 4 examined the reporting of 
adverse events, focusing on those commonly associated with drug related side effects. 
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Overall the studies completed have provided valuable insights into the preferences of kidney 
transplant patients and the extent to which current clinical research address patient relevant 
outcomes. 
 
Chapter 2 
Transplant recipients participating in the qualitative study indicated a willingness to accept 
not only unpleasant side effects of immunosuppression such as weight gain and hair loss, but 
also serious events such as cancer in order to maintain stable and satisfactory allograft 
function and thereby avoid a return to dialysis. Allograft rejection and declining renal 
function were viewed as inevitably leading to graft loss, the fear of which was so dominant 
that only a small number of participants identified death as more important than graft loss. 
Other complications, such as cardiovascular disease, diabetes, cancer and infection, whilst 
considered important were not identified as imminent issues. Whilst cardiovascular disease 
and infection are both major causes of death in kidney transplant recipients (10), participants 
indicated high blood pressure to be important primarily in the context of detrimental effects 
on kidney function, while increased risk of infection was considered to be largely a nuisance.  
 
The four major themes underpinning the ranking of outcomes included: a concern for serious 
consequences; relevance to life circumstances; future outlook; and acceptance, trivialisation 
and tolerance. Overall the transplant recipients described a willingness to tolerate a range of 
side effects in order to realise the benefit of immunosuppression on graft survival. However, 
this was tempered by individual assessment of whether a specific side effect was relevant to 
them and the potential for it to be debilitating. 
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Chapter 3 
The systematic review of randomised controlled trials of maintenance immunosuppression in 
kidney transplantation indicates that quality of life outcomes are rarely reported. Only 1.8% 
of the reports of trials of maintenance immunosuppression included quality of life outcomes. 
There is inconsistency in how quality of life is measured with 22 different instruments 
covering generic and, disease/symptom specific measures across the 23 trials. As these 
instruments provide measures of multiple domains including health status; physical, mental 
and social functioning; symptom frequency and distress; general well-being; psychological 
well-being and treatment satisfaction, it is difficult to make meaningful inferences of the 
impact of different drug regimens on quality of life. Furthermore, few trials (17%) provided a 
basis for evaluating minimally important or clinically significant differences and the majority 
did not report a mean score or mean change in score from baseline, thus making 
interpretation of results problematic. Without this it is difficult to assess whether differences 
reported are of practical or clinical significance.  
 
Collectively, the selective outcome and/or reporting bias for quality of life outcomes was 
apparent with almost all effect sizes (95%) favouring the interventions over the control 
groups. In addition to the methodological limitations this reporting bias further limits the 
ability to draw meaningful assessments of the relationship between differing regimens and 
quality of life.  
 
Chapter 4  
Side effects associated with maintenance immunosuppression after kidney transplantation are 
common and have the potential to profoundly impact on the quality of life of kidney 
transplant patients (11, 12). However, the systematic review of trials of maintenance 
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immunosuppression in kidney transplantation has shown that this is not reflected in the 
reporting of adverse events. In all 30% of the 233 trials failed to report any adverse event 
indicative of drug related side effects. Furthermore, trials that reported adverse events were 
deficient in a number of important areas, including providing definitions and/or justification 
for the adverse events reported, measurement and definition of severity, describing the 
methodology used to measure adverse events, and whether they were reported by the 
clinician or researcher or patient. Despite the lack of justification and detail on definition and 
methodology, adverse events were included in discussions in nearly 80% of the trials and 
were judged to have influenced the conclusions, either positively or negatively in just under 
half.  
 
The reporting of outcomes in trials was heterogeneous with 40 different types of adverse 
events recorded. Of these 26 were reported in fewer than 10% and 16 in less than 2% of trials 
reporting one or more adverse events. Gastrointestinal disorders were the most frequently 
reported adverse event (70% of trials). Within trials for single classes of drugs, data suggests 
selective reporting and/or recording of adverse events. For example, in the calcineurin 
inhibitor trials, 36 different adverse events were reported of which 21 (58%) were reported in 
fewer than 10% of those trials reporting adverse events. In trials focused on mycophenolate 
gastrointestinal disorders were reported in all of the trials, with only three other adverse 
events reported in more than 10% of these trials one of which, abdominal pain, is related to 
gastrointestinal disorders. 
 
The most frequently occurring side effects in reviews of observational studies are unusual 
hair growth, acne, muscle weakness, bruising, sleeplessness, depression fear/anxiety, tremors, 
gum disorders, swollen and painful joints, fatigue, and impotence (11, 12). The top 10 most 
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frequent symptoms reported in a 2009 review of five kidney transplant observational studies 
did not include gastrointestinal disorders the most frequently reported in our review (11). 
Diarrhoea was however, recorded as the fifth most distressful symptom in one study. These 
findings are inconsistent with the adverse events recorded in the review conducted for this 
thesis and further suggest underreporting in randomised controlled trials.  
 
Chapter 5 
The findings of the pilot BWS were used to refine the design, content and administration of 
the final BWS (Chapter 6). The face validity and the low major error rate indicate that the 
BWS is a feasible approach for eliciting preferences for long-term outcomes associated with 
immunosuppression after transplantation. The BWS is particularly suited to kidney 
transplantation as treatment after transplantation is a process of adjusting the level and type of 
immunosuppression to balance benefits (graft survival) against harms (side effects and 
serious adverse outcomes) rather than a choice between distinct treatment options. Describing 
treatment outcomes as multi-attribute single scenarios with differing attribute levels, as in a 
BWS, is more realistic than the choice scenarios of a conventional discrete choice 
experiment. The pilot study has shown that the conduct and analysis of the BWS should 
carefully consider the meaning and understanding of outcomes. Finally, the design of the 
BWS should recognise that the complexity may limit participation and result in selection 
bias.  
 
The findings of the pilot study provided better informed parameters for statistically efficient 
designs and suggest the need for a design format aimed at minimising cognitive burden. In 
particular, the use of a blocked design and a ‘best’ then ‘worst’ then ‘next best’ then ‘next 
Chapter 7 Discussion and conclusions 
 
190 
worst’ format can reduce the number of choice scenarios without compromising statistical 
efficiency.  
 
Chapter 6  
This BWS has demonstrated the overwhelming importance of graft survival to transplant 
recipients, which dominates all other outcomes. Very short duration of graft survival (one 
year) is worse than any outcome, including a 100% risk of dying before graft failure. Five to 
15 years of graft survival is regarded by transplant recipients as equivalent to a high risk of 
serious adverse outcomes including dying before graft failure. It is only beyond 15 years of 
graft survival that low risks of serious adverse outcomes are of equal or greater importance to 
patients, which suggests that this may be an important threshold for their decision making. 
There is a willingness to trade only a small number of years of graft survival to avoid adverse 
outcomes, and then only to achieve an improbably low risk. Graft survival was the only 
attribute positively associated with acceptance of the hypothetical treatment profile. This 
means that on average, acceptance was determined by the years of graft survival. 
 
The prime importance of graft survival is largely consistent with expectations, however, the 
magnitude of dominance means that long duration, of at least 15 years is favoured over high 
risks of serious outcomes including dying. This contrasts with clinical research in kidney 
transplantation that is largely limited to reporting outcomes less than 5 years after 
transplantation (13-17). In the review of adverse event reporting (Chapter 4), of the 233 
randomised controlled trials published between January 2003 and December 2015, 64% were 
less than 2 years duration and only 13% were more than 4 years (18). Clearly, there are 
logistical issues in ascertaining long-term outcomes, but if research is to be relevant and to 
inform decision making, then outcomes need to match patient expectations. 
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7.2. Strengths and limitations 
 
The overall strength of the studies making up this thesis is the combined use of qualitative 
and quantitative techniques to elicit preferences of kidney transplant recipients for outcomes 
after transplantation and the use of systematic reviews for the assessment of clinical research. 
The qualitative study, which allowed evaluation of the views of kidney transplant recipients, 
ensured that the BWS addressed outcomes relevant to patients. Similarly, the systematic 
review of randomised controlled trials has allowed an objective basis for assessing the 
reliability of reporting of patient relevant outcomes. The use of quantitative techniques 
provides for an informed understanding of relative preferences, the interaction between 
patient characteristics and preferences, and an evaluation of the extent to which individuals 
may be willing to make trade-offs in balancing benefits and harms.  
 
The limitations associated with individual studies have been detailed in the relevant chapters, 
however there are limitations that are relevant to the overall findings of the thesis. Firstly, the 
select nature of the participants who were English speaking, predominantly of European or 
Anglo Saxon heritage and well educated. Secondly, outcomes after graft loss and return to 
dialysis were not included. Finally, the preferences and trade-offs described in Chapter 6, are 
for adults who have had a kidney transplant. Children, who have had a transplant, as well as 
children and adults on a dialysis wait-list prior to transplant are likely to have different 
preferences. 
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7.3. What this research adds 
Overall 
Whilst a number of studies have assessed the adverse impacts of side effects associated with 
immunosuppression, few have elicited preferences and priorities for outcomes after 
transplantation. Furthermore, where preferences have been assessed the studies have focused 
on side effects in isolation of serious adverse outcomes and graft and patient survival. This 
limits the understanding of overall preferences as well as the trade-offs an individual may be 
willing to make. 
 
Chapter 2 
A number of studies have evaluated the frequency and associated distress of the large number 
of side effects associated with immunosuppressant medication in kidney transplantation 
populations (11, 12, 19-22). These studies also suggest a high degree of variation in 
identification of the most frequent and distressing side effects, however this may in part 
reflect variation in the dominant drug regimens between the studies and thus variation in side 
effect profiles (23). In these studies patient preference was based on consideration of side 
effects alone and not serious adverse events including graft survival. In contrast, in the study 
reported in Chapter 2, participants were asked to consider and rank the importance of all 
outcomes together rather than side effects in isolation. In this context, participants rated side 
effects as having very low importance compared to graft survival.  
 
In the qualitative study by Orr et al (24), kidney transplant recipients expressed a strong fear 
that their kidney would fail necessitating the need to return to dialysis, with some expressing 
that they would prefer to die. The stress associated with fear of graft failure has been noted as 
being very high and does not appear to diminish with time (25, 26). This underlying fear of 
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graft failure is consistent with ‘kidney function’ and kidney rejection’ being more important 
than survival.   
 
Chapter 3 
An editorial published in the Lancet in 1995 (27) noted three implicit assumptions in quality 
of life outcomes in clinical trials: first, that we know what is being measured; second, that we 
understand why particular variables are being measured and thirdly, that the estimate is valid. 
Based on a review completed in 1994 (28) the editorial considered that there was strong 
evidence that all three assumptions are wrong. Polonsky (29) commented in 2000, that many 
researchers use an arbitrary approach in selecting instruments choosing the most commonly 
used or they assume that quality of life equates to psychosocial status and use measures 
indicative of depression and anxiety. Although quality of life is increasingly measured in 
clinical trials, there is a lack of definition of what is being measured and inadequate attention 
to why or how it is being measured and reported. This has been confirmed in numerous 
systematic reviews of quality of life outcomes in clinical trials across a range of diseases and 
interventions (28, 30-38). These failings are consistent with the findings reported in Chapter 
3 for clinical trials in kidney transplant populations. Whilst the subjective nature of patient 
reported outcomes may contribute to an exaggeration of treatment effects on quality of life 
compared to objective clinical outcomes (39, 40) the observed bias in the quality of life 
outcomes to favour the intervention is consistent with the known and common occurrence of 
outcome reporting bias in randomised controlled trials (41, 42). 
 
Chapter 4 
The harms extension of CONSORT (43) was published in 2004 in response to reviews that 
highlighted inadequacies in reporting of adverse events (44, 45). Subsequent reviews have 
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continued to show inadequacies in reporting of adverse events across a range of disciplines. 
For example reviews of 60 randomised trials on interventions for persistent depressive 
disorder (46), 290 solid organ transplant trials published between 2007 and 2009 (47), 956 
oncology trials published over the periods 2005-2007 and 2010-2012 (48), and 49 
randomised controlled trials of antiretroviral therapy published between 2000 and 2008 (44) 
all showed major deficiencies in reporting with no evidence for improvement with time. 
Similar findings have been reported for trials in gastroenterology (49), cancer drug trials (50, 
51), urology (52), and for trials published in high impact journals (53). Many studies have 
noted the subsequent impact of poor adverse event reporting on systematic reviews and meta-
analyses (49, 54-57). 
 
In contrast to the RCTs reviewed in Chapter 4, in a 2009 review of observational studies the 
top 10 most frequent symptoms reported in the five kidney transplant studies did not include 
gastrointestinal disorders (11). Rather, the most frequently occurring outcomes in these 
observational studies were unusual hair growth, acne, muscle weakness, bruising, 
sleeplessness, depression fear/anxiety, tremors, gum disorders, swollen and painful joints, 
fatigue, and impotence (11, 12). 
 
Chapters 5 and 6 
Patient preferences, and trade-offs between risks of adverse outcomes, side-effects and 
patient/graft survival, have been addressed mostly in the context of the acceptance of donor 
organs of varying quality. A maximum difference scale (similar to a BWS) has been used to 
assess patient and clinicians priorities for deceased donor organs with both identifying donor 
organ quality and function as being most important (58). The longer a patient was on dialysis 
the less importance was placed on function, however, adverse outcomes and graft/patient 
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survival after transplantation were not included. This means that patients may not have 
considered these aspects in their evaluations. In a discrete choice experiment (59), older age 
and time on dialysis was associated with a greater likelihood of accepting high risk organs. 
Attributes included donor age, additional waiting-list time if the organ was rejected and the 
risk of HIV infection and did not include patient/graft survival.  
 
A survey of Slovenian dialysis patients who had chosen to remain on dialysis rather than 
have a transplant identified the prime reason for their decision as being concern for adverse 
and uncertain outcomes following transplantation. The most important outcomes were cancer, 
diabetes and serious infection however, patient and graft survival were not included in the 
survey (60). A modified standard gamble and time trade-off method approach has been used 
to evaluate acceptance of a reduction in life expectancy after treatment of acute rejection 
compared to no treatment and return to dialysis (61). Consistent with Chapter 6, preferences 
were found to vary with patient characteristics including age, gender, time on dialysis and 
waiting time on the transplant list. A significant limitation of all of these studies is that they 
either did not present realistic scenarios or provided restricted attributes from which 
preferences have been elicited. In contrast, the multi attribute approach in the BWS reported 
in Chapters 5 and 6 combined serious adverse outcomes and side effects, with mortality and 
duration of graft survival based on clinically realistic levels.  
 
7.4. Implications for practice 
Advances in immunosuppression after transplantation have led to a reduction in the incidence 
of acute rejection and improvement in short term graft survival, however, long term graft 
survival rates after kidney transplantation have remained largely unchanged (62). The 
selection of immunosuppressive drugs best suited to an individual should involve an 
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evaluation of complications and harms such as cancer, diabetes, CVD, infections and side 
effects, as well as quality of life. In the qualitative study (Chapter 2), kidney transplant 
patients described a high level of tolerance to a wide range of side effects. Individual 
variability in the level of importance placed on side effects was dependent on personal 
experience and relevance. It is not just severity of the side effect but also the ability to self-
manage or cope that are important in determining impact on quality of life (63, 64). Kidney 
transplant recipients also state a willingness to tolerate serious adverse outcomes such as 
cancer and cardiovascular disease in order to maximise graft survival. In the context of 
shared decisions, an objective understanding of the consequences of adverse outcomes and 
the potential for impact on quality of life is critical to ensuring that decisions truly reflect 
individual values and preferences.  
 
Given the strong emotional association with graft survival, and aversion to returning to 
dialysis, objectivity for patients may be difficult. Elicitation of preferences and trade-offs for 
outcomes after transplantation (Chapters 2, and 6) has demonstrated graft survival to be the 
prime outcome of importance for kidney transplant patients. The trade-off between duration 
of graft survival and serious adverse outcomes such as cancer or dying with a functioning 
graft also reflects the strong emotional association with graft survival. The willingness to 
trade years of graft survival is contingent on an unachievable outcome, namely a zero risk.  
 
Given the complexity and uncertainties of outcomes after transplantation, clinicians have a 
major role in building patient knowledge and subsequently in the formation of patient 
preferences. As the reporting of quality of life and adverse events in clinical trials (Chapters 3 
and 4) is inadequate, it is difficult for clinicians to draw meaningful conclusions (other than 
expectation of improvement compared to dialysis) as to likely differences between treatment 
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regimens. Another consequence of the patient focus on graft survival and acceptance and 
trivialisation of side effects is the potential for under reporting of these effects by patients. 
For example, Peters et al (65) described how clinicians underestimated both the prevalence 
and emotional and social impacts of cosmetic side effects experienced by kidney transplant 
recipients. More than half of the recipients stated that they “rarely or never” talked to their 
clinicians about side effects. Furthermore, 84% of the transplant recipients affected by 
cosmetic side effects reported feeling happy to endure the changes for the sake of having the 
transplant (65). Significant under reporting of gastrointestinal side effects by kidney 
transplant recipients to their clinicians has also been noted (66, 67).  
 
Thus, the most important implication for clinical practice arising from these findings is the 
critical role of interactions between patients and clinicians and pre-transplant education, in 
assisting patients to construct preferences that are based on a balanced and, as far as possible, 
objective expectation of consequences. Only then can they make informed decisions aligned 
with their values. Patients will have varying and often limited knowledge of outcomes and 
their expectations will likely differ from those of clinicians (68). The overall aim of 
clinician/patient interactions and, education, should be that patient preferences are well 
founded and that they lead to decisions that align with patient values. This has implications 
not only for decisions related to immunosuppression but also for patient preferences for 
extended criteria and high risk donor organs.  
 
Key areas of focus for clinician/patient interactions and pre transplant education are: 
• Graft and patient survival. Patient expectations should not be distorted by their lack of 
knowledge regarding serious adverse outcomes that have a high probability of causing 
premature death before their graft fails (69). There may be reluctance for clinicians to 
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discuss mortality and life expectancy (70, 71) and, patients may also not be inclined to 
discuss prognostic details of treatment (70, 72). 
• Communication of the benefits and harms of both transplantation and 
immunosuppression. In a recent survey of dialysis centres in the US only 18% 
reported having discussions with patients on the risks and benefits of deceased donor 
transplantation versus live donors (73).  
• Individualised communication and education. Patient factors that influence ability to 
reach decisions aligned with preferences and values should be considered (74). 
Communication style has been shown to be influential in shared decision making. 
Clinicians, albeit inadvertently, may vary their communication style on the basis of 
patient age, and perception of health literacy (70, 75). This variation can result in 
patient dissatisfaction with both the decision process and the decisions made (75).  
• Use of decision aids. It is well established that communication around complex 
treatment decisions, in particular evaluation of benefits and harms, are assisted by the 
use of decision aids and values clarification tools (76). These include those aimed at 
the patient (3) or clinical decision support tools such as that recently published for 
evaluation of transplantation in the elderly (77). 
• Clarification of patient values. Communication and education strategies should use 
techniques aimed at clarifying patient values (78). 
• Use of a structured communication strategy. Finally, approaches to patient education 
and communication should be structured according to a patient-centred framework 
such as that described by McCormack et al (79).  
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7.5. Implications for research 
The implications for research arising from the studies conducted for this thesis largely follow 
from the implications for care discussed in the preceding section and can be grouped into two 
broad areas: 
• Clinical trials; and 
• Patient preferences, patient-centred care and shared decision making. 
 
Clinical trials 
Chapters 3 and 4 identified deficiencies in reporting of outcomes relevant to quality of life 
and adverse events associated with maintenance immunosuppression after kidney 
transplantation. Similar deficiencies have been identified for clinical outcomes (80). Despite 
the many clinical trials, there remains considerable uncertainty as to the frequency and 
severity of side effects and the potential for different treatment regimens to have differing 
impacts on quality of life following transplantation. In short, inclusion of patient reported 
outcomes in clinical trials should pay particular attention to: 
• Identifying outcomes that are relevant to the intervention and to the patient;  
• Using measures that are both valid and meaningful to patients; and 
• Interpreting and reporting the clinical significance of data for populations and 
individuals and not relying solely on statistical significance.  
Standardised guidelines for reporting of quality of life in clinical trials are lacking and 
systematic reviews have largely relied on a checklist published in 1996 (81) or later variants. 
Whilst this provides an overview of important issues, there is a clear need for a standardised 
reporting protocol for quality of life outcomes. 
 
Chapter 7 Discussion and conclusions 
 
200 
As a minimum, reporting of adverse events in trials must adhere to key domains of the 
CONSORT harms extension (45) in particular definition, justification, collection methods, 
and reporting. Attention should be given to adverse events that are commonly experienced or 
important to patients as this can inform patient-centred decision-making. The core outcome 
measures in effectiveness trials (COMET) is an international initiative fostering a consensus 
approach to development of consistent measures and reporting requirements for patient 
important outcomes that should be applied to clinical trials in the kidney transplant 
population (71). 
 
In addition to the above, clinical researchers should be aware that patient focus is on long-
term outcomes that fall well outside of the usual duration of clinical trials in kidney 
transplantation. Clearly, there are logistical issues in ascertaining long-term outcomes, but if 
research is to be relevant and to inform decision making, then outcomes need to match patient 
expectations. 
 
Patient Preferences and shared decision making 
The preference elicitation studies reported in Chapters 5 and 6 have highlighted the 
practicality and value of using quantitative choice based preference elicitation techniques. 
Similar techniques have also been successfully used in chronic kidney disease and with 
people on dialysis (82). In this study, the BWS technique addressed the complex interaction 
of benefits (duration of graft survival) with the harms of immunosuppression which is 
cognitively challenging yet key to making clinical decisions that align with patient 
preferences and values. There are a number of areas of future research relevant to the 
continued application of these techniques that we intend to explore: 
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• It is well known that there are disparities in access to transplantation according to 
socioeconomic status, ethnicity and in marginalised groups such as indigenous 
populations (83-86). Our study population was select in terms of ethnicity and 
education. Application of quantitative preference elicitation techniques in more 
diverse populations groups, including minority and marginalised groups would be of 
value in identifying factors limiting access to transplantation. 
• Consideration of the use of extended criteria donor organs. Ross et al (5) argue that a 
‘rational’ decision for accepting poorer quality organs should be based on risk of 
mortality on the waiting-list, however, this assumes that mortality is the only outcome 
of importance to patients. Our study, and previous qualitative work (87), indicates that 
other factors may be more important for some patients. Acceptance of extended 
criteria organs with resultant short graft survival may contribute to psychological 
distress and morbidity (88) which on balance would favour not accepting a these 
organs. Given the growing use of extended criteria and high risk donor organs, 
understanding the preferences of individuals on the transplant wait list for acceptance 
of less than ideal organs and the factors influencing these preferences is crtical to 
developing guidelines for use of these organs. Preference elicitation would also be of 
value in the development of decision aids for both patients and clinicians. 
• Assessment of the influence on patient preferences of outcomes after returning to 
dialysis. This is of particular relevance to younger patients and preferences may 
influence decisions on acceptance of less than ideal donor organs. 
• There is a need to understand patient preferences for specific actions/interventions 
that might be taken in response to complications or development of comorbidities 
after transplantation. This includes patient preferences for cancer screening and 
programs aimed at minimising cardiovascular disease and skin cancer after 
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transplantation. In contrast, the study in this thesis focussed on broad concepts of 
variation in benefits and harms following transplantation, which assists in identifying 
motivators and flawed or skewed beliefs of outcomes. 
 
Additional research questions also arise from the implications identified for clinician/patient 
interaction and education: 
• Development and evaluation of patient and clinical decision aids. 
• Development and evaluation of techniques for clarifying patient values (79). 
• Evaluation of patient-centred communication and education strategies (78). 
 
7.6. Conclusions  
Graft survival appears to be more important than life itself to kidney transplant recipients and 
the willingness to trade graft survival is contingent on achieving a very low risk of adverse 
outcomes. Whilst patients are willing to accept side effects as being necessary, avoiding a 
high risk of occurrence of debilitating side-effects may for some be as important as serious 
adverse outcomes such as cancer, CVD, diabetes and infection. Preferences and trade-offs for 
outcomes after transplantation show a focus on long-term outcomes that are poorly addressed 
in clinical trials. Furthermore, the reporting of outcomes relevant to quality of life and 
adverse events associated with maintenance immunosuppression is, selective and unreliable, 
and in the case of quality of life rare. These deficiencies limit the ability for clinicians to 
effectively engage with patients in developing individualised care.  
 
Key implications arising from the study are: 
• All clinical decisions both before and after kidney transplantation should incorporate 
patient preferences and values. As patient preferences are framed by beliefs of the 
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consequences of treatment, decision making must be underpinned by a sound 
understanding of benefits and harms of transplantation and immunosuppression. 
• Communication and education both before and after transplantation, must 
acknowledge the overwhelming importance of graft survival and the decisional 
conflicts that this can present for transplant patients.  
• Individual preferences will vary according to medical and non-medical factors both of 
which are relevant in patient-centred care and shared decisions. Similarly, preferences 
should be expected to vary with factors such as age, time on dialysis, and number of 
prior transplants.  
• For clinical trials to support patient-centred care, and facilitate shared decision 
making, they must address outcomes that are both relevant and important to patients.  
• Reporting of outcomes should be to recognised standards to ensure both reliability 
and consistency. 
• The clinical significance of outcomes should always be reported. 
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A. Supplementary Material – Chapter 3. 
A.1. Supplementary Table S1    
 
A.1 Table S1 Search Strategy – OVID Medline 
 
1. Antibodies, Monoclonal/ 
2. monoclonal antibod$.tw. 
3. (polyclonal adj3 antibod$).tw. 
4. Antilymphocyte Serum/ 
5. antilymphocyte.tw. 
6. alg.tw. 
7. lymphocyte$ antibod$.tw. 
8. lymphocyte antiserum$.tw. 
9. muromonab cd$.tw. 
10. thymoglobulin$.tw. 
11. antithymocyte.tw. 
12. atg.tw. 
13. okt3.tw. 
14. okt 3.tw. 
15. thymocyte antibod$.tw. 
16. thymocyte antiserum$.tw. 
17. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 
 
18. Tacrolimus/ 
19. tacrolimus.tw. 
20. prograf.tw. 
21. FK 506.tw. 
22. FK506.tw. 
23. Tsukubaenolide.tw. 
24. fr-900506.tw. 
25. fujimycin.tw. 
26. protopic.tw. 
27. 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 
 
28. Mycophenolic Acid/ 
29. mmf.tw. 
30. Mycophenolate mofetil.tw. 
31. Morpholinoethyl Ester.tw. 
32. Cellcept.tw. 
33. myfortic.tw. 
 
34. 33 or 31 or 28 or 30 or 29 or 32 
35. Sirolimus/ 
36. sirolimus.tw. 
37. rapamycin.tw. 
38. rapamune.tw. 
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39. ay 22-989.tw. 
40. everolimus.tw. 
41. SDZ RAD.tw. 
42. certican.tw. 
 
43. 40 or 37 or 41 or 36 or 42 or 35 or 38 or 39 
44. exp Cyclosporins/ 
45. cyclosporin*.tw. 
46. CSA.tw. 
47. CS A.tw. 
48. 47 or 44 or 46 or 45 
 
49. ((avoid$ or minim$ or free$ or withdraw$ or spar$ or discontinu$ or taper$ or 
conversion$ or convert$) adj25 (predniso$ or corticosteroid$ or steroid$)).tw. 
50. 44 or 45 or 46 or 47 or 48 or 49 
 
51. exp Immunosuppression/ 
52. exp Immunosuppressive Agents/ 
53. 51 or 52 
 
54. 17 or 27 or 34 or 43 or 48 or 50 or 53 
 
55. Kidney Transplantation/ 
56. 54 and 55 
 
57. qol.tw. 
58. quality of life.tw. 
59. hrqol.tw. 
60. "Quality of Life"/ 
61. quality adjusted life years.tw. 
62. quality-adjusted life years/ 
63. qaly.tw. 
64. exp "severity of illness index"/ or sickness impact profile/ 
65. health utility.tw. 
 
66. 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 
 
67. 56 and 66 
 
68. randomized controlled trial.pt. 
69. controlled clinical trial.pt. 
70. randomized.ab. 
71. placebo.ab. 
72. clinical trials as topic.sh. 
73. randomly.ab. 
74. trial.ti. 
75. 68 or 69 or 70 or 71 or 72 or 73 or 74 
76. exp animals/ not humans.sh. 
77. 75 not 76 
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A.2. Supplementary Table S2  
A.2 Table S2. Methodological characteristics of included trials 
 
Study Instrument(s) Hypothesis and 
Rationale 
Psychometric 
Properties 
Validity of 
Instruments 
Adequacy 
of Domains 
Administration Baseline Compliance Timing of 
Assessments 
Missing Data 
Addressed 
Clinical 
Significance 
Presentation of 
Results 
       Total at 
baseline 
HRQoL at 
baseline 
    
Dobells 
(2014) 
BENEFIT 
and 
BENEFIT-
EXT 
SF36; 
MTSOSDS 
Yes (hypothesis) 
Yes (rationale) 
Yes Yes Yes Yes 543 and 
666 
543 and 666 Yes Yes Yes 
 
Yes 
Ortega et al 
(2011)  
GSRS; GIQLI; 
PGWBI; OTE 
Yes (hypothesis) 
Yes (rationale) 
Not 
discussed 
Not discussed 
(cultural validity 
not addressed) 
Yes 
(specific 
and generic 
instruments) 
Unclear 107 88 Yes Yes Not discussed Partial 
(subscales not 
presented for 
primary 
endpoint 
GIQLI. 
Subscales and 
total reported 
for PGWBI and 
GSRS) No SD 
reported. 
Langone et al 
(2011)  
GSRS; GIQLI; 
OTE 
Yes (hypothesis) 
Yes (rationale) 
Yes (by 
reference ) 
Yes (by 
reference) 
Yes 
(specific 
instruments) 
Yes 396 393 Yes Yes Partial. MID 
of 0.3 change 
for GSRS. No 
MID for 
GIQLI 
Partial (GIQLI 
and OTE data 
not presented).  
Sommerer 
(2011)  
GSRS Yes (hypothesis) 
Yes (rationale) 
No (not 
discussed) 
No (not 
discussed) 
Yes Unclear. Not 
stated how data 
was collected. 
128  No baseline 
data for GSRS 
Yes (no 
baseline 
assessment) 
Yes No Partial 
Oppenheimer 
2009  See 
SYMPHONY 
Study  
SF36 Yes (hypothesis) 
Yes (rationale) 
Yes 
(inferred) 
Yes Yes for 
generic 
level. 
However 
SF36 
unlikely to 
have 
sensitivity 
for 
differences 
in side 
effect 
profiles. 
Yes 1645 156 (sub study) 
No SF36 at 
baseline 
Yes Not discussed Not discussed Partial (main 
component 
scores only 
with main data 
presented 
graphically) 
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A.2. Supplementary Table S2 cont. 
Study Instrument(s) Hypothesis and 
Rationale 
Psychometric 
Properties 
Validity of 
Instruments 
Adequacy 
of Domains 
Administration Baseline Compliance Timing of 
Assessments 
Missing Data 
Addressed 
Clinical 
Significance 
Presentation of 
Results 
       Total at 
baseline 
HRQoL at 
baseline 
    
Shehata 
(2009) 
SF36, GSRS, 
GIQLI, OTE 
Yes (hypothesis) 
Yes (rationale) 
Yes 
(inferred) 
Yes  Yes  Yes 129 No baseline 
data 
Yes (no 
baseline 
assessment) 
Yes No Yes 
Bolin (2008)  
Astellas 
Memphis survey No (hypothesis) 
No (rationale) 
Not 
discussed 
Not discussed Not 
discussed 
Not stated 323 No baseline 
data 
Yes (no 
baseline data) 
Yes Not discussed No 
Kahan (2008)  GSRS, GIQLI Yes (hypothesis) 
Yes (rationale) 
Not 
discussed 
Not discussed Yes  Not stated 40 35 Yes Yes Not discussed Partial – total 
GSRS scores 
only. No 
explanation of 
how scores are 
calculated. Did 
not use the 1 to 
7 Likert scale 
for the GSRS 
rather a 0 to 4 
no explanation 
and no 
indication as to 
how this would 
affect the 
psychometric 
properties. 
Russ 2007  
(Johnson et al 
2001) for 
clinical 
outcomes 
SF36. 
KTQ. 
Health 
Thermometer 
Hutchison 
(2202). 
Yes (hypothesis) 
Yes (rationale) 
Yes Yes Yes  Yes 430 418 – excluded 
Polish patients 
Yes Yes Yes (both 
point score 
and effect 
size) 
Partial. (Health 
thermometer 
data at 2 years 
only) 
Walker 
(2007)  
VAS 
(gingivitus). 
VAS (hirsutism) 
SF36 
Partial 
Yes for VAS 
(hypothesis and 
rationale). No 
for SF36 
(hypothesis and 
rationale). 
Yes Yes Yes for 
VAS. 
Unclear for 
SF36. 
Yes 20 20 Yes Yes No Yes 
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A.2. Supplementary Table S2 cont. 
Study Instrument(s) Hypothesis and 
Rationale 
Psychometric 
Properties 
Validity of 
Instruments 
Adequacy 
of Domains 
Administration Baseline 
Compliance 
Timing of 
Assessments 
Missing Data 
Addressed 
Clinical 
Significance 
Presentation 
of Results 
 
       Total at 
baseline 
HRQoL at 
baseline 
    
Artz (2004) 
see Artz 
(2203) for 
clinical 
outcomes 
 
 
MTSOSDS Yes (hypothesis) 
Yes (rationale) 
Yes Yes Yes  No 124 124 Yes Yes Not discussed No. Selective 
reporting of 
total ridits. No 
indication of 
change in 
specific 
symptoms. 
Ridits relative 
to baseline 
rather than 
treatment vs. 
control. 
Kumana 
(2003)  
SF36 (Chinese) No (hypothesis) 
No (rationale) 
Yes 
(inferred) 
Yes  Yes 
(although 
would not 
anticipate 
SF36 to 
pick up 
differences 
for this 
intervention
) 
Yes 124 Not stated No Yes Unclearly – 
defines 
difference of 
10% as being 
indicative of 
unequal 
‘acceptability’
. 
No (text only 
no data) 
Painter 
(2003)  
SF36 Yes (hypothesis) 
Yes (instrument) 
Not 
discussed 
Not discussed Yes. 
Although 
given 
treatment 
might not 
expect SF36 
to show 
differences.  
Yes 23 23 (No baseline, 
first score at 3 
months even 
though steroid 
withdrawal 
occurred at day 
5). 
Yes (only 3 
months and 12 
months 
reported) 
Yes No Yes 
Baltar (2002)  
 
PWGBI 
EQ-5D 
VAS 
Yes (hypothesis) 
Yes (rationale) 
Yes Yes Yes Yes 26 26 Yes (baseline at 
time of 
discharge after 
transplant) 
No No Partial. No 
treatment data 
reported and no 
sub scores for 
PGWBI. Data 
presented for 
the control and 
intervention 
combined.  
Budde (2002)  Welzel-Kohnen 
colour scales for 
assessment of 
general 
wellbeing. 
No (hypothesis) 
No (instrument) 
No No No No 23 Not stated Yes Unclear No No 
  
Appendix A 
 
219 
A.2. Supplementary Table S2 cont. 
Study Instrument(s) Hypothesis and 
Rationale 
Psychometric 
Properties 
Validity of 
Instruments 
Adequacy 
of Domains 
Administration Baseline 
Compliance 
Timing of 
Assessments 
Missing Data 
Addressed 
Clinical 
Significance 
Presentation 
of Results 
 
       Total at 
baseline 
HRQoL at 
baseline 
    
Polsky (2001) 
see Sollinger 
et al (2001) 
EuroQol VAS Yes (hypothesis) 
No (instrument) 
No No Not 
discussed 
Yes 138 135 Yes Yes No Yes 
 Lee (2000)  SF36 (Taiwan) No (hypothesis) 
No (instrument) 
Not 
discussed 
No No (SF36 
lacks 
sensitivity 
for the 
research 
question) 
No 43 Not stated Yes No No Partial. Results 
presented 
graphically. No 
PCS or MCS 
scores 
provided. 
Wang (1999) 
ABSTRACT 
see Kahan 
(2000)  
SF36 
KTQ  
Health 
thermometer 
MHI 
Yes (hypothesis) 
Unclear 
(instrument) 
Partial Partial Yes No 719 0 (no data 
collected at 
baseline) 
Yes No No Partial. 
Abstract report 
only. 
Shield (1997) SF36; Current 
Health; Health 
Outlook; Health 
Distress; 
Flemming Self 
Esteem Scale; 
Bergner Physical 
Appearance 
Yes (hypothesis) 
Yes (rationale) 
Partial Partial. Not all 
components of 
the 
questionnaire 
were validated 
instruments. 
Unclear as to the 
origin of CH, 
HO, and HD. 
Yes Yes 412 303 Yes No Yes Partial. 
Data reported 
for sub groups 
only. No data 
presented for 
the non-
significant 
treatment 
effects. 
Hillbrands 
(1995)  
SIP; 
ABS; 
CES-D 
Yes (hypothesis) 
Yes (rationale) 
Yes Partial. 
(modifications 
and additions 
made that have 
not been 
validated). 
Yes Yes 120 120 Yes Yes No Yes. 
Simmons 
(1987)  
Physical Well 
Being 
Emotional Well 
Being 
(Rosenberg Self 
Esteem Scale) 
Social Well 
Being 
Yes (hypothesis) 
Yes (rationale) 
Unclear Unclear Yes Yes 91 0 (data collected 
at follow up 
only) 
No No No Yes 
Alvarez-
Amador et al 
(1996) 
SIP 
VAS (self-global 
assessment, 
impact of 
disease, impact 
of treatment) 
Yes (hypothesis) 
Yes (rationale) 
Partial. 
Refers to 
validation for 
a short form 
version of 
SIP – no 
details 
provided. 
Unclear.  Yes Unclear. Not 
stated whether 
completed in the 
presence of 
researchers. 
20 20 Not stated Yes No Partial. No 
reference made 
to SIP sub 
scales. 
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Legend for Supplementary Table S2 
 
SF36 – Short Form-36; KTQ – Kidney Transplant Questionnaire; MTSOSDS - Modified Transplant Symptom Occurrence and Distress Scale; PWGBI – Physical Well Being Global Index; 
VAS – Visual Analogue Scale; EQ-5D – EuroQol-5D; MHI – Mental Health Index; CH – Current Health; HO – Health Outlook; HD – Health Distress; FSE – Flemming Self-Esteem; BPA – 
Bergner Physical Appearance; SIP – Sickness Impact Profile; ABS – Affect Balance Scale; CES-D – Centre for Epidemiologic Studies Depression scale ;GSRS - Gastrointestinal Symptom 
Rating Scale; GIQLI – Gastrointestinal Quality of Life Index; OTE – Overall Treatment Effect; ESRD-SCL – End Stage Renal Disease Symptom Checklist 
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A.3. Supplementary Table S3  
A.3. Table S3. Impact of HRQoL and Clinical Outcomes  
 
Study Treatments and Follow Up HRQoL Endpoint Main Clinical Outcome HRQoL Outcome HRQoL Influenced Clinical Decision/Assessment 
Ortega et al (2011) EC-MPS vs. MMF. No 
restriction on other 
immunosuppressants. 
Primary. GIQLI score.  
Secondary. GSRS, 
PGWBI, GIQLI 
subscales, OTE. 
A higher percentage of patients 
in the EC-MPS group were 
receiving intermediate doses of 
MPA compared to the MMF 
group at 12 weeks. No 
difference observed for the 
higher dose. Mean doses were 
the same. 
Both groups showed statistically significant 
improvement in GIQLI from baseline. At 12 
weeks EC-MPS showed better GI HRQoL on 
the basis of GIQLI and PGWBI. Ad hoc 
analysis suggests ability to tolerate higher 
MPA dose in the EC-MPS group compared to 
MMF. The SMD for the GIQLI score at 
follow up is 0.58. 
Yes. The results of HRQoL measures used to 
formulate conclusion and potential benefit of switch 
from MMF to EC-MPS in kidney transplant 
recipients showing signs of GI intolerance to MMF. 
However, no discussion of clinical significance has 
been made. Used partially reported MMF dose data 
to conclude greater tolerability.  
 
Effect size able to be calculated using a SMD. 
Langone et al (2011)  EC-MPS + MMF 
placebo+CNI±steroids vs. 
MMF+EC-MPS 
placebo+CNI±steroids. 
Adults (18 to 75 years) 
transplanted at least 4 weeks 
receiving MMF+CNI±steroid; 
experiencing GI symptom 
burden attributed to MMF. 
Primary. Proportion of 
EC-MPS vs. MMF 
patients who responded to 
the intervention of 
conversion which was 
defined as exceeding the 
MID of 0.3 GSRS score at 
30 days. 
Acute rejection low and 
similar between treatment 
groups. 
No significant difference for the primary 
endpoint. Both groups showed statistically 
significant improvement in GSRS and GIQLI 
from baseline to 30 days, however differences 
between groups were not statistically 
significant. Post hoc analysis showed 
statistically significant improvements with 
EC-MPS compared to MMF for the sub group 
of patients with diabetes and those whose 
transplant occurred more than 6 months and 
less than 12 months prior to commencement 
of the study. The SMD for GSRS change from 
baseline was 0.27 for overall GSRS score. 
Highest SMD being 0.33 for sub score 
(eructation). There was no difference between 
groups for the absolute scores. 
Yes. The results of sub group analyses suggest 
future modifications to the experimental design that 
may potentially lead to better characterization of 
patients with GI symptoms who may benefit from 
conversion to EC-MPS from MMF. Authors 
conclude that the results could indicate clinicians 
over estimated those whose GI symptoms were due 
to MMF. However, this was based on post hoc 
analyses.  
 
Able to calculate OR’s for proportion meeting MID 
of 0.3 change. 
 
Oppenheimer (2009)  1. Standard-CsA. 2. Low-CsA. 
3. Low-Tac. 4. Low SRL. 
Adults (>18years) with low to 
normal immunological risk. 
Follow up = 12 months 
Secondary. Not stated as 
an endpoint in 
SYMPHONY study 
protocols 
Low-dose Tac may be 
advantageous for renal 
function, allograft survival, 
and acute rejection rates, 
compared with low-dose CsA 
or low-dose SRL or with 
standard-dose CsA. 
No significant differences identified, however 
the low-dose Tac group showed the fastest 
improvement. PCS increased from baseline, 
MCS did not. All differences are small. 
Individuals with acute rejection lower MCS at 
6 months. 
Yes. Comment made regarding benefits of Tac in 
relation to QoL. However this is based on serum 
creatinine subgroup analysis and an assumption that 
tacrolimus is associated with better renal function as 
concluded by the main study. However this is not 
supported by the data from the sub study. 
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Study Treatments and Follow Up HRQoL Endpoint Main Clinical Outcome HRQoL Outcome HRQoL Influenced Clinical Decision/Assessment 
Bolin (2008)  1. Low tac. 2. Standard tac. 3. 
Standard CsA. 
Adults (>18 years) at least 6 
months post transplant 
maintained on a CsA based 
regimen. 
Follow up = 12 months 
Assumed to be secondary, 
however not listed with 
secondary efficacy 
outcomes. 
No significant difference in 
incidence of BCAR or biopsy-
confirmed treated rejection in 
the first 12 months. Estimated 
creatinine increased from 
baseline in reduced tac and 
decreased in standard tac and 
CsA. Reduced tac sig different 
to CsA. 
No significant difference between treatment 
groups in the median change from baseline for 
emotional/burden, life/role responsibilities, 
mobility or miscellaneous. Significant 
difference across treatment groups for 
enlarged gums which increased (i.e. poorer 
QoL) in CsA and decreased in tac. GI distress 
score increased from baseline in the reduced 
tac group. 
No. Discussion indicated similar QoL outcomes.  
 
Inadequate reporting to allow effect size to be 
calculated for significant differences in Memphis 
Survey sub scores. 
Kahan (2008)  Immediate conversion from 
MMF to EC-MPS vs. delayed 
(90 days) conversion. Adults 
(>18 years) < 10 years post 
transplant, treated with 
sirolimus and MMF at least 30 
days prior. 
Follow up = 180v days 
 
Not stated, however 
assumed GIQLI and 
GSRS scores were 
primary outcomes. 
No clinical outcomes reported. No significant differences between groups in 
aggregate scores at baseline, 90 days or 180 
days. Note some differences in reported 
symptoms between groups, however not 
assessed using the instrument scores. 
Yes. Concluded that findings suggested conversion 
from MMF to MPS produced benefit even though 
both GSRS and GIQLI were not different. This was 
based on a comparison to a control MMF group. 
Conclusion is not supported by the results. 
Selectively reported and combined results from 
GSRS and GIQLI even though they are different 
instruments. 
Russ (2007) CsA withdrawal vs CsA 
maintenance 
(CsA/SRL/Steroids) 
Follow up = 3 years 
Secondary. Not stated as 
an endpoint in Johnson et 
al 2001 or Mota (2004)  
All six components of the 
chronic allograft damage index 
score were numerically lower 
in SRL-Steroid group. The 
calculated glomerular ﬁltration 
rate at 36 months was 
signiﬁcantly better in the CsA-
withdrawal group 
SF36: Significant treatment by time effects in 
favour of CsA withdrawal in vitality, general 
health, social functioning. 
KTQ: Significant treatment by time effects 
for fatigue and appearance with less fatigue 
with CsA elimination, and no treatment 
differences with appearance, however 
improving appearance score with time. 
Health Thermometer: No significant 
differences at 2 years not reported at 3 years. 
Maximum SMD’s around 0.25.  
Yes in HRQoL report, however the clinical 
outcomes report made the same conclusions without 
HRQoL or any reference to HRQoL assessment 
having been completed. HRQoL stated to be 
consistent with clinical outcomes and to be 
associated with a clinically significant effect on 
fatigue assumed to be due to effects on anaemia, 
however no association with anaemia was 
presented. The MID values were applied to the 
change from baseline, however differences between 
groups at follow up were less than the MIDs. The 
differences could therefore be interpreted as being 
small. 
 
Walker (2007)  Conversion from CsA to 
tacolimus vs CsA 
maintenance. 
Follow-up = 12 months. 
Secondary Tacrolimus treated patients 
had significantly reduced 
pocket depth and gingival 
enlargement measures 
compared with CsA 
maintenance. 
SF36 – no significant differences at baseline 
or follow up between groups. 
VAS – significantly improvement in 
disfigurement and hirsutism rating from 
baseline in tacrolimus group compared to CsA 
group. 
No. Although noted that further assessment of QoL 
in a larger population would be warranted. 
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Study Treatments and Follow Up HRQoL Endpoint Main Clinical Outcome HRQoL Outcome HRQoL Influenced Clinical Decision/Assessment 
Artz (2004)  Conversion of CsA to Tac. 
Follow up = 2 years 
Secondary (assumed). Not 
stated as an endpoint in 
Artz (2003) even though 
it was recorded at baseline 
and all time intervals. 
Conversion to Tac beneficial 
effect on graft function and 
sustained improvement in 
cardiovascular risk profile. 
 
SMD for serum creatinine at 
12 months -0.35 [-0.71, 0.00] 
 
Significant increase in symptom occurrence in 
CsA and decrease in Tac compared to 
baseline. Symptom distress results more 
variable however, at 12 and 24 months CsA 
significantly greater distress than baseline and 
Tac significantly less distress. There is a 
mismatch between most frequent and most 
distressing symptoms.  
Difference between ridits relative to baseline 
<0.06. 
Yes – Tac associated with a reduction in frequency 
and distress of side effects on basis of ridit. The ridit 
has been calculated relative to baseline. This does 
not allow an assessment of the difference between 
tac and CsA. The difference between ridits are small 
(<0.06). No confidence intervals have been 
provided. No discussion of change in specific 
symptoms. However the clinical outcome report 
made the same conclusions. 
Kumana (2003)  Diltiazem/CsA vs 
Placebo/CsA 
Follow up = 6 months 
Secondary (ancillary) The mean daily dosages of 
CsA were significantly lower 
with dilitazem co-treatment.  
SMD -0.55 [-0.93, -0.17] 
 
No significant differences between treatment 
and placebo groups. No data reported. This 
was stated to be an ancillary outcome.  
No. Decision based on primary outcome. 
Painter (2003)  Rapid steroid withdrawal vs 
standard immunosuppression 
Follow up = 12 months 
Primary Prednisone not the cause for 
increased body fat following 
transplantation; however it 
may contribute to decreased 
exercise capacity. 
Peak VO2 at 12 months SMD 
0.01 [-0.83, 0.84] 
Age-predicted VO2 at 12 
months 0.88 [0.00, 1.76] 
Compared to those maintained on steroids, the 
steroid withdrawal group showed greater 
gains in the Vitality Score and the Physical 
Composite Scale on the SF-36 questionnaire. 
SMDs show very large confidence intervals. 
Yes as the SF36 scores taken to be supportive of 
increased exercise capacity, however differences 
were small (<5). The vitality values between the 
groups at 12 months were the same, however pred 
withdrawal had increased and pred maintenance had 
stayed the same. An alternate conclusion is that 
there is no difference as all scores were the same at 
12 months. The SMDs would be consistent with this 
assessment. 
Baltar (2002)  AZA vs MMF.  
Follow up = 12 months 
Primary Acute rejection occurred less 
frequently with MMF, 
however the difference was 
not significant. OR 0.11 
[0.01, 1.11] 
 
The authors note that HRQoL increased 
between 15 days after transplant and one 
month and then decreased during the third and 
six month, however less intensively in 
patients on MMF. However, there were no 
significant treatment differences. The SMD 
between day 15 and the 3rd month for all 
patients (the only data provided) is 0.36 
P=0.20 for PGWBI, 0.48 P=0.08 for VAS and 
0.24 P=0.39 for EQ5D. 
Yes. However, there were no statistically significant 
differences in either clinical or HRQoL outcomes. 
Reasoning used does not appear to be supported. 
Budde (2002)  Steroid withdrawal 
(MMF/CsA) vs steroid 
maintenance (AZA/CsA/Pred). 
Follow-up = 4 years 
Secondary Steroid withdrawal was 
associated with improvement 
in cardiovascular risk factors. 
No difference in colour scales between 
groups. 
No 
Polsky (2001)  see Sollinger et 
al (2001)  
Basiliximab with early CsA vs 
Antithymocyte globulin with 
delayed CsA.  
Follow up = 12 months 
Secondary (not noted in 
clinical report) 
Reported in Sollinger (1999). 
No statistically significant 
treatment differences (acute 
rejection, second graft, delayed 
graft function, 1 year survival) 
There are no statistically significant 
differences in VAS scores at any point in time 
during the first year. 
Yes. VAS scores taken as indicator of equivalence 
of the treatments with respect to tolerance and to 
derive a quality adjusted life year for the first 12 
months. However, was not powered as an 
equivalence trial with VAS as an endpoint. 
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Study Treatments and Follow Up HRQoL Endpoint Main Clinical Outcome HRQoL Outcome HRQoL Influenced Clinical Decision/Assessment 
Lee (2000)  CsA Therapeutic Drug 
Monitoring vs usual care. 
Follow up = 12 months 
n=43 
Unclear No statistically significant 
differences between groups. 
There were no significant differences between 
the groups. The authors state this is likely to 
be a consequence of the high QoL of the 
participants at the start of the study. 
Yes. Stated that the higher scores in the treatment 
arm indicate positive effect on QoL. However there 
were no statistically significant differences in any 
outcomes between groups thus the positive 
conclusion was not supported. 
Wang (1999)  SRL vs AZA 
Follow up = 12 months 
Secondary (not noted in 
clinical report) 
See Kahan (2000). Use of SRL 
reduced occurrence and 
severity of biopsy-confirmed 
acute rejection episodes with 
no increase in complications. 
The efficacy failure rate at 6 
months was significantly 
higher with AZA OR 0.42 
[0.27, 0.67] compared to SRL 
5 mg. The AR rate at 6 months 
was significantly higher with 
AZA OR 0.42 [0.27, 0.67] 
compared to SRL 5. 
 
  
No significant difference between SRL and 
AZA groups in HRQoL domains except for 
small differences in SF36 PCS at 12 months 
and RP sub scale. Estimated SMDs of 0.22 
and 0.30 respectively (based on reported P 
values as no SD provided in abstract).  
Yes. HRQoL stated to be maintained between 
groups as a positive statement for the SRL 
treatment. However, completion rate was low and 
there was no baseline data collected. 
Shield (1997)  Tac vs CsA 
Follow up = 12 months 
Secondary Tac more effective than CsA in 
preventing acute rejection and 
significantly reduces the use of 
antilymphocyte antibody 
preparations. Tac was 
associated with a higher 
incidence of neurologic events 
and post-transplant diabetes 
mellitus. Able to calculate 
OR’s. 
No significant differences between treatments 
with the exception of the BPA which was 
higher in the Tac treatment group. Significant 
improvements following transplant. 
Significant associations with acute rejection 
and hospitalisation. SMDs in the order of 0.5. 
Not able to estimate the SMD for BPA for 
treatment effect as insufficient data reported. 
Yes. However, analysis was mainly on the basis of 
sub groups across both treatments. Suggest that 
tacrolimus is favoured due to result of the Bergner 
Physical Appearance Scale. 
Hillbrands (1995)  CsA vs AZA-prednisone 
Follow up = 12 months 
Primary (assumed) No significant differences 
between groups with the 
exception of creatinine 
clearance which was 
significantly higher in AZA-
Prednisone group at 12 
months. Some physical 
symptoms less frequent in 
AZA-Prednisone group. 
No significant differences between treatment 
groups on any measures. A trend to difference 
in the SIP psychosocial scale for CsA versus 
AZA-Pred. Not able to calculate SMDs as 
results given as medians and interquartile 
ranges. 
Yes. Considered that the measured improvement in 
QoL even in CsA group was informative. Trends 
observed between CsA and AZA-Pred attributed to 
removal of prednisone. Considered that the 
assessment was impeded by the fairly high QoL in 
this group. 
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Study Treatments and Follow Up HRQoL Endpoint Main Clinical Outcome HRQoL Outcome HRQoL Influenced Clinical Decision/Assessment 
Simmons (1987)  CsA vs conventional 
Follow up = 12 months 
Primary No significant differences 
between groups for graft or 
patient survival. 
CsA scored consistently higher on all 
physical, emotional and social well-being 
measures. However differences were not 
significant after controlling for infection and 
rejection. 
Yes. Mainly to emphasise the need to address QoL 
and the relationship between fewer episodes of 
rejection and infection. 
Alvarez-Amador et al (1996)  Deflazacort vs prednisone 
Follow up not stated 
n=20 
Primary No differences between groups 
for creatinine, triglycerides, 
total cholesterol, uric acid and 
serum protein. Deflazacort 
significantly lower fasting 
glucose. No episodes of acute 
rejection. 
SIP decreased (i.e. better QoL) from baseline 
in both groups. Final SIP significantly lower 
in deflazacort group compared to prednisone 
group. Similarly for Impact-of-therapy VAS 
score at follow up.  
Yes. However, note that longer term studies are 
required to evaluate long-term outcomes. 
Sommerer (2011)  Intensified EC-MPS dose plus 
cyclosporine vs. standard EC-
MPS dose plus cyclosporine. 
N=128 
Secondary Acute rejection in intensive 
dose significantly lower than 
standard dose. 
No significant difference in GSRS scores at 
any time. However, no measure of baseline. 
Yes. Non-significant GSRS scores taken to indicate 
similar tolerability between intensive and standard 
dose therefore favouring intensive dose in light of 
clinical outcomes. 
Shehata (2009)  Conversion to EC-MPS vs. 
maintenance of MMF 
N=129 
Secondary The proportion of patients 
receiving a higher dose of 
MPA was significantly greater 
in the EC-MPS group. 
Significant differences noted at varying times 
during trials, however no significant 
differences at follow-up. 
Yes. Significant improvement in GI symptom 
burden (although this was not sustained due to 
improvement in control by follow-up) and higher 
MPA dose supports EC-MPS over MMF. 
Dobells (2014 ) 
BENEFIT and BENEFIT-EXT 
More intensive belatacept vs. 
less intensive belatacept vs. 
cyclosporine. 
N= 666 BENEFIT and 543 
BENEFIT-EXT 
Secondary Belatacept associated with 
superior renal function at 1 
year post transplant. 
Clinically meaningful improvement in post-
transplant HQoL for both treatments with 
association between HQoL and impaired renal 
function. Belatacept treated patients 
associated with fewer immunosuppressant 
related symptoms.. 
Qualified as conclude additional investigation is 
required to understand clinical significance of SF36 
data. 
 
CsA – cyclosporine; Tac – tacrolimus; SRL – sirolimus; AZA - azathioprine  ; MMF – mycophenolate mofetil; EC-MPS – enteric-coated mycophenolate sodium. 
SF36 – Short Form 36; PCS – Physical Component Score; MCS – Mental Component Score; KTQ – Kidney Transplant Questionnaire; PGWBI – Physical Global Well Being Index ; GSRS – 
Gastrointestinal Symptom Rating Scale; GLQI -  ; ESRD-SCL – End Stage Renal Disease Symptom Checklist.  
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A.4 Table S4 Quality of Life Outcomes 
 
Study Study SMD Lower CL 
Upper 
CL Outcome 
Alvarez-Amador 1996 1 -0.10 -0.98 0.79 VAS - Impact of disease 
Alvarez-Amador 1996 1 0.18 -0.71 1.06 Self-global assessment 
Alvarez-Amador 1996 1 0.33 -0.56 1.22 Cushing’s Scale 
Alvarez-Amador 1996 1 0.35 -0.54 1.24 VAS - Impact of therapy 
Alvarez-Amador 1996 1 0.95 0.01 1.89 SIP - total 
Baltar 2002 2 0.24 -0.31 0.78 EQ-5d 
Baltar 2002 2 0.36 -0.19 0.91 PGWBI 
Baltar 2002 2 0.48 -0.07 1.03 VAS - EuroQol 
Dobells 2014 – BENEFIT 3 0.21 0.02 0.40 SF36 - PCS 
Dobells 2014 – BENEFIT 3 0.18 -0.01 0.37 SF36 - MCS 
Dobells 2014 – BENEFIT-EXT 3 0.28 0.07 0.49 SF36 - PCS 
Dobells 2014 – BENEFIT-EXT 3 0.08 -0.13 0.29 SF36 - MCS 
Hilbrands 1995 4 -0.05 -0.41 0.31 SIP - total 
Hilbrands 1995 4 0.00 -0.36 0.36 CES-D 
Hilbrands 1995 4 0.09 -0.26 0.45 SIP - phys 
Hilbrands 1995 4 0.26 -0.09 0.62 ABS 
Hilbrands 1995 4 0.32 -0.04 0.68 SIP - psych 
Langone 2011 5 0.07 -0.13 0.27 OTE 
Langone 2011 5 0.10 -0.10 0.31 GIQLI - total 
Langone 2011 5 0.15 -0.05 0.35 GSRS - total 
Lee 2000 6 0.15 -0.47 0.77 SF36 - RE 
Lee 2000 6 0.27 -0.36 0.89 SF36 - SF 
Lee 2000 6 0.37 -0.26 0.99 SF36 - RP 
Lee 2000 6 0.44 -0.19 1.07 SF36 - MH 
Lee 2000 6 0.45 -0.18 1.07 SF36 - BP 
Lee 2000 6 0.55 -0.09 1.18 SF36 - GH 
Lee 2000 6 0.62 -0.02 1.25 SF36 - VT 
Lee 2000 6 0.76 0.12 1.40 SF36 - PF 
Oppenheimer 2009 7 0.09 -0.22 0.41 SF36 - MCS 
Oppenheimer 2009 7 0.18 -0.14 0.50 SF36 - MCS 
Oppenheimer 2009 7 0.35 0.04 0.67 SF36 - PCS 
Oppenheimer 2009 7 0.47 0.15 0.79 SF36 - MCS 
Oppenheimer 2009 7 0.51 0.19 0.84 SF36 - PCS 
Oppenheimer 2009 7 0.53 0.21 0.85 SF36 - PCS 
Oppenheimer 2009 7 0.54 0.11 0.96 SF36 - MCS 
Ortega 2011 8 0.61 0.22 1.00 GIQLI - total 
Ortega 2011 8 0.81 0.42 1.21 PGWBI 
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Study Study SMD Lower CL 
Upper 
CL Outcome 
Ortega 2011 8 1.56 1.13 2.00 GSRS – total 
Painter 2003 9 -0.07 -0.90 0.77 SF36 - VT 
Painter 2003 9 0.15 -0.69 0.99 SF36 - GH 
Painter 2003 9 0.25 -0.59 1.09 SF36 - MH 
Painter 2003 9 0.25 -0.59 1.09 SF36 - RP 
Painter 2003 9 0.36 -0.49 1.20 SF36 - BP 
Painter 2003 9 0.41 -0.44 1.26 SF36 - RE 
Painter 2003 9 0.48 -0.37 1.33 SF36 - MCS 
Painter 2003 9 0.51 -0.34 1.36 SF36 - PCS 
Painter 2003 9 0.70 -0.16 1.57 SF36 - SF 
Painter 2003 9 0.91 0.02 1.79 SF36 - PF 
Polsky 2001 10 0.06 -0.28 0.40 VAS - EuroQol 
Russ 2007 11 0.00 -0.22 0.22 KTQ-PS 
Russ 2007 11 0.05 -0.16 0.25 SF36 - PF 
Russ 2007 11 0.05 -0.16 0.26 SF36 - BP 
Russ 2007 11 0.06 -0.16 0.28 KTQ-UF 
Russ 2007 11 0.06 -0.14 0.27 SF36 - RE 
Russ 2007 11 0.09 -0.13 0.32 KTQ-AP 
Russ 2007 11 0.13 -0.08 0.34 SF36 - VT 
Russ 2007 11 0.14 -0.07 0.35 SF36 - MH 
Russ 2007 11 0.16 -0.05 0.37 SF36 - RP 
Russ 2007 11 0.19 -0.02 0.40 SF36 - GH 
Russ 2007 11 0.23 0.01 0.45 KTQ-F 
Russ 2007 11 0.23 0.02 0.44 SF36 - SF 
Russ 2007 11 0.27 0.04 0.49 KTQ-E 
Shehata 2009 12 0.16 -0.19 0.51 GIQLI - total 
Shehata 2009 12 0.30 -0.05 0.65 SF36 - PCS 
Shehata 2009 12 0.36 0.01 0.70 SF36 - PCS 
Shehata 2009 12 0.37 0.02 0.72 GIQLI - total 
Shehata 2009 12 0.51 0.16 0.86 GSRS - total 
Shield 1997 13 0.10 -0.20 0.40 SF36 - RE 
Shield 1997 13 0.21 -0.08 0.51 SF36 - MH 
Shield 1997 13 0.25 -0.04 0.54 SF36 - PF 
Shield 1997 13 0.32 0.02 0.61 SF36 - RP 
Shield 1997 13 0.35 0.06 0.65 SF36 - BP 
Shield 1997 13 0.35 0.06 0.65 SF36 - SF 
Shield 1997 13 0.39 0.10 0.69 Health Distress 
Shield 1997 13 0.40 0.10 0.70 BPA 
Shield 1997 13 0.41 0.12 0.71 Current Health 
Shield 1997 13 0.46 0.16 0.77 SF36 - GH 
Shield 1997 13 0.53 0.24 0.83 SF36 - VT 
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A4. Supplementary Table S4 cont. 
Study Study SMD Lower CL 
Upper 
CL Outcome 
Simmons 1987 14 0.29 -0.12 0.71 Physical Well Being 
Simmons 1987 14 0.32 -0.10 0.73 Self-esteem Scale 
Simmons 1987 14 0.33 -0.09 0.75 Social Well Being 
Simmons 1987 14 0.37 -0.05 0.79 Happiness Scale 
Simmons 1987 14 0.43 0.01 0.85 Overall Life Satisfaction 
Simmons 1987 14 0.45 0.03 0.87 Health Satisfaction 
Simmons 1987 14 0.47 0.05 0.88 Family Summary 
Simmons 1987 14 0.47 0.05 0.89 Index of Well Being 
Simmons 1987 14 0.51 0.09 0.93 Index of General Affect 
Simmons 1987 14 0.52 0.09 0.94 Bradburn Happiness 
Sommerer 2011 15 0.14 -0.20 0.49 GSRS - total 
Walker 2007 16 0.16 -0.70 1.01 SF36 - MH 
Walker 2007 16 0.31 -0.58 1.20 SF36 - PF 
Walker 2007 16 0.45 -0.42 1.32 SF36 - SF 
Walker 2007 16 0.54 -0.33 1.42 SF36 - VT 
Walker 2007 16 0.57 -0.36 1.49 SF36 - GH 
Walker 2007 16 0.61 -0.27 1.49 SF36 - BP 
Walker 2007 16 0.69 -0.22 1.60 SF36 - RE 
Walker 2007 16 0.79 -0.18 1.77 SF36 - RP 
Walker 2007 16 1.20 0.22 2.17 VAS - gingivitis 
Walker 2007 16 1.66 0.61 2.71 VAS - hirsutism 
Wang 1999 17 0.22 0.02 0.41 SF36 - PCS 
Wang 1999 17 0.30 0.10 0.50 SF36 - RP 
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A.5. Supplementary Table S5 
A.5 Table S5. Clinical Outcomes 
 
Study and Outcome 
Study SMD Lower CL 
Upper 
CL RR 
Lower 
CL 
Upper 
CL 
Alvarez 1996, Fasting glucose 1 0.59 0.34 1.47 
   
Baltar 2002, Acute rejection 2    5.83 0.79 43.27 
Dobells 2014a, Acute rejection 1 yr 3    0.37 0.22 0.61 
Dobells 2014a, Graft survival 1 yr 3    1.02 0.99 1.05 
Dobells 2014a, Patient survival 1 yr 3    1.03 0.99 1.07 
Dobells 2014b, Acute rejection 1 yr 3    0.81 0.53 1.23 
Dobells 2014b, Graft survival 1 yr 3    1.04 0.98 1.10 
Dobells 2014b, Patient survival 1 yr 3    1.03 0.96 1.11 
Hilbrands 1995, Acute rejection 4    0.85 0.61 1.20 
Hilbrands 1995, Creatinine clearance 4 -0.54 -0.90 -0.17 
   
Langone 2011, Acute rejection 5    3.03 0.12 73.94 
Lee 2000, Acute rejection 6    1.05 0.07 15.69 
Lee 2000, Serum CsA 6 -0.47 -1.07 0.14 
   
Oppenheimer 2009, Acute rejection 7    0.95 0.40 2.28 
Oppenheimer 2009, Acute rejection 7    1.27 0.48 3.31 
Oppenheimer 2009, Acute rejection 7    2.00 0.65 6.11 
Ortega 2011, Serious adverse events 8    0.91 0.30 2.81 
Ortega 2011, Serum Cr 8 0.41 0.04 0.79    
Painter 2003, % age predicted VO2 9 0.91 0.04 1.79 
   
Polsky 2001, Acute rejection 1 yr 10    1.08 0.57 2.02 
Polsky 2001, Graft survival 1 yr 10    0.96 0.88 1.05 
Polsky 2001, Patient survival 1 yr 10    0.97 0.91 1.05 
Russ 2007, Graft survival 1yr 11    1.01 0.98 1.05 
Russ 2007, Graft survival 3yr 11    1.07 1.00 1.15 
Shehata 2009, Max dose 12    1.91 1.18 3.09 
Shield 1997, Acute rejection 13    1.51 1.17 1.94 
Shield 1997, Graft survival 1yr 13    0.99 0.95 1.03 
Shield 1997, Patient survival 1yr 13    1.05 0.99 1.10 
Simmons 1987, Acute rejection 14    2.36 1.62 3.43 
Simmons 1987, Graft survival 1yr 14    0.88 0.76 1.01 
Simmons 1987, Hosp. time 14 0.42 0.16 0.67 
   
Simmons 1987, Patient survival 1yr 14    0.90 0.77 1.04 
Sommerer 2011, Acute rejection 15    5.33 1.23 23.10 
Sommerer 2011, Treatment failure 15 0.05 -0.30 0.40 
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A5. Supplementary Table S5 cont. 
Study and Outcome Study SMD Lower CL 
Upper 
CL RR 
Lower 
CL 
Upper 
CL 
Walker 2007, Gingivitis 16 1.18 0.23 2.14 
   
Walker 2007, Hirsutism 16 0.02 -0.86 0.90 
   
Walker 2007, Periodontal pocket. 16 1.50 0.51 2.50 
   
Wang 1999, Acute rejection 17    1.70 1.27 2.27 
Wang 1999, Efficacy failure 1yr 17    1.51 1.16 1.97 
Wang 1999, Graft survival 1yr 17    0.99 0.95 1.03 
Wang 1999, Patient survival 1yr 17    0.98 0.96 1.10 
 
a BENEFIT study 
b BENEFIT-EXT study 
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B. Supplementary Material – Chapter 4. 
B.1. Supplementary Table S1.  
B.1. Table S1. Harms extension of CONSORT Checklist 
 
Item Item Description Criteria Criteria Description 
1 If the study collected data on harms and 
benefits, the title or abstract should so 
state. 
1a AE mentioned in title 
 
  1b AE mentioned in abstract 
2 If the study collected data on harms and 
benefits, the introduction should so state. 
2a AE addressed in introduction 
3 List addressed AEs with definitions of 
each 
3a Does the methods section provide a list of specific 
AEs to be assessed 
 
  3b Does the study provide justification for the 
selection of AEs  
  3c Does the methods section provide a definition of 
the AEs.  
  3d Was the severity of AEs assessed? 
 
  3e If yes was a validated instrument used and which 
one? 
4 Clarify how harms related information was 
collected. 
4a Is there a description of the method of collection of 
AE data?  
 
  4b If Yes - How was the AE data collected?  e.g. 
patient report, clinician/researcher assessment, 
interviews, diary.   
 
  4c Is the timing of AE data collection described. e.g. 
baseline, follow-up.  
5 Describe plans for presenting and 
analysing information on harms 
5 Does the methods section provide a description of 
the methods for analysis of AEs? 
6 Describe for each arm the participant 
withdrawals that are a result of harms and 
their experiences with the allocated 
treatment 
6a Does the study report withdrawals or conversions 
attributed to AEs? (this may be stated as inability to 
tolerate drugs or similar wording)  
 
  6b If yes what was the percentage withdrawal or 
conversion from each arm due to AEs or inability 
to tolerate treatment?  
  6c Does the study report specify the AEs leading to 
withdrawal or inability to tolerate treatment? 
7 Provide the denominators for analyses of 
harm. 
7a Does the study report the number at baseline for 
each arm?  
  7b Does the study report the number included in any 
analysis of AEs? 
8 Present the absolute risk per arm and per 
AE type …. and present appropriate 
metrics etc. 
8a Does the study present quantitative data for AEs? 
 
  8b Does the study tabulate results for AEs? 
 
  8c Does the study present results of AEs separately for 
each arm? 
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B.1. Supplementary Table S1 cont. 
Item Item Description Criteria Criteria Description 
9 Describe any sub group analyses. 9 Has the study conducted any sub-group analyses 
with respect to AEs? 
10 Provide a balanced discussion of benefits 
and harms with emphasis on study 
limitations etc. 
10a Are AEs addressed in the discussion? 
 
  10b If yes did AE results influence study conclusions?  
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B.2. Supplementary Table S2.  
B.2. Table S2. Adverse events reported in trials published between January 2003 and December 2015 of interventions of maintenance 
immunosuppression following kidney transplantation.   
Adverse event All 
n=163 
 
n (%) 
Rank CNI 
n=90 
 
n (%) 
Rank Mycophenolic Acid 
n=21 
n (%) 
Rank Belatacept n=4 
 
n (%) 
Rank mTORi 
n=24 
 
n (%) 
Rank Steroid 
n=24 
 
n (%) 
Rank 
Gastrointestinal 116 (71) 1 55 (61) 1 21 (100) 1 4 (100) 1 22 (92) 1 14 (58) 1 
Peripheral oedema 55 (34) 2 35 (39) 2 1 (5) 7 3 (75) 3 14 (58) 2 2 (8) 10 
Skin disorders 42 (26) 3 25 (28) 3 1 (5) 8   11 (46) 3 5 (21) 5 
Tremor 38 (23) 4 21 (23) 6 3 (14) 2   2 (8) 15 11 (46) 2 
"Adverse Event" 37 (23) 5 22 (24) 4 1 (5) 9 4 (100) 2 5 (21) 8 6 (25) 3 
Pain (musculo-skeletal) 34 (21) 6 19 (21) 7 1 (5) 10 1 (25) 5 8 (33) 5 5 (21) 4 
Ging. overgrowth 32 (20) 7 22 (24) 5 2 (10) 5   6 (25) 6 2 (8) 13 
Other oral 32 (20) 8 18 (20) 8 1 (5) 11 1 (25) 4 10 (42) 4 2 (8) 11 
Wound complications 22 (13) 9 15 (17) 9 1 (5) 12   5 (21) 9 1 (4) 16 
Pain (headache) 20 (12) 10 11 (12) 13 3 (14) 3 1 (25) 6 5 (21) 7   
Fever symptoms 19 (12) 11 14 (16) 10     5 (21) 11   
Hirsutism 19 (12) 12 14 (16) 11   1 (25) 8 2 (8) 16 2 (8) 12 
Musculoskeletal 16 (10) 13 13 (14) 12     1 (4) 19 2 (8) 14 
Pain (abdominal) 16 (10) 14 9 (10) 15 3 (14) 4 1 (25) 7 3 (13) 13   
Sleep disorders 15 (9) 15 11 (12) 14     4 (17) 12   
Nervous system 
disorders 14 (9) 16 8 (9) 16   1 (25) 9 1 (4) 20 4 (17) 6 
Respiratory 14 (9) 17 7 (8) 17 1 (5) 13   5 (21) 10 1 (4) 17 
Alopecia 11 (7) 18 7 (8) 18       4 (17) 8 
Weight gain 10 (6) 19 3 (3) 23 2 (10) 6   1 (4) 18 4 (17) 7 
Ocular 8 (5) 20 4 (4) 21     1 (4) 21 3 (13) 9 
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B.2. Supplementary Table S2 cont. 
Adverse event All 
n=163 
 
n (%) 
Rank CNI 
n=90 
 
n (%) 
Rank Mycophenolic Acid 
n=21 
n (%) 
Rank Belatacept n=4 
 
n (%) 
Rank mTORi 
n=24 
 
n (%) 
Rank Steroid 
n=24 
 
n (%) 
Rank 
General disorder 7 (4) 21 6 (7) 19   1 (25) 10     
Gout 7 (4) 22 6 (7) 20       1 (4) 20 
Nasal 5 (3) 23 2 (2) 28     3 (13) 14   
Pain (not defined) 5 (3) 24 3 (3) 24     1 (4) 22 1 (4) 18 
Pain (menstrual) 4 (2) 25 4 (4) 22         
Paraesthesia 4 (2) 26 3 (3) 25     1 (4) 23   
Psychiatric disorder 4 (2) 27 3 (3) 26   1 (25) 11     
Anxiety 3 (2) 28 2 (2) 29 1 (5) 14       
Appearance change 3 (2) 29 1 (1) 33 1 (5) 15     1 (4) 19 
Reproductive 3 (2) 30 3 (3) 27         
Appetite 2 (1) 31 2 (2) 30         
Cushingoid 2 (1) 32         2 (8) 15 
Dizziness 2 (1) 33 1 (1) 34 1 (5) 16       
Flushing 2 (1) 34 1 (1) 35 1 (5) 17       
Impotence 2 (1) 35 2 (2) 31         
Pain (urination) 2 (1) 36       2 (8) 17   
Rectal 2 (1) 37 2 (2) 32         
Haematemesis 1 (1) 38       1 (4) 24   
Pain (chest) 1 (1) 39       1 (4) 25   
Pain (wound) 1 (1) 40 1 (1) 36         
 
CNI – calcineurin inhibitors, mTORi – mTOR inhibitors. 
* - unspecified adverse events 
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B.3. Supplementary Table S3  
Table S3 trials reporting adverse events 
Study Type Side Effects reported 
(Abou-Jaoude, Irani-Hakime et al. 
2003) 
CSA v TAC AE - not detailed 
(Albano, Berthoux et al. 2009, 
Dantal, Berthoux et al. 
2010)[CALLISTRO] 
mTORi wound healing, gastrointestinal disorders, peripheral edema, constipation 
(Albano, Alamartine et al. 2012) mTORi peripheral edema, aphthous stomatitis, , chest pain, dehydration 
(Alexander, Goodman et al. 2006) CNI Sparing mouth ulcers 
(Andres, Budde et al. 2009) CNI Sparing gastrointestinal disorders; ; general disorders; edema; musculoskeletal disorders; nervous system disorders; tremor 
(Anil Kumar, Irfan et al. 2008) CSA v TAC gastrointestinal side effects, complications of wound healing 
(Arns, Breuer et al. 2005) MMF v ECMPS nausea, headache, flushing, dizziness,  
(Artz, Boots et al. 2004) CSA v TAC alopecia, headache, , tremor, toxic exanthema (rash), gingival hyperplasia, severe osteoporosis, increased hair growth, hair loss, 
fatigue, bruises, excessive appetite, poor concentration, changed bodily appearance, poor vision, fragile skin, swollen ankles, 
insomnia, impotence, painful menstruation, warts, back pain, muscle weakness, stomach complaints, and nightmares 
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Study Type Side Effects reported 
(Baboolal 2003) CNI Sparing joint pain, edema lower limb 
(Barsoum, Morsey et al. 2007) CNI Sparing peripheral edema, oral ulcers, rectal ulcers 
(Bechstein, Paczek et al. 2013) CNI Sparing peripheral edema, , vomiting, nausea 
(Bemelman, de Maar et al. 2009) CNI Sparing flu-like syndrome, ankle edema, , abdominal pain, rash, dysmenorrhea 
(Benfield, Bartosh et al. 2010) Steroid Sparing Cushingoid Features Assessment Score 
(Bolin, Shihab et al. 2008) CSA v TAC gingival hyperplasia, hypertrichosis, alopecia, bone fracture, Changes in appetite, sleep habits, weight gain, hair growth, sexual 
interest, gastrointestinal side effects 
(Briggs, Dudley et al. 2003) CSA v TAC tremor 
(Buchler, Caillard et al. 2007, 
Lebranchu, Snanoudj et al. 2012) 
mTORi acne, hypertrichosis/hirsutism, gingival hypertrophy, mouth ulcers/aphthous stomatitis, , peripheral edema. 
(Budde, Curtis et al. 2003, Budde, 
Glander et al. 2004) 
MMF v ECMPS any GI AE, upper GI AE, dyspepsia (reflux), nausea, gastro-esophageal reflux disease, non-upper GI AE,  
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Study Type Side Effects reported 
(Budde, Neumayer et al. 2004) mTORi edema, headache, gastrointestinal disorders, fever, aphthous stomatitis, fatigue, influenza-like symptoms, epistaxis 
(Budde, Knoll et al. 2005, Budde, 
Knoll et al. 2006) 
MMF v ECMPS gastrointestinal AE, dyspepsia, nausea, vomiting, , serious gastrointestinal AE, abdominal pain, aphthous stomatitis, ulcerative colitis, 
constipation, , diverticulum, duodenal ulcer, dyspepsia, flatulence, gastrointestinal hemorrhage, gastro-esophageal reflux disease, 
gingival hyperplasia, nausea, vomiting, loose stools, fecal abnormality, lip ulceration, rash, polyarthritis.  
(Budde, Bosmans et al. 2007) CNI Sparing not detailed 
(Budde, Bauer et al. 2007) [sub study 
of Budde, 2003] 
MMF v ECMPS gastrointestinal AE 
(Budde, Becker et al. 2011, Budde, 
Lehner et al. 2012, Lehner, Budde et 
al. 2014, Budde, Lehner et al. 2015) 
CNI Sparing back pain, edema, wound pain, impaired healing, fever, headache, physical weakness, , mouth ulcers, gastroenteritis, peripheral 
edema (>=5% 0f patients) 
(Budde, Rath et al. 2015) CNI Sparing AEs >=10%, mouth ulcers, peripheral edema, cough, diatthoea, acne, arthralgia . 
(Burkhalter, Oettl et al. 2012, 
Bunnapradist, Ciechanowski et al. 
2013) 
CNI Sparing arthralgia, not detailed (side effects), aphthous stomatitis. 
(Cantarovich, Rostaing et al. 2010) Steroid Sparing Not detailed and not quantified 
(Chadban 2013) CNI Sparing gastrointestinal events; constipation, nausea, , vomiting, reflux (gastro esophageal and esophagitis), abdominal pain, gingival 
hypertrophy, dyspepsia, epigastric discomfort. 
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Study Type Side Effects reported 
(Chadban, Eris et al. 2014) CNI Sparing AEs, wound complications, peripheral edema 
(Chan, Greenstein et al. 2008) CNI Sparing nausea, edema, peripheral edema, tremor, groin pain, joint pain 
(Chan, Andres et al. 2012) CNI Sparing nausea, constipation, procedural pain, peripheral edema, insomnia, tremor 
(Charpentier, Groth et al. 2003) mTORi arthralgia, edema, constipation, gingival hyperplasia, tremor 
(Charpentier, Rostaing et al. 2003) CSA v TAC tremor, fever 
(Chen, Tsai et al. 2008) CSA v TAC fever, poor wound healing, myelosuppression 
(Cheung, Wong et al. 2006) CSA v TAC acne, hirsutism, gum hyperplasia 
(Ciancio, Burke et al. 2008, Ciancio, 
Gaynor et al. 2011) 
MMF v ECMPS any upper GI AE, nausea, vomiting, epigastric pain, any lower GI AE, , GI bleeding, any upper/lower GI AE 
(Cibrik, Meier-Kriesche et al. 2007) CNI Sparing hirsutism, nausea, constipation, , vomiting, dyspepsia, abdominal pain, abdominal distension 
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Study Type Side Effects reported 
(Dean, Lund et al. 2004) mTORi Peripheral edema, abdominal pain, wound complications 
(Ding, Xue et al. 2014) EC-MPS AEs, GI disorders, , constipation, dyspepsia, flatulence, nausea, vomiting 
(Dresske, Zavazava et al. 2003) Steroid Sparing tremor, alopecia, acne, achillodynia 
(Dresske, Haendschke et al. 2006) Steroid Sparing tremor, alopecia, acne, achillodynia, cataract 
(Dudley, Pohanka et al. 2005) CNI Sparing abdominal pain, weight loss, vomiting and/or nausea, anorexia. 
Durrbach, 2008 (Durrbach, Rostaing 
et al. 2008) 
mTORi mouth ulcer, aphthous stomatitis, gingival hypertrophy,, abdominal pain, epistaxis 
(Durrbach, Pestana et al. 2010, 
Larsen, Grinyo et al. 2010, Medina-
Pestana, Grinyo et al. 2012, 
Charpentier, Medina Pestana et al. 
2013) 
Belatacept constipation,  nausea 
(Ekberg, Tedesco-Silva et al. 2007, El 
Agroudy, el Dahshan et al. 2009, 
Grinyo, Ekberg et al. 2009) 
CNI Sparing gastrointestinal AE, abdominal pain, , constipation, vomiting, dyspepsia, peripheral edema, fever, nervous system, headache, delayed 
wound healing 
(Ekberg, Grinyo et al. 2007) CNI Sparing hirsutism, gingival hyperplasia, gout, neurological changes such as tremor 
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Study Type Side Effects reported 
(El Agroudy, el Dahshan et al. 2009) AZA MMF vomiting, abdominal colic 
(Euvrard, Morelon et al. 2012) mTORi edema, acne, mouth ulcers, cough, arthralgia, , rash, exercise dyspnea 
(Fangmann, Arns et al. 2010) CNI Sparing adverse events (not detailed), gastrointestinal, neurological 
(Ferguson, Grinyo et al. 2011) Belatacept nausea, constipation, mouth ulcers, tremor 
(Ferreira, Machado et al. 2005) CNI Sparing physical weakness, joint pain, muscle cramps, paresthesia, trembling, gum hypertrophy 
(Filler, Webb et al. 2005) CSA v TAC not detailed 
(Flechner, Goldfarb et al. 2007) mTORi abdominal pain, hematemesis-ulcer, -dehydration, mucositis-oral ulcer, gingival hypertrophy/hypertrichosis, tremors/seizures, 
cataract extraction 
(Flechner, Glyda et al. 2011) CNI Sparing peripheral edema, , tremor, delayed wound healing, acne 
(Flechner, Gurkan et al. 2013) mTORi gum hyperplasia, hirsutism, fever, headache, pain , constipation, , nausea, vomiting, peripheral edema, acne, dysuria (painful 
urination) 
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Study Type Side Effects reported 
(Franz, Regeniter et al. 2010) CNI Sparing fever, impaired wound healing 
(Frimat, Cassuto-Viguier et al. 2006) CNI Sparing gastrointestinal disorders,  
(Gaber, Kahan et al. 2008) CSA v TAC peripheral edema, nausea, pain, fever, tremor, delayed wound healing, acne, gingival hyperplasia, hirsutism 
(Gaston, Kaplan et al. 2009) CNI Sparing Diarrhea 
(Glander, Sommerer et al. 2010) MMF gastrointestinal events, constipation, nausea, vomiting, flatulence, gingival hyperplasia 
(Glotz, Charpentier et al. 2010) CNI Sparing tremor, acne, wound healing, peripheral edema 
(Gonwa, Johnson et al. 2003) CSA v TAC not detailed 
(Gonwa, Mendez et al. 2003) mTORi impaired wound healing 
(Gourishankar, Houde et al. 2010) MMF constipation, dyspepsia, nausea, vomiting, weight loss, tremor. 
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Study Type Side Effects reported 
(Grenda, Watson et al. 2010, Webb, 
Douglas et al. 2015) 
Steroid Sparing vomiting, nervous system disorders, skin disorders, musculoskeletal disorders, tremor, important other (including but limited to 
gastrointestinal) 
(Grinyo, Campistol et al. 2004) CNI Sparing headache, anxiety, edema, osteonecrosis 
(Guba, Pratschke et al. 2010, Guba, 
Pratschke et al. 2012) 
CNI Sparing wound healing disorders, gastrointestinal disorders, , abdominal pain, general and application site disorders, edema, fever, 
musculoskeletal and connect tissue disorders, acne, nervous system disorders, respiratory disorders 
(Hamdy, El Agroudy et al. 2005, 
Hamdy, Bakr et al. 2008) 
CNI Sparing osteonecrosis, wound healing 
(Han, Park et al. 2012) CNI skin rash, gastrointestinal system disorder 
(Heilman, Younan et al. 2011) mTORi oral ulcers, edema, rash,  
(Heller, van Gelder et al. 2007, van 
Gelder, Silva et al. 2008) 
MMF weight loss 
(Hernandez, Miquel et al. 2007) CNI Sparing fever , stomach complaint, fatigue 
(Hocker, Weber et al. 2009, Hocker, 
Weber et al. 2010) 
Steroid Sparing gingival hyperplasia, hypertichosis 
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Study Type Side Effects reported 
(Hocker, van Gelder et al. 2011)  MMF diarrhea 
(Hoogendijk-van den Akker, Harden 
et al. 2013) 
mTORi slow wound healing, , fatigue, rash, acne, aphthous stomatitis, flu-like symptoms, edema 
(Juarez, Barrios et al. 2006) Steroid Sparing not detailed 
(Kahan, Karlix et al. 2003) mTORi peripheral edema, , arthralgia, rash, headache, epistaxis 
(Kahan, Podbielski et al. 2008) MMF v ECMPS GIQLI, GSRS, feeling unwell, flatulence, eructations, stress, appearance change, bloating 
(Kamar, Garrigue et al. 2006, 
Rostaing, Mourad et al. 2006, 
Mourad, Karras et al. 2007) 
CNI peripheral edema , anxiety, insomnia, tremor, abdominal pain, nausea, GI complaints, gingival hyperplasia. 
(Kamar, Rostaing et al. 2012) CNI Sparing peripheral edema, abdominal pain, constipation, gout, tremor, rash, pruritus 
(Kandaswamy, Melancon et al. 2005) Steroid Sparing mouth sores, GI, neurotoxicity, hair loss, cosmetic changes (hirsutism and gingival hyperplasia. 
(Kaplan, Meier-Kriesche et al. 2005) CSA v TAC headache, lower abdominal pain 
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Study Type Side Effects reported 
(Kramer, Montagnino et al. 2005) CSA v TAC bone fractures, hirsutism, gingival hyperplasia 
(Kramer, Del Castillo et al. 2008) CSA v TAC bone fractures, cosmetics 
(Kramer, Charpentier et al. 2010) CNI constipation, nausea, vomiting, abdominal pain, peripheral edema,  tremor, headache, insomnia, arthralgia, dysmenorrhea, testicular 
disorders, night sweats 
(Kreis, Oberbauer et al. 2004) CNI Sparing edema, gingival hyperplasia, healing abnormal, rectal disorder, ileus 
(Kumar, Xiao et al. 2005) Steroid Sparing weight gain 
(Laftavi, Stephan et al. 2005) Steroid Sparing alopecia, bone pain 
(Langer 2012) CNI Sparing gastrointestinal disorders, skin and subcutaneous tissue disorders, general disorders and administration site conditions, nervous 
system disorders, psychiatric disorders, constipation, , peripheral edema, edema, fever, procedural pain, acne, headache, insomnia, 
alopecia, tremor, insomnia 
(Langone, Chan et al. 2011) MMF v ECMPS abdominal distension, , dyspepsia, nausea, flatulence, eructation, upper abdominal pain, lower abdominal pain, intestinal functional 
disorder, gastro-esophageal reflux disease, constipation, vomiting 
(Larsen, Grinyo et al. 2010, Vincenti, 
Charpentier et al. 2010, Rostaing, 
Vincenti et al. 2013) 
Belatacept constipation, nausea, peripheral edema, nervous system disorders (5yr), psychiatric disorders (5yr), general disorders (5yr), tremor. 
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Study Type Side Effects reported 
(Le Meur, Büchler et al. 2007, 
Premaud, Rousseau et al. 2010) 
MMF GI events (no break down). ND 
(Lebranchu, Thierry et al. 2009) CNI Sparing mouth ulcer, , peripheral edema, acne 
(Lee, Kim et al. 2010) CSA v TAC gingival hyperplasia 
(Lo, Egidi et al. 2004) CNI Sparing gastroenteritis, abdominal pain 
(Lorber, Mulgaonkar et al. 2005) mTORi abdominal pain, constipation, , nausea, vomiting, fatigue, edema, peripheral edema, pyrexia, arthralgia, back pain, pain in limb, 
headache, tremor, insomnia, dyspnea, acne, mouth ulceration, weight increase 
(Machado, Felipe et al. 2004) mTORi gastrointestinal disorders, , asthenia (physical weakness), arthralgia, cramps, paresthesia, trembling, gum hypertrophy 
(Margreiter, Klempnauer et al. 2008) CNI vomiting, tremor. 
(Martinez-Mier, Mendez-Lopez et al. 
2006) 
CNI Sparing severe acne, hirsutism, gastroenteritis, dehydration, mouth sores 
(Mjornstedt, Sorensen et al. 2012, 
Mjornstedt, Schwartz et al. 2015) 
CNI Sparing edema, acne, mouth ulcers, cough, headache, muscle pain, , fatigue, hirsutism, joint pain, dizziness 
Appendix B 
 
246 
Study Type Side Effects reported 
(Montagnino, Sandrini et al. 2008) Steroid Sparing not detailed, arthralgia 
(Mourer, Hartigh et al. 2012) CNI Sparing gingival overgrowth, gout, neuropathy 
(Murphy, Waller et al. 2003) CSA v TAC not detailed 
(Nashan, Curtis et al. 2004) CNI Sparing nausea, dyspnea, cough, fever 
(Nematalla, Bakr et al. 2007) Steroid Sparing Bone and joint pain, acne,  
(Oberbauer, Kreis et al. 2003, 
Oberbauer, Segoloni et al. 2005) 
CNI Sparing edema, cataracts, healing abnormal, ileus,  gum hyperplasia, acne, joint disorder, joint pain, stomatitis 
(Oh, Huh et al. 2015) CNI Sparing AEs, GI disorders, skin disorders, nervous system disorders, eye disorders, psychiatric disorders, reproductive disorders, ear and 
labyrinth disorders, general disorders, musculoskeletal disorders. 
(Park, Kim et al. 2006) CSA v TAC not detailed 
(Parraga-Linares, Almendros-
Marques et al. 2009) 
CSA v TAC gingival hyperplasia 
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Study Type Side Effects reported 
(Pascual, Segoloni et al. 2003) CNI Sparing adverse events (not detailed) 
(Pescovitz, Vincenti et al. 2007) mTORi peripheral edema, , constipation, headache, tremor, insomnia, pruritis, pyrexia, acne, pharyngolaryngeal pain, impaired healing, 
dysuria, dyspepsia, fatigue, edema, dyspnea, vomiting 
(Ponticelli, Carmellini et al. 2014) Steroid Sparing AEs, peripheral edema,  
(Rathi, Rajkumar et al. 2015) CSA v TAC Side effects - weight gain, hirsutism, tremors 
(Remuzzi, Lesti et al. 2004) MMF diarrhea 
(Rostaing, Cantarovich et al. 2005) Steroid Sparing gout, dyspnea 
(Rostaing, Massari et al. 2011) CNI Sparing fever 
(Rostaing, Hertig et al. 2015) CNI Sparing AEs, mouth ulcers, acne, rash, gingival hypertrophy, pyrexia 
(Russ, Campbell et al. 2003) CNI Sparing not detailed 
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Study Type Side Effects reported 
(Russ, Segoloni et al. 2005) CNI Sparing vomiting, cough 
(Salgo, Gossmann et al. 2010) CNI Sparing mouth/tongue ulcers, leg edema, , cough, joint pain, dyspnea, angioedema 
(Salvadori, Holzer et al. 2003, 
Salvadori and Study 2005)  
MMF v ECMPS upper GI AE, non-upper GI AE (no break down). 
(Salvadori, Scolari et al. 2009) CNI Sparing general disorders, fever, peripheral edema, musculoskeletal and connective tissue disorders, joint pain, gastrointestinal disorders, , 
constipation 
(Sampaio, Pinheiro-Machado et al. 
2008) 
mTORi diarrhea 
(Sarwal, Ettenger et al. 2012) Steroid Sparing GI AEs and SAEs, vomiting, nausea, stomatitis, Skin and tissue disorders, nervous system disorders, body disfigurement 
(Cushingoid) 
(Saunders, Bicknell et al. 2003) CNI Sparing joint pain, headaches, gastrointestinal symptoms, peripheral edema 
(Schena, Pascoe et al. 2009) CNI Sparing stomatitis, mouth ulcers, acne, , peripheral edema, fever, skin rash 
(Seckinger, Sommerer et al. 2008) CNI Sparing stomatitis, muscle pain 
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Study Type Side Effects reported 
(Shehata, Bhandari et al. 2009) MMF v ECMPS serious GI AE: , nausea, vomiting; GI AE, gingival pain, decreased appetite, headache, gastric disorder, dehydration, dyspnea 
(Silva, Yang et al. 2007, Silva, Yang 
et al. 2014)  
CSA v TAC Gastrointestinal disorders, tremor, paresthesia, eye disorders, insomnia, alopecia, hypertrichosis, reproductive system and breast 
disorders, peripheral edema, gingival hyperplasia 
(Smith, Newstead et al. 2008) CNI Sparing Rash, mouth ulcers, arthralgia, shingles, angioedema 
(Sommerer, Glander et al. 2011, 
Arns, Sommerer et al. 2013) 
MMF GI SAEs, abdominal pain, constipation, , dyspepsia, flatulence, nausea, vomiting, impaired healing. 
(Stoves, Newstead et al. 2004) CNI Sparing gastrointestinal disturbance, insomnia, acne, progressive hair loss, acute gout 
(Sulowicz, Bachleda et al. 2007) MMF 
 
(Sunder-Plassmann, Reinke et al. 
2012) 
MMF AEs and SAE - Not defined.  Peripheral edema, , headache 
(Suwelack, Gerhardt et al. 2004) CNI Sparing diarrhea 
(Takahashi, Uchida et al. 2013) CNI Sparing AEs, constipation, , acne, headache, Gingival hypertrophy/injury, gingivitis, tremor, hirsutism, hypertrichosis, edema, stomatitis, 
wound healing, insomnia 
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Study Type Side Effects reported 
(Talaulikar, Srishyla et al. 2003) CNI adverse events (not detailed) 
(Tang, Chan et al. 2006) CSA v TAC gouty arthritis, tremor, hot flushes, pruritus and skin rashes, fever 
(Tarantino, Passerini et al. 2004) CNI Gum hypertrophy, hirsutism, paresthesia, tremors, tendinitis,  
(Tedesco-Silva, Garcia et al. 2010) CNI Sparing abdominal pain, mouth ulcers, peripheral edema, acne, hirsutism 
(Tedesco-Silva, Cibrik et al. 2010, 
Shihab, Lee et al. 2013) 
CNI Sparing gastrointestinal disorders, constipation, nausea, vomiting, general disorders and administration site conditions, peripheral edema, 
tremor, gingival hyperplasia, gingival hypertrophy, hirsutism, impaired healing, stomatitis/oral ulcers 
(Tedesco-Silva, Felipe et al. 2015) mTORi AEs, AEs >10% - acne, mouth ulcers, esophageal pain, constipation, peripheral edema 
(Ter Meulen, van et al. 2004) Steroid Sparing Gastrointestinal 
 
(Thervet, Pfeffer et al. 2003, Stefoni, 
Midtved et al. 2005)  
CNI hirsutism, arthralgia, not defined 
(Thierry, Mourad et al. 2012) Steroid Sparing AEs and SAE - Not defined.  , constipation, abdominal pain 
Appendix B 
 
251 
Study Type Side Effects reported 
(van Hooff, Squifflet et al. 2003) mTORi Not detailed, fever, neurological disorders 
(Vanrenterghem, van Hooff et al. 
2005, Pascual, van Hooff et al. 2006) 
Steroid Sparing Tremor, , not defined, fractures and bone and joint disease 
(Vincenti, Larsen et al. 2005, 
Vincenti, Blancho et al. 2010) 
Belatacept Edema, tremor, hypertrichosis, , arthralgia, peripheral edema, cough, nausea, pain in extremity, headache, back pain, vomiting, 
abdominal pain 
(Vincenti, Monaco et al. 2003) Steroid Sparing AEs and SAE - Not defined.   
(Vincenti, Mendez et al. 2005, 
Vincenti, Friman et al. 2007) 
CSA v TAC not detailed 
(Vincenti, Schena et al. 2008) Steroid Sparing abdominal pain, constipation, , nausea, vomiting, tremor, weight gain 
(Vitko and Ferkl 2010) CNI GI disorders, gingival hyperplasia 
(Vitko, Tedesco et al. 2004) mTORi arthralgia (joint pain), constipation,  
(Vitko, Tedesco et al. 2004) mTORi arthralgia (joint pain), constipation,  
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Study Type Side Effects reported 
(Vitko, Margreiter et al. 2004, Vitko, 
Margreiter et al. 2005) 
mTORi tremor, constipation, not defined 
(Vitko, Klinger et al. 2005, Kramer, 
Klinger et al. 2012) 
Steroid Sparing edema, peripheral edema 
(Vitko, Wlodarczyk et al. 2006) 2006 mTORi 
 
(Waid and Group 2005, Shihab, Waid 
et al. 2008) 
CSA v TAC not detailed 
(Walker, Cottrell et al. 2007) CSA v TAC gingival hyperplasia and hypertrichosis 
(Walker, Thomas et al. 2008) MMF 
 
(Watson, Firth et al. 2005) CNI Sparing acute gout, bone pain, , menstrual pain, nose bleed, fatigue, gum hypertrophy, headache/migraine, indigestion, leg edema, mouth 
ulcers, rash, acne, vomiting 
(Wlodarczyk, Walaszewski et al. 
2005) 
Steroid Sparing tremor 
(Wlodarczyk, Squifflet et al. 2009) CNI tremor, headache,  
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Study Type Side Effects reported 
(Woodle, First et al. 2008, Shihab, 
Lee et al. 2013) 
Steroid Sparing GI SAEs, cataracts, weight change, ND 
(Woodle, Peddi et al. 2010) Steroid Sparing not defined, weight gain 
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B.4. Figure 1S.  
B.3. Figure 1S.Adverse events reported in randomised controlled trials of maintenance immunosuppression in kidney transplant patients plotted 
as the proportion reporting the adverse events (a) All trials n=163, (b) calcineurin inhibitors n=90, (c) mTOR inhibitors n= 24, (d) 
mycophenolate n=21(e) belatacept n=4,.(f) steroid sparing n=24. The following adverse events are unspecified; adverse events, nervous system 
disorders, general disorders, pain (not defined), psychiatric disorders, and appearance disorders 
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Figure 1S. (cont.) 
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Figure 1S. (cont.) 
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C. Supplementary Material – Chapter 6. 
C.1. Note 1 
 
Best-worst Scaling Survey Utility Functions 
 
 
𝑉𝑉𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 = 𝐴𝐴𝐴𝐴𝐴𝐴𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 +  𝛽𝛽𝑎𝑎𝑎𝑎𝑎𝑎1 ∗ 𝐴𝐴𝐴𝐴𝐴𝐴1 +  𝛽𝛽𝑎𝑎𝑎𝑎𝑎𝑎2 ∗ 𝐴𝐴𝐴𝐴𝐴𝐴2 +  𝛽𝛽𝑎𝑎𝑎𝑎𝑎𝑎3 ∗ 𝐴𝐴𝐴𝐴𝐴𝐴3 +  𝛽𝛽𝑎𝑎𝑎𝑎𝑎𝑎4 ∗ 𝐴𝐴𝐴𝐴𝐴𝐴4 +  𝛽𝛽𝑎𝑎𝑎𝑎𝑎𝑎5
∗ 𝐴𝐴𝐴𝐴𝐴𝐴5 +  𝛽𝛽𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝑎𝑎𝐺𝐺𝐺𝐺𝑎𝑎 ∗ 𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺 +  𝛽𝛽𝐴𝐴𝐴𝐴𝐺𝐺𝑎𝑎𝐺𝐺𝐺𝐺𝑎𝑎 ∗ 𝐴𝐴𝐴𝐴𝐺𝐺 +  𝛽𝛽𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝑎𝑎𝐺𝐺𝐺𝐺𝑎𝑎 ∗ 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴+  𝛽𝛽𝑇𝑇𝑇𝑇𝑇𝑇𝑖𝑖𝑇𝑇𝐺𝐺𝑎𝑎𝐺𝐺𝐺𝐺𝑎𝑎 ∗ 𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝐺𝐺 +   𝛽𝛽𝑇𝑇𝑇𝑇𝐴𝐴𝐴𝐴𝑎𝑎𝐺𝐺𝐺𝐺𝑎𝑎 ∗ 𝑇𝑇𝑇𝑇𝐴𝐴𝐴𝐴 +  𝛽𝛽𝐷𝐷𝑖𝑖𝑎𝑎𝐷𝐷𝑎𝑎𝐺𝐺𝐺𝐺𝑎𝑎 ∗ 𝐷𝐷𝑇𝑇𝐷𝐷𝐷𝐷+  𝛽𝛽𝐶𝐶𝐴𝐴𝑇𝑇𝐴𝐴𝐴𝐴𝑎𝑎𝐺𝐺𝐺𝐺𝑎𝑎 ∗ 𝐴𝐴𝐴𝐴𝑇𝑇𝐴𝐴𝐴𝐴 
 
𝑉𝑉𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 = 𝐺𝐺𝜆𝜆𝑎𝑎𝑎𝑎
∗ �𝐴𝐴𝐴𝐴𝐴𝐴𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 + 𝛽𝛽𝑎𝑎𝑎𝑎𝑎𝑎1 ∗ 𝐴𝐴𝐴𝐴𝐴𝐴1 +  𝛽𝛽𝑎𝑎𝑎𝑎𝑎𝑎2 ∗ 𝐴𝐴𝐴𝐴𝐴𝐴2 + 𝛽𝛽𝑎𝑎𝑎𝑎𝑎𝑎3 ∗ 𝐴𝐴𝐴𝐴𝐴𝐴3 +  𝛽𝛽𝑎𝑎𝑎𝑎𝑎𝑎4 ∗ 𝐴𝐴𝐴𝐴𝐴𝐴4+  𝛽𝛽𝑎𝑎𝑎𝑎𝑎𝑎5 ∗ 𝐴𝐴𝐴𝐴𝐴𝐴5 +  𝛽𝛽𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝑎𝑎𝐴𝐴𝐺𝐺𝐺𝐺𝑎𝑎 ∗ 𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺 +  𝛽𝛽𝐴𝐴𝐴𝐴𝐺𝐺𝑎𝑎𝐴𝐴𝐺𝐺𝐺𝐺𝑎𝑎 ∗ 𝐴𝐴𝐴𝐴𝐺𝐺 +  𝛽𝛽𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝑎𝑎𝐴𝐴𝐺𝐺𝐺𝐺𝑎𝑎
∗ 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 +  𝛽𝛽𝑇𝑇𝑇𝑇𝑇𝑇𝑖𝑖𝑇𝑇𝐺𝐺𝑎𝑎𝐴𝐴𝐺𝐺𝐺𝐺𝑎𝑎 ∗ 𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝐺𝐺 +   𝛽𝛽𝑇𝑇𝑇𝑇𝐴𝐴𝐴𝐴𝑎𝑎𝐴𝐴𝐺𝐺𝐺𝐺𝑎𝑎 ∗ 𝑇𝑇𝑇𝑇𝐴𝐴𝐴𝐴 +   𝛽𝛽𝐷𝐷𝑖𝑖𝑎𝑎𝐷𝐷𝑎𝑎𝐴𝐴𝐺𝐺𝐺𝐺𝑎𝑎 
∗ 𝐷𝐷𝑇𝑇𝐷𝐷𝐷𝐷 +  𝛽𝛽𝐶𝐶𝐴𝐴𝑇𝑇𝐴𝐴𝐴𝐴𝑎𝑎𝐴𝐴𝐺𝐺𝐺𝐺𝑎𝑎 ∗ 𝐴𝐴𝐴𝐴𝑇𝑇𝐴𝐴𝐴𝐴� 
 
𝑉𝑉𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 = 𝐺𝐺𝜆𝜆𝑎𝑎𝑎𝑎 ∗ (𝐴𝐴𝐴𝐴𝐴𝐴𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 + 𝛽𝛽𝑎𝑎𝑎𝑎𝑎𝑎1 ∗ 𝐴𝐴𝐴𝐴𝐴𝐴1 +  𝛽𝛽𝑎𝑎𝑎𝑎𝑎𝑎2 ∗ 𝐴𝐴𝐴𝐴𝐴𝐴2 +  𝛽𝛽𝑎𝑎𝑎𝑎𝑎𝑎3 ∗ 𝐴𝐴𝐴𝐴𝐴𝐴3 +  𝛽𝛽𝑎𝑎𝑎𝑎𝑎𝑎4 ∗ 𝐴𝐴𝐴𝐴𝐴𝐴4+  𝛽𝛽𝑎𝑎𝑎𝑎𝑎𝑎5 ∗ 𝐴𝐴𝐴𝐴𝐴𝐴5 +  𝛽𝛽𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝑎𝑎𝐺𝐺𝐺𝐺𝑎𝑎 ∗ 𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺 + 𝛽𝛽𝐴𝐴𝐴𝐴𝐺𝐺𝑎𝑎𝐺𝐺𝐺𝐺𝑎𝑎 ∗ 𝐴𝐴𝐴𝐴𝐺𝐺 +  𝛽𝛽𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝑎𝑎𝐺𝐺𝐺𝐺𝑎𝑎
∗ 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 +  𝛽𝛽𝑇𝑇𝑇𝑇𝑇𝑇𝑖𝑖𝑇𝑇𝐺𝐺𝑎𝑎𝐺𝐺𝐺𝐺𝑎𝑎 ∗ 𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝐺𝐺 +   𝛽𝛽𝑇𝑇𝑇𝑇𝐴𝐴𝐴𝐴𝑎𝑎𝐺𝐺𝐺𝐺𝑎𝑎 ∗ 𝑇𝑇𝑇𝑇𝐴𝐴𝐴𝐴 +   𝛽𝛽𝐷𝐷𝑖𝑖𝑎𝑎𝐷𝐷𝑎𝑎𝐺𝐺𝐺𝐺𝑎𝑎 ∗ 𝐷𝐷𝑇𝑇𝐷𝐷𝐷𝐷+  𝛽𝛽𝐶𝐶𝐴𝐴𝑇𝑇𝐴𝐴𝐴𝐴𝑎𝑎𝐺𝐺𝐺𝐺𝑎𝑎 ∗ 𝐴𝐴𝐴𝐴𝑇𝑇𝐴𝐴𝐴𝐴) 
 
𝑉𝑉𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 = 𝐺𝐺𝜆𝜆𝑎𝑎𝑎𝑎
∗ �𝐴𝐴𝐴𝐴𝐴𝐴𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 +  𝛽𝛽𝑎𝑎𝑎𝑎𝑎𝑎1 ∗ 𝐴𝐴𝐴𝐴𝐴𝐴1 +  𝛽𝛽𝑎𝑎𝑎𝑎𝑎𝑎2 ∗ 𝐴𝐴𝐴𝐴𝐴𝐴2 +  𝛽𝛽𝑎𝑎𝑎𝑎𝑎𝑎3 ∗ 𝐴𝐴𝐴𝐴𝐴𝐴3 +  𝛽𝛽𝑎𝑎𝑎𝑎𝑎𝑎4 ∗ 𝐴𝐴𝐴𝐴𝐴𝐴4+  𝛽𝛽𝑎𝑎𝑎𝑎𝑎𝑎5 ∗ 𝐴𝐴𝐴𝐴𝐴𝐴5 +  𝛽𝛽𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝑎𝑎𝐴𝐴𝐺𝐺𝐺𝐺𝑎𝑎 ∗ 𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺 +  𝛽𝛽𝐴𝐴𝐴𝐴𝐺𝐺𝑎𝑎𝐴𝐴𝐺𝐺𝐺𝐺𝑎𝑎 ∗ 𝐴𝐴𝐴𝐴𝐺𝐺 +  𝛽𝛽𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝑎𝑎𝐴𝐴𝐺𝐺𝐺𝐺𝑎𝑎
∗ 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 +  𝛽𝛽𝑇𝑇𝑇𝑇𝑇𝑇𝑖𝑖𝑇𝑇𝐺𝐺𝑎𝑎𝐴𝐴𝐺𝐺𝐺𝐺𝑎𝑎 ∗ 𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝐺𝐺 +   𝛽𝛽𝑇𝑇𝑇𝑇𝐴𝐴𝐴𝐴𝑎𝑎𝐴𝐴𝐺𝐺𝐺𝐺𝑎𝑎 ∗ 𝑇𝑇𝑇𝑇𝐴𝐴𝐴𝐴 +   𝛽𝛽𝐷𝐷𝑖𝑖𝑎𝑎𝐷𝐷𝑎𝑎𝐴𝐴𝐺𝐺𝐺𝐺𝑎𝑎 
∗ 𝐷𝐷𝑇𝑇𝐷𝐷𝐷𝐷 +  𝛽𝛽𝐶𝐶𝐴𝐴𝑇𝑇𝐴𝐴𝐴𝐴𝑎𝑎𝐴𝐴𝐺𝐺𝐺𝐺𝑎𝑎 ∗ 𝐴𝐴𝐴𝐴𝑇𝑇𝐴𝐴𝐴𝐴� 
 
Where: 
 
− BF denotes that the parameter is associated with the best choice, BS the next 
best choice, WF the worst choice, and WS the next worst choice. 
− 𝑉𝑉𝑎𝑎𝑎𝑎𝑎𝑎## is the attribute utility. 
− 𝐴𝐴𝐴𝐴𝐴𝐴𝑎𝑎𝑎𝑎𝑎𝑎## is the attribute specific constant. 
− 𝛽𝛽𝑎𝑎𝑎𝑎𝑎𝑎𝐺𝐺 is the attribute level coefficient with n=1 to 5 levels. 
− 𝐴𝐴𝐴𝐴𝐴𝐴𝐺𝐺 is the attribute level with n=1 to 5 levels. 
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− 𝛽𝛽𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺## is the attribute coefficient for the covariate 𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺. Other 
covariates are: Age, number of years since the last transplant (𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝐺𝐺), the 
number of transplants (𝑇𝑇𝑇𝑇𝐴𝐴𝐴𝐴), the number of years on dialysis prior to 
transplantation (𝐷𝐷𝑇𝑇𝐷𝐷𝐷𝐷); and the number of comorbidities (𝐴𝐴𝐴𝐴𝑇𝑇𝐴𝐴𝐴𝐴). 
− Best denotes that the coefficient is associated with the best and the next best 
choice and Worst that it is associated with the worst and the next worst choice. 
− 𝜆𝜆𝜆𝜆𝐴𝐴, 𝜆𝜆𝜆𝜆𝜆𝜆, 𝜆𝜆𝜆𝜆𝐴𝐴 are scales for the ‘next-best’, ‘worst’ and ‘next-worst’ 
choices respectively and are inversely related to the error variance. The scale 
value for the ‘best’ choice is given a value of ‘1’.  
 
C.2. Note 2 
 
Utility function for a Yes selection to the question “If you were offered a treatment that 
resulted in all of the above outcomes, would you take it?”: 
 
𝑉𝑉𝑦𝑦𝐺𝐺𝐺𝐺 = 𝐴𝐴𝐴𝐴𝐴𝐴𝑦𝑦𝐺𝐺𝐺𝐺 +  𝛽𝛽𝑖𝑖𝐺𝐺𝑖𝑖 ∗ 𝐼𝐼𝐺𝐺𝐼𝐼 +  𝛽𝛽𝑤𝑤𝐴𝐴𝑎𝑎 ∗ 𝜆𝜆𝐴𝐴𝐴𝐴 +  𝛽𝛽𝐺𝐺𝑎𝑎𝐺𝐺𝑎𝑎𝐺𝐺𝐴𝐴 ∗ 𝐺𝐺𝐷𝐷𝐺𝐺𝐴𝐴𝐺𝐺𝐴𝐴 +  𝛽𝛽𝑀𝑀𝐴𝐴𝐴𝐴𝐺𝐺 ∗ 𝑀𝑀𝐴𝐴𝐴𝐴𝐺𝐺 +  𝛽𝛽𝐶𝐶𝐶𝐶𝐷𝐷
∗ 𝐴𝐴𝑉𝑉𝐷𝐷 +   𝛽𝛽𝐺𝐺𝑖𝑖𝑎𝑎𝑑𝑑𝐺𝐺𝑎𝑎𝐺𝐺𝐺𝐺 ∗ 𝐷𝐷𝑇𝑇𝐷𝐷𝐷𝐷𝐺𝐺𝐴𝐴𝐺𝐺𝐺𝐺 + 𝛽𝛽𝐺𝐺𝐺𝐺𝑎𝑎𝑖𝑖𝑎𝑎 ∗ 𝐺𝐺𝐺𝐺𝐷𝐷𝐼𝐼𝐴𝐴 + 𝛽𝛽𝐷𝐷𝑦𝑦𝑖𝑖𝐺𝐺𝐴𝐴 ∗ 𝐷𝐷𝐷𝐷𝑇𝑇𝐺𝐺𝐴𝐴+   𝛽𝛽𝑐𝑐𝑎𝑎𝐺𝐺𝑐𝑐𝐺𝐺𝐺𝐺 ∗ 𝐴𝐴𝐷𝐷𝐺𝐺𝐶𝐶𝐺𝐺𝐺𝐺 
 
C.3. Note 3 
 
Benefit/harms trade-off for graft survival and the risk of occurrence of the adverse outcomes 
were estimated following the overall approach described by de Bekker-Grob, Rose and 
Bliemer (2013) (1). The benefit/harm traded off or the marginal rates of substitution (MRS) 
can be estimated from the following equation:   
 𝑀𝑀𝐴𝐴𝐴𝐴 = Δ𝐴𝐴𝐺𝐺𝑎𝑎𝑖𝑖𝑎𝑎
Δ𝑎𝑎𝑎𝑎𝑎𝑎
=  −  𝑑𝑑𝑑𝑑a𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑g
𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑
=  −  𝛽𝛽att
𝛽𝛽graft   
 
Where U is the attribute level coefficient (rather than the utility as in a discrete choice 
experiment) and if a linear relationship with the attribute level is assumed: 
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 𝑈𝑈𝑎𝑎 = 𝛽𝛽att ∗ 𝐺𝐺𝑇𝑇𝐺𝐺𝑟𝑟 + 𝐶𝐶𝐴𝐴𝐺𝐺𝐺𝐺𝐴𝐴𝐷𝐷𝐺𝐺𝐴𝐴 
 𝑈𝑈𝐴𝐴 = 𝛽𝛽graft ∗ 𝐷𝐷𝐺𝐺𝐷𝐷𝐺𝐺𝐺𝐺 + 𝐶𝐶𝐴𝐴𝐺𝐺𝐺𝐺𝐴𝐴𝐷𝐷𝐺𝐺𝐴𝐴 
 
The pilot study (2) indicated that the relationship between attribute level coefficients may not 
be linear for all attributes. A first order exponential decay curve was fitted to the adverse 
outcome coefficient curves using GraphPad Prism V6 while the relationship for years of graft 
duration was modelled as linear. The general equation for first order exponential decay is: 
𝑈𝑈𝑎𝑎 =  (𝑌𝑌0 − 𝑝𝑝𝐷𝐷𝐷𝐷𝐴𝐴𝐺𝐺𝐷𝐷𝑝𝑝) ∗  𝐺𝐺(−𝛽𝛽att*risk)    + 𝑝𝑝𝐷𝐷𝐷𝐷𝐴𝐴𝐺𝐺𝐷𝐷𝑝𝑝 
 
The derivative of this function is: 
 
−𝑟𝑟 ∗ (𝑌𝑌0 − 𝑝𝑝𝐷𝐷𝐷𝐷𝐴𝐴𝐺𝐺𝐷𝐷𝑝𝑝) ∗  𝐺𝐺(−𝑘𝑘*risk)    
 
Therefore an estimate of the MRS is given by the following:  
 
 𝑀𝑀𝐴𝐴𝐴𝐴 = Δ𝐴𝐴𝐺𝐺𝑎𝑎𝑖𝑖𝑎𝑎
Δ𝑎𝑎𝑎𝑎𝑎𝑎
=  −  −𝑘𝑘∗(𝑌𝑌0−𝑝𝑝𝐷𝐷𝑎𝑎𝑎𝑎𝐺𝐺𝑎𝑎𝑝𝑝)∗𝐺𝐺(−𝛽𝛽att∗𝑑𝑑𝑟𝑟𝑟𝑟𝑟𝑟)
𝛽𝛽graft   
 
Where Y0 is equal to the attribute level coefficient model at 0% risk obtained from the MNL, 
and plateau is the Y value at infinite X obtained from the curve fit. As the MRS is a ratio, the 
confidence limits were estimated using the Krinsky Robb procedure as described by de 
Bekker-Grob, Rose and Bleimer (1). 
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C.4. Supplementary Table S1  
C.4 Table S1. Attribute specific constants from a multinominal logit model of the best-worst 
scaling survey. 
 
 
Attribute Choice β SE 95% CI P 
Cancer Best -2.52 1.14 (-4.75,-0.29) 0.03 
 Worst -0.503 1.17 (-2.80,1.79) 0.67 
CVD Best -2.81 1.14 (-5.04,-0.58) 0.01 
 Worst -0.334 1.29 (-2.86,2.19) 0.79 
Diabetes Best 1.18 0.89 (-0.56,2.92) 0.18 
 Worst -0.887 1.51 (-3.85,2.07) 0.56 
Dying Best -1.98 1.09 (-4.12,0.16) 0.07 
 Worst 2.52 1.14 (0.29,4.75) 0.03 
Gastro Best 0.859 0.997 (-1.10,2.81) 0.39 
 Worst -1.24 1.31 (-3.81,1.33) 0.34 
Graft survival Best 1.24 0.785 (-0.30,2.78) 0.11 
 Worst -2.76 1.37 (-5.45,-0.07) 0.04 
Infection Best 1.28 0.958 (-0.60,3.16) 0.18 
 Worst -2.75 1.69 (-6.06,0.56) 0.1 
Mood Best -2.01 1.08 (-4.13,0.11) 0.06 
 Worst -0.256 1.15 (-2.51,2.00) 0.82 
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C.5. Supplementary Table S2  
C.5. Table S2. Attribute level coefficients from a multinominal logit model of the best-worst 
scaling survey. 
 
 Value β SE P 95%CI β * (Normal) 95%CI 
Dying 0% 6.52 0.37 <0.001 (5.79,7.25) 1.00 (0.92,1.08) 
 25% 0.896 0.25 <0.001 (0.41,1.38) 0.41 (0.36,0.46) 
 75% -1.19 0.26 <0.001 (-1.70,-0.68) 0.20 (0.14,0.25) 
 100% -1.39 0.27 <0.001 (-1.92,-0.86) 0.17 (0.12,0.23) 
Graft 25y 3.81 0.30 <0.001 (3.23,4.39) 0.72 (0.66,0.78) 
 15y 1.37 0.22 <0.001 (0.94,1.80) 0.46 (0.42,0.51) 
 5y -1.28 0.21 <0.001 (-1.68,-0.88) 0.19 (0.14,0.23) 
 1y -3.06 0.25 <0.001 (-3.54,-2.58) 0.00 (-0.05,0.05) 
Cancer 0% 4.66 0.33 <0.001 (4.01,5.31) 0.81 (0.74,0.87) 
 10% 0.336 0.29 0.25 (-0.23,0.90) 0.35 (0.30,0.41) 
 30% -0.983 0.28 <0.001 (-1.54,-0.43) 0.22 (0.16,0.27) 
 50% -1.65 0.30 <0.001 (-2.23,-1.07) 0.15 (0.09,0.21) 
CVD 0% 3.92 0.37 <0.001 (3.19,4.65) 0.73 (0.65,0.80) 
 10% 1.35 0.35 <0.001 (0.66,2.04) 0.46 (0.39,0.53) 
 30% -0.175 0.33 0.59 (-0.82,0.47) 0.30 (0.23,0.37) 
 50% -1.63 0.34 <0.001 (-2.29,-0.97) 0.15 (0.08,0.22) 
Mood 0% 3.79 0.32 <0.001 (3.17,4.41) 0.72 (0.65,0.78) 
 25% 0.634 0.29 0.03 (0.07,1.20) 0.39 (0.33,0.44) 
 75% -0.798 0.28 <0.001 (-1.35,-0.24) 0.24 (0.18,0.29) 
 100% -1.5 0.29 <0.001 (-2.06,-0.94) 0.16 (0.10,0.22) 
Infection 0% 3.26 0.37 <0.001 (2.53,3.99) 0.66 (0.58,0.74) 
 10% 1.69 0.34 <0.001 (1.02,2.36) 0.50 (0.43,0.57) 
 30% 0.528 0.34 0.12 (-0.14,1.20) 0.37 (0.30,0.44) 
 50% -1.39 0.36 <0.001 (-2.10,-0.68) 0.17 (0.10,0.25) 
Gastro 0% 3.13 0.33 <0.001 (2.49,3.77) 0.65 (0.58,0.71) 
 25% 1.51 0.31 <0.001 (0.90,2.12) 0.48 (0.41,0.54) 
 75% 0.023 0.31 0.94 (-0.59,0.63) 0.32 (0.26,0.39) 
 100% -1.44 0.34 <0.001 (-2.11,-0.77) 0.17 (0.10,0.24) 
Diabetes. 0% 2.18 0.29 <0.001 (1.62,2.74) 0.55 (0.49,0.61) 
 10% 0.297 0.27 0.27 (-0.23,0.82) 0.35 (0.30,0.41) 
 30% -0.759 0.28 0.01 (-1.31,-0.21) 0.24 (0.18,0.30) 
 50% -1.89 0.29 <0.001 (-2.46,-1.32) 0.12 (0.06,0.18) 
Weight 0% 1.88 0.27 <0.001 (1.35,2.41) 0.52 (0.46,0.57) 
 25% 0.817 0.27 <0.001 (0.28,1.35) 0.40 (0.35,0.46) 
 75% -0.193 0.26 0.45 (-0.69,0.31) 0.30 (0.25,0.35) 
 100% -0.608 0.27 0.03 (-1.14,-0.07) 0.26 (0.20,0.31) 
 
* Normalized from 0 ‘worst’ to 1 ‘best’. 
** Normalized relative to ‘dying’ 
CVD -cardiovascular disease 
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C.6. Supplementary Table S3  
C.6. Table S3. Benefit/harm trade-off between adverse outcomes and graft survival. The value indicates the number of years of graft survival that would be 
traded in order to achieve a given risk for the adverse outcome. 
 
Outcome Benefit/harm trade-off  - years of graft survival (95%CI) 
Risk 
0% 10% 20% 30% 
Cancer 3.10 (2.10,4.69) 0.94 (0.63,1.42) 0.28 (0.19,0.43) 0.09 (0.06,0.13) 
Dying before graft fails  1.66 (1.12,2.51) 1.01 (0.69,1.53) 0.62 (0.42,0.94) 0.38 (0.26,0.57) 
CVD 1.21 (0.82,1.83) 0.74 (0.50,1.12) 0.46 (0.31,0.69) 0.28 (0.19, 0.42) 
Diabetes 0.87 (0.59,1.32) 0.54 (0.37, 0.82) 0.34 (0.23,0.51) 0.21 (0.14, 0.31) 
Anxiety/depression 0.81 (0.55,1.22) 0.56 (0.38,0.85) 0.39 (0.26,0.59) 0.27 (0.18,0.41) 
Serious infection 0.58 (0.39,0.88) 0.50 (0.34,0.76) 0.43 (0.29,0.66) 0.38 (0.25,0.57) 
Diarrhoea/nausea 0.39 (0.26,0.59) 0.36 (0.24,0.54) 0.33 (0.22,0.50) 0.30 (0.20,0.46) 
Weight gain 0.19 (0.13,0.28) 0.16 (0.11,0.24) 0.14 (0.09,0.21) 0.12 (0.08,0.18) 
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C.7. Supplementary Table S4  
C.7. Table S4. Odds ratios for best and worst choices, an odds ratio greater than 1 means that on average it is more likelihood that the outcome will be selected 
and less than 1 means there is a lower likelihood of selection.   
 
Covariate Serious 
infection P 
Diarrhoea 
nausea P 
Depression 
anxiety P CVD P Diabetes P 
Graft 
survival P Dying P Cancer P 
Older Age: Best 0.94 0.00 0.94 0.00 0.95 0.01 0.99 0.57 0.95 0.00 0.98 0.15 0.97 0.08 0.98 0.20 
Worst 1.04 0.14 1.02 0.32 1.01 0.45 0.98 0.35 0.99 0.62 1.07 0.00 1.03 0.09 1.03 0.07 
Comorbidities: 
Best 
1.22 0.09 1.17 0.20 1.21 0.20 1.08 0.58 1.21 0.08 1.23 0.03 1.20 0.17 0.88 0.44 
Worst 0.85 0.43 0.75 0.10 0.95 0.73 0.89 0.50 0.47 0.00 0.60 0.00 0.73 0.04 0.83 0.23 
Years on dialysis: 
Best 
0.91 0.33 1.12 0.29 1.10 0.43 0.84 0.17 1.05 0.62 1.23 0.01 1.10 0.38 1.05 0.67 
Worst 0.91 0.61 1.07 0.63 1.10 0.45 1.39 0.03 1.35 0.09 1.20 0.23 1.20 0.16 1.21 0.14 
Women: Best 1.23 0.48 1.18 0.60 2.77 0.00 2.89 0.00 1.48 0.15 1.68 0.03 0.72 0.34 2.38 0.01 
Worst 0.89 0.82 2.47 0.03 2.13 0.04 1.74 0.20 2.15 0.13 1.79 0.19 1.11 0.78 1.66 0.18 
More than 1 
transplant: Best 
1.77 0.25 1.46 0.46 8.58 0.00 4.62 0.00 2.69 0.03 3.03 0.00 4.10 0.01 4.26 0.01 
Worst 2.54 0.22 1.51 0.55 1.76 0.34 4.62 0.01 2.71 0.18 3.22 0.08 1.28 0.67 1.88 0.29 
Time since 
transplant: Best 
1.02 0.33 0.99 0.77 1.01 0.85 1.00 0.89 1.02 0.49 0.95 0.02 1.01 0.86 1.07 0.02 
Worst 0.95 0.30 1.02 0.52 0.99 0.69 0.92 0.04 0.93 0.15 0.96 0.23 0.97 0.35 0.95 0.10 
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C.8. Supplementary Table S5.  
C.8. Table S5. Attribute coefficients and odds ratios calculated using a mixed logit 
multinominal model for the Yes/No choice for the question at the end of each of 10 scenarios 
– “If you were offered treatment that resulted in all of the above outcomes, would you take 
it?”. Odds ratio >1 implies that on average participants are more likely to choose YES and <1 
more likely to choose NO given an increase in attribute level. 
 
 
Variables Coefficients     
 
β SE P Odds ratio 
95% 
LCL 
95% 
UCL 
YES 2.14 1.32 0.11    
       
Serious infection 0.003 0.035 0.94 1.00 0.94 1.07 
Weight gain 0.006 0.009 0.54 1.01 0.99 1.02 
Diarrhoea/nausea -0.007 0.009 0.45 0.99 0.98 1.01 
Depression/anxiety -0.022 0.012 0.07 0.98 0.96 1.00 
CVD -0.023 0.024 0.36 0.98 0.93 1.03 
Diabetes 0.011 0.028 0.70 1.01 0.96 1.07 
Graft survival 0.430 0.118 <0.001 1.54 1.22 1.94 
Dying -0.042 0.015 0.04 0.96 0.93 0.99 
Cancer -0.039 0.024 0.10 0.96 0.92 1.01 
 
 
